NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Flamm CR, Aronson N, Bohn R, et al. Use of Epoetin for Anemia in Chronic Renal Failure. Rockville (MD): Agency for Healthcare Research and Quality (US); 2001 Aug. (Evidence Reports/Technology Assessments, No. 29.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Use of Epoetin for Anemia in Chronic Renal Failure

Use of Epoetin for Anemia in Chronic Renal Failure.

Show details

Bibliography

  1. Abels R Rate of progression of chronic renal failure in predialysis patients treated with erythropoietin Semin Nephrol 1990Mar 10(2 Suppl 1):20–5. [PubMed: 2192413]
  2. Abensur H [Substitutive treatment of renal function] Arq Bras Cardiol 199565(1):81–3. [PubMed: 8546603]
  3. Abraham PA, Opsahl JA, Keshaviah PR, et al Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin Am J Kidney Dis 1990Nov;16(5):438–46. [PubMed: 2239934]
  4. Abraham PA, Opsahl JA, Rachael K M, et al Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients Am J Nephrol 199010(2):128–36. [PubMed: 2349956]
  5. Abraham PA Health care payment policies: lessons from erythropoietin Am J Kidney Dis 199322(4):596–597. [PubMed: 8213802]
  6. Abraham PA Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects Am J Nephrol 199010(Suppl 2):7–14. [PubMed: 2260619]
  7. Acchiardo SR, Moore LW, Sargent JA, et al Is hematologic response to iron and erythropoietin in hemodialysis patients affected by other factors? ASAIO Trans 199137(3):M183–5. [PubMed: 1751102]
  8. Acchiardo SR, Quinn BP, Burk LB, et al Are high flux dialysis and erythropoietin treatment in a collision course? ASAIO Trans 198935(3):308–10. [PubMed: 2688711]
  9. Acchiardo SR, Quinn BP, Moore LW, et al Evaluation of hemodialysis patients treated with erythropoietin Am J Kidney Dis 199117(3):290–4. [PubMed: 1996571]
  10. Acharya VN, Sinha DK, Almeida AF, et al Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis J Assoc Physicians India 199543(8):539–42. [PubMed: 8772973]
  11. Adair C, Lappin TR, Cotes PM Changes in concentrations of atp and other nucleotides in erythrocytes during erythropoietin treatment in haemodialysis patients Biochem Soc Trans 199220(2):–. [PubMed: 1397658]
  12. Adamson JW The promise of recombinant human erythropoietin Semin Hematol 198926(2 Suppl. 2):5–8. [PubMed: 2658101]
  13. Adamson JWW, Egrie JC, Browne JK, et al The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report. Behring Inst Mitt. 1988;83:188–92. [PubMed: 3071336]
  14. Adamson JW, Eschbach JW Erythropoietin for end-stage renal disease N Engl J Med 1998339(9):625–7. [PubMed: 9718384]
  15. Adamson JW, Eschbach JW Management of the anaemia of chronic renal failure with recombinant erythropoietin Q J Med 198973(272):1093–101. [PubMed: 2694210]
  16. Adamson JW, Schuster M, Allen S, et al Effectiveness of recombinant human erythropoietin therapy in myelodysplastic syndromes Acta Haematol 199287(Suppl 1):20–4. [PubMed: 1574963]
  17. Adamson JW, Vapnek D Recombinant erythropoietin to improve athletic performance. N Engl Med. 1991;324:698–9. [PubMed: 1994258]
  18. Agroyannis B, Dalmangas A, Tzanatos H, et al Effect of acetate and erythropoietin on fetal hemoglobin in hemodialyzed uremic patients (4) Blood 199585(12):3765–3766. [PubMed: 7540074]
  19. Ahmad R, Hand M Recombinant erythropoietin for the anemia of chronic renal failure N Engl J Med 1987317(3):169–70. [PubMed: 3600706]
  20. Ahn JH, Yoon KS, Lee WI, et al Bone marrow findings before and after treatment with recombinant human erythropoietin in chronic hemodialyzed patients Clin Nephrol 199543(3):189–95. [PubMed: 7774077]
  21. Ahsan N Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study J Am Soc Nephrol 19989(4):664–8. [PubMed: 9555669]
  22. Ahsan N Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study J Am Soc Nephrol 9989(4):664–668. [PubMed: 9555669]
  23. Akcicek F, Ozkahya M, Cirit M, et al The efficiency of fractionated parenteral iron treatment in CAPD patients. Adv Perit Dial. 1997;13:109–12. [PubMed: 9360661]
  24. Akiba T, KoshikawaS, Mimura N, et al Randomized double-blind study of subcutaneous recombinant human erythropoietin in predialysis uraemic patients Nephrol Dial Transplant 19927(7):–.
  25. Albertazzi A, Di Liberato L, Daniele F, et al Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study Int J Artif Organs 199821(1):12–8. [PubMed: 9554820]
  26. Albitar S, Genin R, Fen-Chong M, et al High-dose alfacalcidol improves anaemia in patients on haemodialysis Nephrol Dial Transplant 199712(3):514–518. [PubMed: 9075133]
  27. Albitar S, Meulders Q, Hammoud H, et al Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant. 1995;10:40–3. [PubMed: 8524493]
  28. Alexander SR, Sullivan EK, Harmon WE, et al Maintenance dialysis in North American children and adolescents: a preliminary report. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Kidney Int Suppl. 1993;43:S104–9. [PubMed: 8246361]
  29. Alexander SR Pediatric uses of recombinant human erythropoietin: the outlook in 1991 Am J Kidney Dis 199118(4 Suppl 1):42–53. [PubMed: 1928079]
  30. Alfurayh O, Sobh M, Barri Y, et al Aluminum overload and response to recombinant human erythropoietin inpatients under chronic haemodialysis Nephrol Dial Transplant 19927(9):939–943. [PubMed: 1328942]
  31. Allegra V, Martimbianco L, Mengozzi G, et al Erythropoietin and cardiovascular risk Blood Purif 199513(6):301–13. [PubMed: 8821194]
  32. Allegra V, Martimbianco L, Vasile A Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet Nephrol Dial Transplant 199712(5):924–32. [PubMed: 9175044]
  33. Altun B, Erdem Y, Haznedaroglu I, et al Effect of recombinant human erythropoietin on soluble interleukin 2 receptor (SIL-2R) levels in haemodialysis patients Nephrol Dial Transplant 199510(11):–. [PubMed: 8643199]
  34. Amar J, Chamontin B, Vernier I, et al [Arterial blood pressure changes, circadian rhythm and arterial elasticity in hemodialysed patients] Arch Mal Coeur Vaiss 199487(7):921–924. [PubMed: 7702436]
  35. American Thoracic Society Quality of life resource: The Nottingham Health Profile (NHP). Available at: http://www​.atsqol.org/nott.html. Accessed April 2000.
  36. Amerling R, Levin NW Erythropoietin update Kidney 199326(1):1–8.
  37. Amgen, Inc Epogen® (epoetin alfa) prescribing information. In: Physicians' desk reference. 53rd ed. Montvale: Medical Economics Press; 1999.
  38. Anagnostou A, Kurtzman NA The anemia of chronic renal failure Semin Nephrol 19855(2):115–27. [PubMed: 3843785]
  39. Anderson S Effects of erythropoietin in predialysis patients Am J Kidney Dis 199117(5 Suppl 1):103–6. [PubMed: 2024665]
  40. Anon Correction of the anemia of end-stage renal disease with recombinant human erythropoietin N Engl J Med 1987317(4):249–51. [PubMed: 3600716]
  41. Anon Increase haemoglobulin and objective QoL Drugs And Therapy Perspectives 199811(10):14–16.
  42. Anon Iritis-like reactions due to epoetin Geneesmiddelenbulletin 199630(8):–.
  43. Anon The investigation of erythropoietin resistance Pract. Pediatr 19932(5):7–8.
  44. Anon USRDS research studies Am J Kidney Dis 199118(5 Suppl 2):105–10. [PubMed: 1951351]
  45. Anon Adult screening for anemia and hemoglobinopathies Nurse Pract 1995Dec20(12):48–51.
  46. Anon Analytical methods: technical notes Am J Kidney Dis 1991 Nov18(5 Suppl 2):111–27. [PubMed: 1951352]
  47. Anon Anemia guidelines suggest iron as missing link in managing hematocrits Nephrol News Issues 1997Oct11(10):–. [PubMed: 9391390]
  48. Anon CDC criteria for anemia in children and childbearing-aged women MMWR Morb Mortal Wkly Rep 1989Jun 9 38(22):400–4. [PubMed: 2542755]
  49. Anon CDC releases new reference criteria for anemia screening Am Fam Physician 1989 Sep40(3):–. [PubMed: 2610199]
  50. Anon Current trends: CDC criteria for anemia in children and childbearing-aged women Am J Dis Child 1990144(2):151–152.
  51. Anon DOQI Guidelines/fifth in a series. A focus on iron management for better HCTs Nephrol News Issues 1997 Sep11(9):–. [PubMed: 9348872]
  52. Anon Effect of recombinant human erythropoietin on renal function deterioration in patients with anemia and progressive renal failure J Nephrol 19914(4):269–273.
  53. Anon Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian Erythropoietin Study Group Am J Nephrol 199111(1):23–6. [PubMed: 2048574]
  54. Anon Epoetin alfa: clinical trial therapy ANNA J 1989 Aug16(5):344–8. [PubMed: 2673077]
  55. Anon Erythropoietin 1991-biology, clinical use, and impact on patients: an international symposium. February 8-9, 1991, Nashville, Tennessee Am J Kidney Dis 1991 Oct18(4 Suppl 1):1–116. [PubMed: 1681726]
  56. Anon Erythropoietin for anemia and related indications Perspect Clin Pharm 19908(4):27–29.
  57. Anon Erythropoietin for anemia Med Lett Drugs Ther 1989 Sep 2231(801):85–6. [PubMed: 2671624]
  58. Anon Erythropoietin in chronic renal failure Natl Med J India 19892(4):159–161.
  59. Anon HCFA anemia cooperative project unveiled at ASN Dialysis And Transplantation 199625(1):–.
  60. Anon Human recombinant erythropoietin Urologe Ausg B 198929(5):299–301.
  61. Anon Medication use among dialysis patients in the DMMS Am J Kidney Dis 199832(2 Suppl. 1):S60–S68. [PubMed: 9713408]
  62. Anon NKF-DOQI reports significant progress in the drafting of ESRD clinical practice guidelines Dial Transplant 199625(5):242,244,248,250,252–3,257-8.
  63. Anon Recombinant human erythropoietin: implications for nephrology. Proceedings of a symposium. Quebec City, Canada Semin Nephrol 1990 Mar10(2 Suppl 1):1–72. [PubMed: 2356365]
  64. Anon Recormon (r) Munch Med Wochenschr 1991133(37):–.
  65. Anon Results of the cross-Canada survey of recombinant human erythropoietin (r-HuEPO) therapy programs. The Medicine Group (Canada) Ltd J CANNT 1992Summer 2(3):11–5. [PubMed: 1515304]
  66. Anon Subcutaneous erythropoietin in the treatment of renal anemia? Fortschr Med 1991109(19):–.
  67. Anon Treatment modalities for ESRD patients. USRDS. United States Renal Data System Am J Kidney Dis 1997 Aug30(2 Suppl 1):S54–66. [PubMed: 9259693]
  68. Antonoff A EPO-one year later: a look at rehabilitation. Patient attitude key in impacting the job rate Nephrol News Issues 1990 Jun4(6):33–4, 48. [PubMed: 2402310]
  69. Arinsoy T, Ozdemir O, Arik N, et al Recombinant human erythropoietin treatment may induce antithrombin-III depletion Nephron 199262(4):480–1. [PubMed: 1300451]
  70. Aronoff GR, Duff DR, Sloan RS, et al The treatment of anemia with low-dose recombinant human erythropoietin Am J Nephrol 199010Suppl 2:40–3. [PubMed: 2260617]
  71. Asano Y [Complications of long-term hemodialysis patients and the countermeasures] Nippon Naika Gakkai Zasshi 1992 Aug 1081(8):1273–8. [PubMed: 1431471]
  72. Ashai NI, Paganini EP, Wilson JM Intravenous versus subcutaneous dosing of epoetin: a review of the literature Am J Kidney Dis 199322(2 Suppl. 1):23–31. [PubMed: 8352268]
  73. Asimacopoulos PJ, Skoumas IN, Yawn DH, et al Angina pectoris caused by pernicious anemia Chest 1994 Mar105(3):653–4. [PubMed: 8131519]
  74. Auer J, Oliver DO, Winearls CG The quality of life of dialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol Suppl. 1990;131:61–5. [PubMed: 2075472]
  75. Auer J, Simon G, Stevens J, et al Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia Perit Dial Int 199212(1):40–2. [PubMed: 1543779]
  76. Auerbach M, Winchester J, Wahab A, et al A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients Am J Kidney Dis 1998 Jan31(1):81–6. [PubMed: 9428456]
  77. Aufricht C, Balzar E, Steger H, et al Subcutaneous recombinant human erythropoietin in children with renal anemia on continuous ambulatory peritoneal dialysis Acta Paediatr 1993 Nov82(11):959–62. [PubMed: 8111178]
  78. Aunsholt NA, Steffensen G, Povlsen JV, et al Lymphocytotoxic panel reactive antibodies in hemodialyzed patients treated with recombinant human erythropoietin Nephron 199159(3):–. [PubMed: 1758547]
  79. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients Effectiveness and safety of recombinant human erythropoietin in predialysis patients Nephron 199261(4):399–403. [PubMed: 1501735]
  80. Avram MM, Sreedhara R, Batish R, et al Characteristics of very long-term survivors on hemodialysis (HD); Survival up to 30 years. J Am Soc Nephrol. 1996;7:–.
  81. Avram MM Update in nephrology '97: hypertension, lipids, and uremia therapy Am J Kidney Dis 199730(6):896–898. [PubMed: 9417765]
  82. Bagon JA, Vernaeve H, De Muylder X, et al Pregnancy and dialysis Am J Kidney Dis 1998 May31(5):756–65. [PubMed: 9590184]
  83. Bailie GR, Plitnick R, Eisele G, et al Experience with subcutaneous erythropoietin in CAPD patients. Adv Perit Dial. 1991;7:292–5. [PubMed: 1680449]
  84. Bailie GR Erythropoietin and iron use in peritoneal dialysis patients: Report from the 1997 HCFA end-stage renal disease core indicators project Am J Kidney Dis 199933(6):1187–89. [PubMed: 10352214]
  85. Bajo MA, Selgas R, Miranda B, et al Medium term response to H-R erythropoietin in CAPD patients: the influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity. Adv Perit Dial. 1991;7:296–300. [PubMed: 1680450]
  86. Balaskas EV, Melamed IR, Gupta A, et al Effect of erythropoietin treatment on nutritional status of continuous ambulatory peritoneal dialysis patients Perit Dial Int 199313(Suppl 2):S544–9. [PubMed: 8399661]
  87. Baldamus CA, Steffen AM, Brunner R, et al Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin. Contrib Nephrol. 1990;82:79–85. [PubMed: 2093531]
  88. Baldus M, Brass H [What are the potentials of erythropoietin?] Krankenpfl J 1993 Jan-Feb31(1-2):23–8. [PubMed: 8445873]
  89. Baldus M, Brass H Erythropoietin - a new approach in the treatment of renal anemia Nieren- Hochdruckkr 199019(5):170–177.
  90. Balkovetz DF, Frazier C, Sanders PW Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit [6] Nephrol Dial Transplant 199813(11):2979–80. [PubMed: 9829525]
  91. Barany P, Clyne N, Hylander B, et al Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis Perit Dial Int 199515(1):54–60. [PubMed: 7734561]
  92. Barany P, Divino Filho JC, Bergstrom J High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients Am J Kidney Dis 1997 Apr29(4):565–8. [PubMed: 9100046]
  93. Barany P, Fehrman I, Godoy C Long-term effects on lymphocytotoxic antibodies and immune reactivity in hemodialysis patients treated with recombinant human erythropoietin Clin Nephrol 1992 Feb37(2):90–6. [PubMed: 1551255]
  94. Barany P, Freyschuss U, Pettersson E, et al Treatment of anaemia in haemodialysis patients with erythropoietin: long-term effects on exercise capacity Clin Sci 199384(4):441–447. [PubMed: 8482049]
  95. Barany P, Pettersson E, Ahlberg M, et al Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin Clin Nephrol 1991 Jun35(6):270–9. [PubMed: 1873941]
  96. Barany P, Pettersson E, Konarski-Svensson JK Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin Nephrol Dial Transplant 19938(5):426–32. [PubMed: 8393547]
  97. Barany P Endocrinology and PD: optimal treatment of anemia in peritoneal dialysis patients Perit Dial Int 199616(Suppl 1):S260–6. [PubMed: 8728204]
  98. Barany P Physiological effects of correcting anemia in hemodialysis patients (HD pts) to a normal HB. J Am Soc Nephrol. 1996;7:–.
  99. Bargman J Erythropoietin: a hormone finds a purpose J Rheumatol 199118(8):1121–1123. [PubMed: 1941810]
  100. Bargman J Recombinant human erythropoietin in patients on peritoneal dialysis Perit Dial Int 19899(4):245–6. [PubMed: 2488375]
  101. Bartova V, Nemecek K, Lachmanova J Erythropoietin or blood transfusion? Vnitr Lek 199339(5):445–450. [PubMed: 8351875]
  102. Bartunkova J, Fucikova T, Sulkova S, et al Influence of erythropoietin and some lymphocyte and granulocyte functions in dialyzed patients Cas Lek Cesk 1989128(42):1332–35. [PubMed: 2598245]
  103. Bartunkova J, Sulkova S, Cebecauer M [The effect of recombinant erythropoietin on candidicidal activity of polymorphonuclear leukocytes in hemodialyzed patients] Cas Lek Cesk 1995 Dec 6134(23):756–9. [PubMed: 8599817]
  104. Baskin S, Lasker N Erythropoietin-associated hypertension N Engl J Med 1990323(14):–.
  105. Bass EB, Jenckes MW, Fink NE, et al Use of focus groups to identify concerns about dialysis Medical Decision Making 199919(3):287–295. [PubMed: 10424835]
  106. Bassi S, Montini G, Edefonti A, et al Cardiovascular function in a chronic peritoneal dialysis pediatric population on recombinant human erythropoietin treatment Perit Dial Int 199313(Suppl 2):S267–9. [PubMed: 8399585]
  107. Beard JL, Haas JD, Tufts D, et al Iron deficiency anemia and steady-state work performance at high altitude J Appl Physiol 1988 May64(5):1878–84. [PubMed: 3134329]
  108. Beccari M, Romagnoni M, Sorgato G Seizures in dialysis patients treated with recombinant erythropoietin Nephrol Dial Transplant 199510(3):423–4. [PubMed: 7792048]
  109. Beccari M Seizures in dialysis patients treated with recombinant erythropoietin: review of the literature and guidelines for prevention Int J Artif Organs 199417(1):5–13. [PubMed: 8188400]
  110. Becker N, Brandt JR, Sutherland TA, et al Improved outcome of young children on nightly automated peritoneal dialysis Pediatr Nephrol 1997 Dec11(6):676–9. [PubMed: 9438640]
  111. Bedani PL, Cecchetti E, Gilli P Effectiveness of subcutaneous low-dose erythropoietin in patients with chronic renal failure despite functional iron deficiency Nephron 199571(4):459–60. [PubMed: 8587628]
  112. Beer J Treatment of anaemia in chronic renal failure Nurs Times 1988 Nov 23-2984(47):55–7. [PubMed: 3211795]
  113. Beguin Y, Fillet G [Erythropoietin: diagnostic and therapeutic use] Rev Med Liege 1990 Jun45(6):261–7. [PubMed: 2367756]
  114. Beguin Y, Loo M, R'Zik S, et al Early prediction of response to recombinant human erythropoietin inpatients with the anemia of renal failure by serum transferrin receptor and fibrinogen Blood 199382(7):2010–2016. [PubMed: 8400253]
  115. Beguin Y, Loo M, R'Zik S, et al Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin Br J Haematol 1995 Jan89(1):17–23. [PubMed: 7833259]
  116. Beguin Y, Sautois B, Fillet G Diagnostic and therapeutic aspects of erythropoietin Med Hyg 199149(1897):2034–40.
  117. Beguin Y A risk-benefit assessment of epoetin in the management of anaemia associated with cancer Drug Safety 199819(4):269–82. [PubMed: 9804442]
  118. Bellinghieri G, Savica V, De Gregorio C, et al Use of erythropoietin in ischemic and arrhythmic cardiopathy of hemodialyzed patients. Contrib Nephrol. 1994;106:135–7. [PubMed: 8174359]
  119. Belsha CW, Berry PL Effect of hyperparathyroidism on response to erythropoietin in children on dialysis Pediatr Nephrol 1998 May12(4):298–303. [PubMed: 9655362]
  120. Bennett L The anaemia research nurse in effective multi-disciplinary management of patients on erythropoietin EDTNA-ERCA Journal 199824(3):38–9. [PubMed: 10392079]
  121. Bennett TA, Todd MW, Sandroni S Criteria for use of epoetin Clin Pharm 199110(4):303–6. [PubMed: 2032449]
  122. Bennett WM A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease J Am Soc Nephrol 1991 Jan1(7):990–8. [PubMed: 1883969]
  123. Bennett WM Side effects of erythropoietin therapy Am J Kidney Dis 1991 Oct18(4 Suppl 1):84–6. [PubMed: 1928085]
  124. Benz RL, Pressman MR, Hovick ET et al A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO Study) Am J Kidney Dis 199934(6):1089–95. [PubMed: 10585319]
  125. Benz RL Relationship between anemia of chronic renal failure (ACRF) and sleep, sleep disorders and daytime alertness: benefits if normalizing hematocrit (The SLEEPO Trial) J Am Soc Nephrol. 1996;7:–.
  126. Beresford CH Erythropoietin N Z Med J 1989 Apr 26102(866):185–6. [PubMed: 2652007]
  127. Beresford CH Therapeutics. Iron deficiency New Zealand Med. J 1992105(930):110–111. [PubMed: 1553116]
  128. Bergen DC, Ristanovic R, Gorelick PB, et al Seizures and renal failures Int J Artif Organs 199417(5):247–251. [PubMed: 7960192]
  129. Berger J, Aguayo VM, San Miguel JL, et al Definition and prevalence of anemia in Bolivian women of childbearing age living at high altitudes: the effect of iron-folate supplementation Nutr Rev 1997 Jun55(6):247–56. [PubMed: 9279061]
  130. Berger J, Aguayo VM, Tellez W, et al Weekly iron supplementation is as effective as 5 day per week iron supplementation in Bolivian school children living at high altitude European Journal Of Clinical Nutrition 199751(6):381–6. [PubMed: 9192196]
  131. Berglund B, Birgegard G, Hemmingsson P Serum erythropoietin in cross-country skiers Med Sci Sports Exerc 198820(2):208–9. [PubMed: 3367758]
  132. Berglund B High-altitude training. Aspects of haematological adaptation Sports Med 1992 Nov14(5):289–303. [PubMed: 1439397]
  133. Bergstrom J New aspects of erythropoietin treatment J Intern Med 1993233(6):445–62. [PubMed: 8099117]
  134. Beris P Indication and contraindication: application of recombinant human erythropoietin as blood substitute Therapiewoche Schweiz 199410(12):636–40.
  135. Berns JS, Cahill C, Okupinski V, et al Improving management of anemia using CQI techniques Nephrol News Issues 1997 Sep11(9):11–3. [PubMed: 9348865]
  136. Berns JS, DeOreo PB Clinical applications of iron management in hemodialysis patients Seminars in Dialysis 199912(4):249–56.
  137. Besarab A, Bolton WK, Browne JK, et al The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 1998 Aug 27339(9):584–90. [PubMed: 9718377]
  138. Besarab A, Flaharty KK, Erslev AJ, et al Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration J Am Soc Nephrol 1992 Mar2(9):1405–16. [PubMed: 1627763]
  139. Besarab A, Golper TA Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients ASAIO Trans 1991 Jul-Sep37(3):M395–6. [PubMed: 1751205]
  140. Besarab A, McCrea JB Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? ASAIO J 1993 Jan-Mar39(1):11–8. [PubMed: 8439674]
  141. Besarab A, Medina F, Musial E, et al Recombinant human erythropoietin does not increase clotting in vascular accesses ASAIO Trans 1990 Jul-Sep36(3):M749–53. [PubMed: 2252802]
  142. Besarab A, Ross RP, Nasca TJ The use of recombinant human erythropoietin in predialysis patients Curr Opin Nephrol Hypertens 1995 Mar4(2):155–61. [PubMed: 7600046]
  143. Besarab A Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration Am J Kidney Dis 1993 Aug22(2 Suppl 1):13–22. [PubMed: 8352267]
  144. Besarab A Parenteral iron therapy: Safety and efficacy Seminars in Dialysis 199912(4):237–42.
  145. Beusterien KM, Nissenson AR, Port FK, et al The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients J Am Soc Nephrol 1996 May7(5):763–73. [PubMed: 8738812]
  146. Bezerra HM, Maia GP, Bezerra Neto FA, et al [Severity of acquired cystic kidney disease determines improvement in chronic kidney failure anemia] Rev Assoc Med Bras 1997 Jan-Mar43(1):4–8. [PubMed: 9224984]
  147. Bhandari S, Norfolk D, Brownjohn AM, et al Novel haematological parameters in patients receiving recombinant human erythropoietin and undergoing haemodialysis Hematology 19983(1):67–75.
  148. Bianchetti MG, Hammerli I, Roduit C, et al Epoetin alfa in anaemic children or adolescents on regular dialysis Eur J Pediatr 1991 May150(7):509–12. [PubMed: 1915505]
  149. Biggers PB Administering epoetin alfa. More RBCs with fewer risks Nursing 1991 Apr21(4):–. [PubMed: 2020418]
  150. Birmingham DJ, Shen XP, Hartman JA, et al Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients Kidney Int 1996 Aug50(2):543–9. [PubMed: 8840284]
  151. Blagg CR The socioeconomic impact of rehabilitation Am J Kidney Dis 1994 Jul24(1 Suppl 1):S17–21; discussion S31-2. [PubMed: 8023834]
  152. Blake GJ Epoetin alfa for renal and H. I.V.-positive patients Nursing 1992 Nov22(11):–. [PubMed: 1454269]
  153. Bloomfield RJ, Wilson IJ Nomifensine, acute hemolytic anemia, and renal failure Ann Intern Med 1986105(5):–. [PubMed: 3767177]
  154. Blumberg A, Zehnder Treatment of the anemia of renal failure with recombinant human erythropoietin Ther. Umsch 198845(12):895–9. [PubMed: 3065970]
  155. Boccardo P, Remuzzi A Hemostasis in renal failure Intensivmedizin Und Notfallmedizin 199835(6):382–9.
  156. Bocker A, Reimers E, Nonnast-Daniel B, et al Effect of erythropoietin treatment on O2 affinity and performance in patients with renal anemia. Contrib Nephrol. 1988;66:165–75. [PubMed: 3391031]
  157. Boineau FG, Lewy JE, Roy S, et al Prevalence of anemia and correlations with mild and chronic renal insufficiency J Pediatr 1990116(2):S60–S62. [PubMed: 2299484]
  158. Bolton WK What crit? Am J Kidney Dis 199933(6):1177–79. [PubMed: 10352212]
  159. Bommer J, Alexiou C, Muller-Buhl U, et al Recombinant human erythropoietin therapy in haemodialysis patients -- dose determination and clinical experience Nephrol Dial Transplant 19872(4):238–42. [PubMed: 3118264]
  160. Bommer J, Huber W, Tewes G, et al Treatment of polytransfused hemodialysis patients with recombinant human erythropoietin. Contrib Nephrol. 1988;66:131–8. [PubMed: 3391027]
  161. Bommer J, Kugel M, Schoeppe W, et al Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol. 1988;66:85–93. [PubMed: 3292151]
  162. Bommer J, Muller-Buhl E, Ritz E, et al Recombinant human erythropoietin in anaemic patients on haemodialysis Lancet 19871(8529):–. [PubMed: 2880204]
  163. Bommer J Hypertension under rhepo therapy Nieren-Hochdruckkr 199322(11):605–8.
  164. Bommer J Response to EPO therapy Przegl Lek 199249(1-2):36–7. [PubMed: 1455003]
  165. Boning D, Maassen N, Jochum F, et al After-effects of a high altitude expedition on blood Int J Sports Med 1997 Apr18(3):179–85. [PubMed: 9187971]
  166. Boran M, Dalva I, Yazicioglu A, et al Correction of anaemia in haemodialysis patients with recombinant human erythropoietin Int Urol Nephrol 199325(2):197–203. [PubMed: 8365853]
  167. Boratynska M, Magott M, Szewczyk Z [Treatment with human recombinant erythropoietin and nutritional status of patients on long term dialysis] Przegl Lek 199653(5):402–5. [PubMed: 8754401]
  168. Boratynska M, Mazanowska O, Szewczyk Z [Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin] Pol Merkuriusz Lek 1996 Nov1(5):329–31. [PubMed: 9273209]
  169. Boratynska M, Szewczyk Z, Szepietowski T, et al [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis] Przegl Lek 199047(11):741–5. [PubMed: 2098840]
  170. Borgna-Pignatti C Hematopoietic disorders and growth factors Curr Opin Pediatr 19913(1):87–94.
  171. Borrego FJ, Miguel JL, Zamorano A, et al [The treatment of anemia in patients on hemodialysis with recombinant human erythropoietin] Med Clin (Barc) 1991 Nov 2397(18):687–92. [PMC free article: PMC263984] [PubMed: 1770818]
  172. Bozfakioglu S, Alptekin N, Seckin S, et al Red cell lipid peroxidation and antioxidant system in chronic renal failure patients treated with recombinant human erythropoietin Nephron 199261(2):228–9. [PubMed: 1630552]
  173. Brandt JR, Avner ED, Hickman RO, et al Safety and efficacy of erythropoietin in children with chronic renal failure Pediatric Nephrol 199913(2):143–7. [PubMed: 10229004]
  174. Branger B, Vecina F, Zabadani B, et al Subcutaneous erythropoietin administration in predialysis patients: a single centre prospective study Nephrol Dial Transplant 199510Suppl 6:36–9. [PubMed: 8524492]
  175. Braumann KM Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron. 1991;58:129–34. [PubMed: 1865966]
  176. Brenner BM, Lazarus JM Chronic renal failure. In: Harrisons:Principles and practice of internal medicine. 13th ed. Vol. 2. New York: McGraw-Hill Inc. Health Professions Division; 1994. p. 1274-81.
  177. Briggs WA, Gimenez LF Clinical application of recombinant erythropoietin in predialysis renal failure Hematol Oncol Clin North Am 1994 Oct8(5):927–32. [PubMed: 7852215]
  178. Brown CD, Friedman EA Clinical and blood rheologic stability in erythropoietin-treated predialysis patients. Am J Nephrol. 1990;10 Suppl 2:29–33. [PubMed: 2260615]
  179. Brown CD Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year. Contrib Nephrol. 1991;88:182–9. [PubMed: 2040181]
  180. Brown JH, Maxwell AP, Doherty CC Subcutaneous erythropoietin therapy and hypertensive encephalopathy Nephrol Dial Transplant 19905(7):553–4. [PubMed: 2130309]
  181. Brown TM, Brown RL Neuropsychiatric consequences of renal failure Psychosomatics 199536(3):244–53. [PubMed: 7638311]
  182. Brown WS, Marsh JT, Wolcott D, et al Cognitive function, mood and P3 latency: effects of the amelioration of anemia in dialysis patients Neuropsychologia 199129(1):35–45. [PubMed: 2017307]
  183. Brunet P, Berland Y, Merzouk T, et al Effect of recombinant human erythropoietin treatment in uremic patients on oxygen affinity of hemoglobin Nephron 199466(2):147–52. [PubMed: 8139733]
  184. Brunkhorst R, Nonnast-Daniel B, Koch KM, et al Hypertension as a possible complication of recombinant human erythropoietin therapy. Contrib Nephrol. 1991;88:118–25; discussion 126. [PubMed: 2040173]
  185. Buemi M, Allegra A, Aloisi C, et al Different answer to recombinant human erythropoietin in anephric and non-anephric haemodialyzed patients Nephron 199056(2):218–9. [PubMed: 2243581]
  186. Buemi M, Allegra A, Aloisi C, et al Influence of the treatment with recombinant human erythropoietin on plasma concentration of interleukin-1-alpha and tumour necrosis factor-alpha in hemodialyzed subjects Nephron 199364(2):333–4. [PubMed: 8321378]
  187. Buemi M, Allegra A, Corica F, et al Recombinant erythropoietin and the cardiovascular risk in uremia Recenti Progressi In Medicina 199889(9):456–8. [PubMed: 9796377]
  188. Buemi M, Allegra A, Frisina N Erythropoietin: not only renal anaemia Giornale Italiano Di Nefrologia 199512(1):9–15.
  189. Bunn HF Anemia associated with chronic disorders. In: Harrisons: Principles and practice of internal medicine. 13th ed., Vol. 2. New York: McGraw-Hill Inc. Health Professions Division; 1994b. p.1732-34.
  190. Bunn HF Pathophysiology of the anemias. In: Harrisons: Principles and practice of internal medicine. 13th ed., Vol. 2. New York: McGraw-Hill Inc. Health Professions Division; 1994a. p. 1717-21.
  191. Burden R Management of chronic renal failure Practitioner 1991235(1499):154–60. [PubMed: 2034582]
  192. Burke JR Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Australian and New Zealand Paediatric Nephrology Association Pediatr Nephrol 1995 Oct9(5):558–61. [PubMed: 8580009]
  193. Burrows-Hudson S CQI and anemia management: maximizing positive outcomes. Case study of the anemic patient ANNA J 1997 Apr24(2):254–60; quiz 261. [PubMed: 9180430]
  194. Burtsev VI, Grankin VI, Briukhovetskii AG, et al [Some aspects of current treatment of patients with terminal chronic renal insufficiency] Klin Med (Mosk) 1993 Jan71(1):33–6. [PMC free article: PMC358319] [PubMed: 8046902]
  195. Butera E Case management of the anemic patient. Epoetin alfa: focus on quality of life ANNA J 1992 Aug19(4):410–1. [PubMed: 1520032]
  196. Buur T, Lundberg M Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients Clin Nephrol 1990 Nov34(5):230–5. [PubMed: 2268981]
  197. Cameron JS European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 1999;14:61–5. [PubMed: 10334669]
  198. Cameron JS Towards the millennium: a history of renal anaemia and the optimal use of epoetin. Nephrology Dial Transplant. 1999;14:10–21. [PubMed: 10334663]
  199. Campistrus N, Gadola L, Gossio E, et al Acute leukemia and erythropoietin: cause or casual relationship? Nephron 199569(1):–. [PubMed: 7891782]
  200. Campos A, Garin EH Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO) Clin Pediatr (Phila) 1992 Feb31(2):94–9. [PMC free article: PMC358331] [PubMed: 1544282]
  201. Canadian Erythropoietin Study Group Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis BMJ 1990 Mar 3300(6724):573–8. [PMC free article: PMC1662387] [PubMed: 2108751]
  202. Canaud B, Bennhold I, Delons S, et al What is the optimum frequency of administration of r-huepo for correcting anemia in hemodialysis patients? Dial Transplant. 1995;4:306–9.
  203. Canaud B, Bouloux C, Rivory JP, et al Erythropoietin-induced changes in protein nutrition: quantitative assessment by urea kinetic modeling analysis Blood Purif 19908(5):301–8. [PubMed: 2091690]
  204. Canaud B, Polito-Bouloux C, Garred LJ, et al Recombinant human erythropoietin: 18 months' experience in hemodialysis patients Am J Kidney Dis 1990 Feb15(2):169–75. [PubMed: 2301388]
  205. Canaud B, Polito-Bouloux C, Rivory JP, et al [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis] Nephrologie 199011(1):5–10. [PubMed: 2374643]
  206. Cannata-Andia JB Aluminium toxicity: its relationship with bone and iron metabolism Nephrol Dial Transplant 199611(Suppl 3):69–73. [PubMed: 8840317]
  207. Cannella G, Paoletti E Clues for understanding the pathogenesis of left ventricular hypertrophy in chronic uremia [editorial] Int J Artif Organs 1998 Jul21(7):378–83. [PubMed: 9745991]
  208. Capelli JP, Kushner H, Camiscioli T, et al Factors affecting survival of hemodialysis patients utilizing urea kinetic modeling. A critical appraisal of shortening dialysis times Am J Nephrol 199212(4):212–23. [PubMed: 1481868]
  209. Carlini R, Obialo CI, Rothstein M Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients Am J Hypertens 1993 Feb6(2):103–7. [PubMed: 8471228]
  210. Carlson HE, Graber ML, Gelato MC, et al Endocrine effects of erythropoietin Int J Artif Organs 1995 Jun18(6):309–14. [PubMed: 8593965]
  211. Carson JL, Duff A, Poses RM, et al Effect of anaemia and cardiovascular disease on surgical mortality and morbidity Lancet 1996348(9034):1055–60. [PubMed: 8874456]
  212. Caruso U, Leone L, Cravotto E, et al Effects of l-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: a pilot study Dialysis Transplant 199827(8):498–506.
  213. Casadevall N [Physiology of erythropoietin and its therapeutic use] Ann Pharm Fr 199654(4):151–6. [PubMed: 8881101]
  214. Casadevall N Erythropoietin and autologous blood predeposit: from the physiological secretion to rational exogenic supplementation Nouvelle Revue Francaise D'hematologie 199537(Suppl. 1):S11–S15. [PubMed: 7478980]
  215. Casadevall N Erythropoietin therapy Rev Med Interne 199112(6 Suppl.):–.
  216. Catlin DH, Hatton CK Use and abuse of anabolic and other drugs. Adv Intern Med. 1991;36:399–24. [PubMed: 1673818]
  217. Cavdar C, Camsari T, Semin I, et al Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin Scand J Urol Nephrol 1997 Aug31(4):371–5. [PubMed: 9290168]
  218. Cazzola M Erythropoietin: biology and clinical applications Forum Trends Exp Clin Med 19933(4):344–61.
  219. Cazzola M How and when to use erythropoietin Curr Opin Hematol 19985(2):103–8. [PubMed: 9570702]
  220. Cengiz K, Islek I Does erythropoietin cause epilepsy Nephron 199673(2):320–1. [PubMed: 8773367]
  221. Chagnac A, Weinstein T, Zevin D, et al Effects of erythropoietin on glucose tolerance in hemodialysis patients Clin Nephrol 1994 Dec42(6):398–400. [PubMed: 7882604]
  222. Chambers JK Case study of the anemic patient: epoetin alfa -- focus on blood pressure ANNA J 1994 Apr21(2):154–7. [PubMed: 8080316]
  223. Chambers JK Epoetin alfa: focus on inflammation and infection. Case study of the anemic patient ANNA J 1998 Jun25(3):353–6. [PubMed: 9801493]
  224. Chan WS, Okun N, Kjellstrand CM Pregnancy in chronic dialysis: a review and analysis of the literature Int J Artif Organs 1998 May21(5):259–68. [PubMed: 9684907]
  225. Chapman RF, Stray-Gundersen J, Levine BD Individual variation in response to altitude training J Appl Physiol 1998 Oct85(4):1448–56. [PubMed: 9760340]
  226. Cheng IK, Cy C, Chan MK, et al Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study Clin Nephrol 1991 May5(5):207–12. [PubMed: 1855328]
  227. Chiba S, Kikuchi M [Clinical significance of erythropoietin] Rinsho Byori 1985 Mar33(3):323–9. [PubMed: 4010004]
  228. Chmielewski CM Case study of the anemic patient: epoetin alfa -- focus on erythrokinetics ANNA J 1995 Aug22(4):420–3. [PubMed: 7654091]
  229. Churchill DN, Muirhead N, Goldstein M, et al Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients Clin Nephrol 1995Mar 43(3):184–8. [PubMed: 7774076]
  230. Churchill DN, Muirhead N, Goldstein M, et al Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin J Am Soc Nephrol 1994 Apr4(10):1809–13. [PubMed: 8068879]
  231. Churchill DN, Taylor DW, Cook RJ, et al Canadian Hemodialysis Morbidity Study Am J Kidney Dis 1992 Mar19(3):214–34. [PubMed: 1553966]
  232. Churchill DN Results of the Canadian morbidity study in end-stage renal disease patients treated by hemodialysis Semin Nephrol 1990 Mar10(2 Suppl 1):66–72. [PubMed: 2356368]
  233. Clemens MR Antioxidant therapy in hematological disorders. Adv Exp Med Biol. 1990;264:423–33. [PubMed: 2244523]
  234. Clyne N, Jogestrand T Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients Nephron 199260(4):390–6. [PubMed: 1584314]
  235. Cohen JA, Brattich M Epoetin alfa: focus on maintaining a higher, stable, Hct. Case study of the anemic patient ANNA J 1997 Oct24(5):574–80. [PubMed: 9392740]
  236. College J Epoetin alfa -- focus on nutritional therapy. Case study of the anemic patient ANNA J 1996 Aug23(4):416–9. [PubMed: 8900689]
  237. Collins A, Hao W, Ebben J, et al Hematocrit associated outcomes in incident peritoneal and hemodialysis patients. In: Abstracts, XVth International Congress of Nephrology, Buenos Aires, Argentina. May 2-6, 1999c. p. 70 (Abstract #280)
  238. Collins A, Hao W, Ebben J, et al Anemia correction in incident peritoneal dialysis patients is associated with lower hospitalization risk. J Am Soc Nephrol. 1999a;10:–.
  239. Collins A, Hao W, Ebben J, et al Higher hematocrit levels in incident hemodialysis patients are associated with lower hospitalization risks. J Am Soc Nephrol. 1999b;0:157A–158A.
  240. Collins AJ, Ebben JP, Ma X Clinical factors associated with changing hematocrit levels in hemodialysis patients. Semin Dialysis. 1999;12:S92–S96.
  241. Collins AJ, Keane WF Higher haematocrit levels: do they improve patient outcomes, and are they cost effective? Nephrol Dial Transplant 1998 Jul13(7):1627–9. [PubMed: 9681700]
  242. Collins AJ, Ma JZ, Xia A, et al Trends in anemia treatment with erythropoietin usage and patient outcomes Am J Kidney Dis 1998 Dec32(6 Suppl 4):S133–41. [PubMed: 9892380]
  243. Coppo R, Porcellini MG, Bonaudo R, et al Providing the right stuff: feeding children with chronic renal failure J Nephrol 1998 Jul-Aug11(4):171–6. [PubMed: 9702867]
  244. Corea AL Case management of the anemic patient: epoetin alfa -- focus on cognitive function ANNA J 1993 Jun20(3):350–3. [PubMed: 8352632]
  245. Costagliola C, Romano L, Scibelli G, et al Anemia and chronic renal failure: a therapeutical approach by reduced glutathione parenteral administration Nephron 199261(4):404–8. [PubMed: 1501736]
  246. Cotter DJ, Thamer M, Kimmel PL, et al Secular trends in recombinant erythropoietin therapy among the U. S. hemodialysis population: 1990-1996 Kidney International 199854(6):2129–39. [PubMed: 9853279]
  247. Cotton SL, Holechek MJ Management of anemia using recombinant human erythropoietin in patients on chronic hemodialysis ANNA J 1989 Dec16(7):463–8. [PubMed: 2604448]
  248. Cuero CJ, Perez Guardia E, de Rivera C [Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis] Rev Med Panama 1996 Jan-May21(1-2):55–9. [PubMed: 8966240]
  249. Culp K, Flanigan M, Taylor L, et al Vascular access thrombosis in new hemodialysis patients Am J Kidney Dis 199526(2):341–6. [PubMed: 7645539]
  250. Cutler M Administration of epoetin alfa. Case study of the anemic patient ANNA J 1997 Aug24(4):459–65. [PubMed: 9325701]
  251. Dabbagh S, Carroll CE, Fleishmann LE Recombinant human erythropoietin (rHuEPO) in pediatric pre-dialysis patients: a prospective study J Am Soc Nephrol 19912(3):–.
  252. Dabbagh S, Ryckaert, Carroll CE, et al Long-term follow-up of the efficacy of recombinant human erythropoietin (rHuEPO) in children maintained on hemo- (HD) and continuous peritoneal dialysis (CCPD) J Am Soc Nephrol 19912(3):–.
  253. Dainiak N The role of androgens in the treatment of anemia of chronic renal failure Semin Nephrol 1985 Jun5(2):147–54. [PubMed: 3843789]
  254. Dale GL, Alberio L Is there a correlation between raised erythropoietin and thrombotic events in sickle-cell anaemia? Lancet 1998 Aug15 352(9127):566–7. [PubMed: 9716076]
  255. Davenport A, King RF, Ironside JW, et al The effect of treatment with recombinant human erythropoietin on the histological appearance and glycogen content of skeletal muscle in patients with chronic renal failure treated by regular hospital haemodialysis Nephron 199364(1):89–94. [PubMed: 8502342]
  256. Davenport A, Will EJ, Khanna SK, et al Blood lactate is reduced following successful treatment of anaemia in haemodialysis patients with recombinant human erythropoietin both at rest and after maximal exertion Am J Nephrol 199212(5):357–62. [PubMed: 1489006]
  257. Davenport A The effect of treatment with recombinant human erythropoietin on skeletal muscle function in patients with end-stage renal failure treated with regular hospital hemodialysis Am J Kidney Dis 1993 Nov22(5):685–90. [PubMed: 8238014]
  258. Davison AM Management of pre-existing disorders in pregnancy: renal disease Prescribers' Journal 199737(1):46–53.
  259. Davison AM The dialysis patient today Nephrol Dial Transplant 199510(Suppl 10):2–6. [PubMed: 8825425]
  260. de Fijter CW, Popp-Snijders C, Oe LP, et al Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients? Haematologica 1995 Jul-Aug80(4):332–4. [PubMed: 7590502]
  261. de Leeuwe JN [Risks and considerations in air travel for patients with lung or heart disorders] Ned Tijdschr Geneeskd 1985129(26):1228–30. [PubMed: 4022170]
  262. De Marchi S, Cecchin E, Falleti E, et al Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients J Am Soc Nephrol 1997 Jul8(7):1147–56. [PubMed: 9219165]
  263. De Paoli Vitali E, Guglielmini C, Casoni I, et al Serum erythropoietin in cross-country skiers Int J Sports Med 19889(2):99–101. [PubMed: 3384528]
  264. de Sousa FT, Prata MM, Barbas JV, et al [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience] Acta Med Port 1990 Nov-Dec3(6):347–52. [PubMed: 2089856]
  265. Deamer RL, Prichard JG, Koenker N, et al Temafloxacin-induced hemolytic anemia and renal failure Clin Pharm 199312(5):380–2. [PubMed: 8391409]
  266. Debska-Slizien A, Biedunkiewicz B, Rutkowski B [Effect of human recombinant erythropoietin (r-EPO) on behavior of iron status parameters in patients with chronic renal failure treated with dialysis] Pol Arch Med Wewn 1994 Sep92(3):207–15. [PubMed: 7808929]
  267. Debska-Slizien A, Rutkowski B, Niemierko J, et al [Subcutaneous administration of recombinant human erythropoietin (R-EPO) in the treatment of anemia in predialysis patients with chronic renal failure] Pol Arch Med Wewn 1991 Jun85(6):334–40. [PubMed: 1896396]
  268. Deierhoi MH, Barger BO, Hudson SL, et al The effect of erythropoietin and blood transfusions on highly sensitized patients on a single cadaver renal allograft waiting list Transplantation 1992 Feb53(2):363–8. [PubMed: 1738931]
  269. Delano BG, Lundin AP, Galonsky R, et al Dialyzer urea and creatinine clearances are not significantly altered in erythropoietin treated maintenance hemodialysis patients ASAIO Trans 1990 Jan-Mar36(1):36–9. [PubMed: 2306389]
  270. Delucchi A, Fuentes A, Rodriguez E, et al Recombinant erythropoietin in children under hemodialysis Rev Chil Pediatr 199263(6):303–7.
  271. Deniston OL, Luscombe FA, Buesching DP, et al Effect of long-term epoetin beta therapy on the quality of life of hemodialysis patients ASAIO Trans 1990 Jul-Sep36(3):M157–60. [PubMed: 2123632]
  272. DeOreo PB Treatment of anemia of chronic renal failure Dialysis Transplant 199726(12):842–4.
  273. Depner TA, Rizwan S, James LA Effectiveness of low dose erythropoietin: a possible advantage of high flux hemodialysis ASAIO Trans 1990 Jul-Sep36(3):M223–5. [PubMed: 2252662]
  274. deStrihou C Should anaemia in subtypes of CRF patients be managed differently? Nephrol Dial Transplant. 1999;14:37–45. [PubMed: 10334666]
  275. Dhondt AW, Vanholder RC, Ringoir SM Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients Nephrol Dial Transplant 1995 Nov10(11):2107–9. [PubMed: 8643177]
  276. Di Iorio B, Terracciano V Bullous dermatosis in end-stage renal disease. Aluminum, iron and erythropoietin (1) Trace Elements And Electrolytes 199714(3):–.
  277. Dickey LL, Griffith HM, Kamerow DB Put prevention into practice: preventive care for anemia. U.S. Department of Health and Human Services J Am Acad Nurse Pract 1994 Jun6(6):267–9. [PubMed: 7702942]
  278. Diez-Ruiz A, Weiss G, Artner-Dworzak E, et al Association between haemoglobin and neopterin concentrations in haemodialysis patients treated with erythropoietin Eur J Haematol 1993 Sep51(3):175–6. [PubMed: 8405333]
  279. Dine G, Boffa GA, Van Lierde F, et al Erythropoietin and physical training at mid altitude (2200 m) Sci Sports 19949(3):167–8.
  280. Djukanovic LJ, Lezaic V [Treatment of anemia in patients with chronic renal insufficiency with recombinant human erythropoietin] Srp Arh Celok Lek 1996 Mar-Apr124(3-4):93–7. [PubMed: 9102827]
  281. Dorhout Mees EJ, Ok E Erythropoietin hypertension: fact or fiction? Int J Artif Organs 1997 Aug20(8):415–7. [PubMed: 9323502]
  282. Drinovec J, Varl J Subcutaneous erythropoietin in the treatment of renal anaemia Przegl Lek 199249(1-2):38–40. [PubMed: 1455004]
  283. Drueke T, Zins B, Bererhi L, et al [Use of recombinant erythropoietin in the treatment of anemia of chronic renal insufficiency] Presse Med 1989 Jun 2418(25):1235–7. [PubMed: 2525772]
  284. Drueke T, Zins B, Naret C, et al Erythropoietin and chronic renal failure Nouv Rev Fr Hematol 198931(2):97–8. [PubMed: 2771635]
  285. Drueke TB, Barany P, Cazzola M, et al Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients Clin Nephrol 1997 Jul48(1):1–8. [PubMed: 9247771]
  286. Duclos J, Olea C, Aguirre H, et al [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view] Rev Med Chil 1995 Apr123(4):451–5. [PubMed: 8525189]
  287. Duclos J, Sieberth H G, Mann H [Is it necessary to supplement with folic acid patients in chronic dialysis treated with erythropoietin?] Rev Med Chil 1993 Jan121(1):30–5. [PubMed: 8235161]
  288. Duff DR, Golper TA, Sloan RS, et al Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients Am J Kidney Dis 1991 Jul18(1):60–4. [PubMed: 2063856]
  289. Dunn CJ, Markham A Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure Drugs 1996 Feb51(2):299–318. [PubMed: 8808169]
  290. Dunn CJ, Wagstaff A J Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients Drugs Aging 1995 Aug7(2):131–56. [PubMed: 7579784]
  291. Durand-Zaleski I, Goldfarb B, Blum-Boisgard C, et al Cost of treating predialysis patients with recombinant human erythropoietin Nephrol Dial Transplant 19938(4):311–4. [PubMed: 8390004]
  292. Dy GR, Bloom EJ, Ijelu GK, et al Effect of recombinant human erythropoietin on vascular access. ASAIO Trans 1991 Jul-Sep;37(3):M274-5. [PubMed: 1751146]
  293. Dyras P, Pietrzyk J A, Sancewicz-Pach K, et al [Clinical and metabolic effects of erythropoietin administration in hemodialyzed children] Przegl Lek 199653(11):793–6. [PubMed: 9173441]
  294. Eckardt KU, Drueke T, Leski M, et al Unutilized reserves: the production capacity for erythropoietin appears to be conserved in chronic renal disease. Contrib Nephrol. 1991;88:18–31; discussion 32-4. [PubMed: 2040180]
  295. Eckardt KU Cardiovascular consequences of renal anaemia and erythropoietin therapy Nephrol Dial Transplant 19994(5):1317–23. [PubMed: 10344393]
  296. Eggers PW, Greer J, Jencks S The use of Health Care Financing Administration data for the development of a quality improvement project on the treatment of anemia Am J Kidney Dis 1994 Aug24(2):247–54. [PubMed: 8048432]
  297. Ehmer B, Messinger D, Scigalla P Influence of recombinant erythropoietin on transfusion need and iron metabolism variables in patients with end-stage renal failure Nieren-Hochdruckkr 199019(5):184–91.
  298. Ehrich JH, Loirat C, Brunner FP, et al Report on management of renal failure in children in Europe, XXII, 1991 Nephrol Dial Transplant 19927(Suppl. 2):36–48. [PubMed: 1338120]
  299. Eicher ER Better dead than second J Lab Clin Med 1992 Sep120(3):359–60. [PubMed: 1517679]
  300. Eisele G, Bailie GR, Clement C, et al Erythropoietin in continuous ambulatory peritoneal dialysis: experience with subcutaneous administration Perit Dial Int 199212(1):34–6. [PubMed: 1543777]
  301. Elisaf MS, Bairaktari E, Tzallas C, et al Atherogenic lipid and lipoprotein parameters in hemodialysis patients Dialysis Transplant 199524(11):642–6,648-50,660.
  302. Ellis PW EPO and renal nutrition-one year later. Evidence lacking in appetite improvement Nephrol News Issues 1990 Jun4(6):–. [PubMed: 2402308]
  303. El-Reshaid K, Johny KV, Sugathan TN, et al End-stage renal disease and renal replacement therapy in Kuwait -epidemiological profile over the past 4one-half years Nephrol. Dial. Transplant 19949(5):532–8. [PubMed: 8090333]
  304. Engfred K, Kjaer M, Secher NH, et al Hypoxia and training-induced adaptation of hormonal responses to exercise in humans Eur J Appl Physiol Occup Physiol 199468(4):303–9. [PubMed: 8055887]
  305. Eridani S Erythropoietin. Chapter for the monograph on haemopoietic growth factors Biotherapy 19902(4):294–8. [PubMed: 2176513]
  306. Ermolenko VM, Khvoinitskii VA, Suprun EK, et al [The effect of correcting anemia with recombinant erythropoietin on the central hemodynamic indices of patients on regular hemodialysis] Ter Arkh 199264(7):86–8. [PubMed: 1440377]
  307. Ermolenko VM, Lashutin SV, Rudakov AG, et al [The effect of treatment with human recombinant erythropoietin on the functional status of patients on maintenance hemodialysis] Ter Arkh 199163(6):81–6. [PubMed: 1948755]
  308. Erslev AJ, Besarab A Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure [editorial] Kidney Int 1997 Mar51(3):622–30. [PubMed: 9067892]
  309. Erslev AJ Erythropoietin coming of age N Engl J Med 1987316(2):101–3. [PubMed: 3785351]
  310. Erslev AJ Erythropoietin N Engl J Med 1991 May 9324(19):1339–44. [PubMed: 2017231]
  311. Eschbach JW Erythropoietin-associated hypertension N Engl J Med 1990323(14):999–1000. [PubMed: 2402271]
  312. Eschbach JW The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin [clinical conference] Kidney Int 1989 Jan35(1):134–48. [PubMed: 2651751]
  313. Eschbach JW, Abdulhadi MH, Browne JK, et al Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial Ann Intern Med 1989 Dec 15111(12):992–1000. [PubMed: 2688507]
  314. Eschbach JW, Adamson JW Anemia of end-stage renal disease (ESRD) Kidney Int 1985 Jul28(1):1–5. [PubMed: 3900528]
  315. Eschbach JW, Adamson JW Guidelines for recombinant human erythropoietin therapy Am J Kidney Dis 1989 Aug14(2 Suppl 1):2–8. [PubMed: 2667349]
  316. Eschbach JW, Adamson JW Modern aspects of the pathophysiology of renal anemia. Contrib Nephrol. 1988;66:63–70. [PubMed: 3292149]
  317. Eschbach JW, Aquiling T, Haley NR, et al The long-term effects of recombinant human erythropoietin on the cardiovascular system Clin Nephrol 199238Suppl 1:S98–103. [PubMed: 1295715]
  318. Eschbach JW, Downing MR, Egrie JC, et al USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients. Contrib Nephrol. 1989;76:160–5. [PubMed: 2684518]
  319. Eschbach JW, Egrie JC, Downing MR, et al Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial N Engl J Med 1987 Jan 8316(2):73–8. [PubMed: 3537801]
  320. Eschbach JW, Egrie JC, Downing MR, et al The safety of epoetin-alpha: results of clinical trials in the United States. Contrib Nephrol. 1991;88:72–80. [PubMed: 2040198]
  321. Eschbach JW, Glenny R, Robertson T, et al Normalizing the hematocrit (HCT) in hemodialysis patients (HDP) with EPO improves quality of life (Q/L) and is safe. J Am Soc Nephrol. 1993;4:–.
  322. Eschbach JW, Kelly MR, Haley NR, et al Treatment of the anemia of progressive renal failure with recombinant human erythropoietin N Engl J Med 1989 Jul 20321(3):158–63. [PubMed: 2747747]
  323. Estrella R, Hercberg S, Maggy G, et al Evaluation of iron-deficiency anemia by an iron supplementation trial in children living at a 2,800-m altitude Clin Chim Acta 1987 Apr 15164(1):1–6. [PubMed: 3581476]
  324. Ettenger RB, Marik J, Grimm P The impact of recombinant human erythropoietin therapy on renal transplantation Am J Kidney Dis 1991 Oct18(4 Suppl 1):57–61. [PubMed: 1928081]
  325. Evans JH, Brocklebank JT, Bowmer CJ, et al Pharmacokinetics of recombinant human erythropoietin in children with renal failure Nephrol Dial Transplant 19916(10):709–14. [PubMed: 1754107]
  326. Evans RW, Rader B, Manninen DL The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group JAMA 1990 Feb 9263(6):825–30. [PubMed: 2404150]
  327. Evans RW Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: a comparative analysis Am J Kidney Dis 1991 Oct18(4 Suppl 1):62–70. [PubMed: 1928082]
  328. Evans SJ Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients Nephron 199776(1):–. [PubMed: 9171310]
  329. Evens PE Update to Epogen information in article on future drug expenditures Am J Health Syst Pharm 1995 Jun 1552(12):1348–9. [PubMed: 7656127]
  330. Evers J Cardiac hemolysis and anemia refractory to erythropoietin: on anemia in dialysis patients Nephron 199571(1):–. [PubMed: 8538832]
  331. Ewing S, Crosby DL Renal transplantation for porphyria cutanea tarda N Engl J Med 1997336(11):–. [PubMed: 9064521]
  332. Exeni R, Donato H, Rendo P, et al Low levels of serum erythropoietin in children with endemic hemolytic uremic syndrome Pediatric Nephrol 199812(3):226–30. [PubMed: 9630043]
  333. Fabris F, Cordiano I, Girolami A Platelet count and volume in children with renal failure treated with human recombinant erythropoietin Platelets 19912(1):53–4. [PubMed: 21043963]
  334. Faller B, Slingeneyer A, Waller M, et al Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study Clin Nephrol 1993 Sep40(3):168–75. [PubMed: 8403573]
  335. Faller JP, Simon G, Rodier L, et al Acute renal failure, cholestatic jaundice, thrombocytopaenia and haemolytic anemia due to ajmaline hypersensitivity Ann Med Interne 1985136(5):386–8.
  336. Farley DO Financing of end-stage renal disease care: past, present, and future Adv Ren Replace Ther 1994 Apr1(1):24–31. [PubMed: 7641085]
  337. Faulds D, Sorkin EM Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis Drugs 1989 Dec38(6):863–99. [PubMed: 2693045]
  338. Fazakas L, Taraba I, Hering A Anabolic steroids in the treatment of anemia in patients on hemodialysis Nieren Hochdruckkr 198615(11):502–4.
  339. Fearing MO Case management of the anemic patient. Epoetin alfa: focus on sexual dysfunction ANNA J 1992 Dec19(6):570–1. [PubMed: 1292419]
  340. Fellner SK, Lang RM, Neumann A, et al Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin Kidney Int 1993 Dec44(6):1309–15. [PubMed: 8301932]
  341. Fernandez A, Hortal L, Rodriguez JC, et al Anemia in dialysis: its relation to acquired cystic kidney disease and serum levels of erythropoietin Am J Nephrol 199111(1):12–5. [PubMed: 2048573]
  342. Fernandez A, Vega N, Jimenez F, et al Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients Am J Nephrol 199212(4):207–11. [PubMed: 1481867]
  343. Ferrare, DeVita MV, Zabetakis PM, et al Bioelectric impedance and hemodynamic analysis in hemodialysis patients receiving rhuepo Dialysis Transplant 199322(11):668,672–5.
  344. Fillastre JP, Singlas E Pharmacokinetics of newer drugs in patients with renal impairment Clin Pharmacokin 199120(4):293–310. [PubMed: 2036748]
  345. Fine RN Subcutaneous recombinant human erythropoietin treatment of children undergoing peritoneal dialysis. Contrib Nephrol. 1991;89:186–9. [PubMed: 1893725]
  346. Fischer C, Scigalla P, Park W, et al Influence of rhEPO therapy on the protein metabolism of hemodialysis patients with terminal renal insufficiency. Contrib Nephrol. 1989;76:250–6. [PubMed: 2684526]
  347. Fishbane S, Frei GL, Maesaka JK Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation Am J Kidney Dis 199526(1):41–6. [PubMed: 7611266]
  348. Fishbane S, Kowalski EA, Imbriano LJ, et al The evaluation of iron status in hemodialysis patients J Am Soc Nephrol 19967(12):2654–7. [PubMed: 8989744]
  349. Fishbane S, Lynn RI The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients Clin Nephrol 1995 Oct44(4):238–40. [PubMed: 8575123]
  350. Fishbane S, Maesaka JK Iron management in end-stage renal disease Am J Kidney Dis 1997 Mar29(3):319–33. [PubMed: 9041207]
  351. Fisher JW Erythropoietin: physiologic and pharmacologic aspects Proc Soc Exp Biol Med 1997216(3):358–69. [PubMed: 9402140]
  352. Fitts SS, Guthrie MR, Blagg CR Exercise coaching and rehabilitation counseling improve quality of life for predialysis and dialysis patients Nephron 199982(2):115–21. [PubMed: 10364702]
  353. Fivush BA, Jabs K, Neu AM, et al Chronic renal insufficiency in children and adolescents: the 1996 Annual Report of NAPRTCS. North American Pediatric Renal Transplant Cooperative Study Pediatr Nephrol 1998 May12(4):328–37. [PubMed: 9655366]
  354. Flechner SM Etiology and pathogenesis of renal failure Curr Opin Urol 19933(2):99–106.
  355. Foley RN, Parfrey PS, Harnett JD, et al The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease Am J Kidney Dis 199628(1):53–61. [PubMed: 8712222]
  356. Foley RN, Parfrey PS, Morgan J, et al A randomized controlled trial of complete vs. partial correction of anemia in hemodialysis patients with asymptomatic concentric LV hypertrophy or LV dilatation. J Am Soc Nephrol. 1998;9:–.
  357. Foley RN, Parfrey PS Commentary: cardiomyopathy of anemia and the potential of erythropoietin Perit Dial Int 1997 Mar-Apr17(2):117–8. [PubMed: 9159828]
  358. Foley RN A randomized controlled trial of complete vs. partial correction of anemia in hemodialysis patients with asymptomatic concentric LV hypertrophy or LV dilatation. J Am Soc Nephrol. 1998;9:–.
  359. Foley RN The cardiovascular effects of r-huepo in end-stage renal disease Erythropoiesis: New dimensions in the treatment of anaemia 19956(1):3–7.
  360. Franke W, Scherhag Tolerability and efficacy of multidose formulations of epoetin beta Clinical Drug Investigation 199713(4):199–206.
  361. Frankenfield DL, Prowant BF, Flanigan MJ, et al Trends in clinical indicators of care for adult peritoneal dialysis patients in the United States from 1995 to 1997. Kidney Int. 1999;55:1998–2010. [PubMed: 10231465]
  362. Frenken LA, Koene RA [Recombinant human erythropoietin] Ned Tijdschr Geneeskd 1988 Mar 5132(10):432–4. [PubMed: 3347279]
  363. Frenken LA, Koene RA [The use of erythropoietin] Ned Tijdschr Geneeskd 1991 Feb 2135(5):163–6. [PubMed: 2002863]
  364. Frenken LA, Verberckmoes R, Michielsen P, et al Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients Nephrol Dial Transplant 19894(9):782–6. [PubMed: 2516609]
  365. Friedlaender MM, Azem O, Rubinger D, et al Effect of human recombinant erythropoietin therapy on panel reactive antibodies in chronic dialysis patients Isr J Med Sci 1996 Sep32(9):730–6. [PubMed: 8865827]
  366. Friedlander MA, Hricik DE Optimizing end-stage renal disease therapy for the patient with diabetes mellitus Semin Nephrol 1997 Jul17(4):331–45. [PubMed: 9241718]
  367. Friedman EA, Delano BG Recombinant human erythropoietin in the diabetic patient Semin Nephrol 1990 Mar10(2 Suppl 1):35–9. [PubMed: 2192415]
  368. Frifelt JJ, Tvedegaard E, Bruun K, et al Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly Perit Dial Int 1996 Nov-Dec16(6):594–8. [PubMed: 8981527]
  369. Fuchs J Case study of the anemic patient: epoetin alfa-focus on inflammation ANNA J 1994 Feb21(1):78–81. [PubMed: 8141637]
  370. Fukushima Y, Nakamoto Y, Miura AB, et al The inhibitory factors of hematopoiesis in chronic hemodialysis patients treated with recombinant human erythropoietin Tohoku J Exp Med 1990161(3):217–25. [PubMed: 2247892]
  371. Gabriel R Treating renal anaemia with erythropoietin Br Med J 1990300(6728):–.
  372. Gagnadoux MF, Loirat C, Bertheleme JP, et al [Treatment of anemia in hemodialyzed children using recombinant human erythropoietin (Eprex). Results of a French multicenter clinical trial] Nephrologie 199415(3):207–11. [PubMed: 7969713]
  373. Gahl GM, Eckardt KU Erythropoietin 1997: a brief update Perit Dial Int 199717Suppl 2:S84–90. [PubMed: 9163805]
  374. Garcia Martin F, Carrascosa Vallejo T, Martin Escobar E, et al [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis] Rev Clin Esp 1990 May186(9):419–22. [PubMed: 2247677]
  375. Gareau R, Brisson GR, Chenard C, et al Possible discrimination between training in altitude and erythropoietin doping Science And Sports 199510(2):81–2.
  376. Gareau R, Gagnon MG, Ayotte C, et al rHuEPO increases urinary excretion of fibrin degradation products in haemodialysed patients Thromb Haemost 1993 Aug 270(2):373–4. [PubMed: 8236152]
  377. Gerbase-DeLima M, Frugiuele PL, Lieber, et al Cellular immunity in multitransfused nonuremic patients Transplant Proc 198517(6):2432–34.
  378. Ghysen A Erythropoietin as medication of the future in renal failure Louvain Med 1989108(5):315–320.
  379. Gibson SP, Cockwell P, Robinson BH, et al Responsiveness to recombinant human erythropoietin Nephrol Dial Transplant 19938(6):–. [PubMed: 8394543]
  380. Gillio AP Potential use of recombinant human hematopoietic growth factors in pediatrics Curr Opin Pediatr 19924(2):319–26.
  381. Gilman C Case management of the anemic patient. Epoetin alfa: focus on pediatric dialysis patients ANNA J 1992 Oct19(5):496–7. [PubMed: 1456798]
  382. Giorgianni V Anemia in association with chronic renal failure: treatment with recombinant erythropoietin Rass Med Interna 199011(5):295–8.
  383. Gokal R, Mallick NP Continuous ambulatory peritoneal dialysis Prescr J 199232(6):251–6.
  384. Goldberg N, Lundin AP, Delano B, et al Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin Am Heart J 1992 Aug124(2):424–7. [PubMed: 1386184]
  385. Goldwasser P, Avram MM, Collier JT, et al Correlates of vascular access occlusion in hemodialysis Am J Kidney Dis 199424(5):785–94. [PubMed: 7977320]
  386. Golper TA The effect of recombinant erythropoietin on the early hematocrit rise after CAPD initiation Perit Dial Int 199212(1):37–9. [PubMed: 1543778]
  387. Goodnough LT, Despotis GJ, Hogue CW Jr, et al On the need for improved transfusion indicators in cardiac surgery Ann Thorac Surg 199560(2):473–80. [PubMed: 7646127]
  388. Goodnough LT Recombinant human erythropoietin - Could it be used in a better way? In: Alternative Approaches to Human Blood Resources in Clinical Practice, CTS Sibinga, PC Das, JC Fratantoni, eds. Dordrecht: Kluwer Academic Publishers; 1998. p. 75-9.
  389. Gore C, Craig N, Hahn A, et al Altitude training at 2690m does not increase total haemoglobin mass or sea level VO2max in world champion track cyclists J Sci Med Sport 1998 Sep1(3):156–70. [PubMed: 9783517]
  390. Graf H, Mayer G, Cada EM, et al Effectiveness of recombinant human erythropoietin in the treatment of transfusion dependent anaemia in patients on chronic haemodialysis Wien Klin Wochenschr 198799(24):855–9. [PubMed: 3439185]
  391. Graf H Effectiveness and safety of recombinant human erythropoietin in predialysis patients J Am Soc Nephrol 19912(3):–.
  392. Granolleras C, Branger B, Beau M C, et al Experience with daily self-administered subcutaneous erythropoietin. Contrib Nephrol. 1989;76:143–7. [PubMed: 2684516]
  393. Granolleras C, Branger B, Deschodt G, et al Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients. Contrib Nephrol. 1990;82:49–54. [PubMed: 2093526]
  394. Granolleras C, Branger B, Deschodt G, et al Two years experience of daily self-administered subcutaneous erythropoietin Blood Purif 19908(5):268–71. [PubMed: 2091686]
  395. Granolleras C, Branger B, Shaldon S, et al Subcutaneous erythropoietin: a comparison of daily and thrice weekly administration. Contrib Nephrol. 1991;88:144–8; discussion 149-51. [PubMed: 2040176]
  396. Graudal N, Galloe AM, Nielsen OJ Erythropoietin in chronic obstructive pulmonary disease. Relationship between serum erythropoietin, blood hemoglobin and lung function -effect of the calcium antagonist isradipine on serum erythropoietin Respiration 199158(3-4):141–4. [PubMed: 1836066]
  397. Gretz N, Lasserre JJ, Meisinger E, et al Potential side-effects of erythropoietin Lancet 1987 Jan 31(8523):–. [PubMed: 2879127]
  398. Grimm AM, Flaharty KK, Hopkins LE, et al Economics of epoetin therapy Clin Pharm 19898(11):807–10. [PubMed: 2509130]
  399. Grunze M, Kohlmann M, Mulligan M, et al Mechanisms of improved physical performance of chronic hemodialysis patients after erythropoietin treatment Am J Nephrol 199010(Suppl 2):15–8; discussion 18-23. [PubMed: 2124412]
  400. Grutzmacher P, Bergmann M, Low-Friedrich I, et al Cardiac effects of long-term treatment of renal anemia by recombinant erythropoietin Nieren-Hochdruckkr 199019(5):192–8.
  401. Grutzmacher P, Bergmann M, Weinreich T, et al Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis. Contrib Nephrol. 1988;66:104–13. [PubMed: 3292143]
  402. Grutzmacher P, Scheuermann E, Low I, et al Correction of renal anaemia by recombinant human erythropoietin: effects on myocardial function. Contrib Nephrol. 1988;66:176–84. [PubMed: 3292146]
  403. Grzeszczak W, Zukowska-Szczechowska E, Galwas B, et al [Concentrations of lead in blood of patients with chronic renal failure] Pol Arch Med Wewn 1994 Apr91(4):247–56. [PubMed: 8072884]
  404. Grzeszczak W, Zukowska-Szczechowska E [Circadian rhythm of pituitary-thyroid hormones in patients with chronic renal failure treated by hemodialysis] Pol Arch Med Wewn 199492(Spec No):21–30. [PubMed: 7731896]
  405. Gunga HC, Frommhold M, Hildebrandt W, et al Erythropoietin production during flights with pressurised aircrafts Lancet 1996 Aug 10348(9024):–. [PubMed: 8709772]
  406. Gunga HC, Kirsch K, Rocker L, et al Time course of erythropoietin, triiodothyronine, thyroxine, and thyroid-stimulating hormone at 2,315 m J Appl Physiol 1994 Mar76(3):1068–72. [PubMed: 8005846]
  407. Gunga HC, Rocker L, Behn C, et al Shift working in the Chilean Andes (> 3,600 m) and its influence on erythropoietin and the low-pressure system J Appl Physiol 1996 Aug81(2):846–52. [PubMed: 8872655]
  408. Guthrie M, Cardenas D, Eschbach JW, et al Effects of erythropoietin on strength and functional status of patients on hemodialysis Clin Nephrol 1993 Feb39(2):97–102. [PubMed: 8448925]
  409. Haberl M Erythropoietin Aust Nurses J 1990 Sep20(2):–.
  410. Haedersdal C, Mehlsen J, Stenver D, et al Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure Angiology 1994Mar 45(3):231–4. [PubMed: 8129205]
  411. Halstenson CE, Macres M, Katz SA, et al Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta Clin Pharmacol Ther 1991 Dec50(6):702–12. [PubMed: 1752115]
  412. Hanicki Z, Sulowicz W, Stepniewski M, et al [Recombinant human erythropoietin stimulates synthesis of fetal hemoglobin in patients with renal anemia treated by repeated hemodialysis] Pol Arch Med Wewn 1991 Jun85(6):352–5. [PubMed: 1716757]
  413. Hanicki Z, Sulowicz W, Stepniewski M, et al Recombinant human erythropoietin stimulates synthesis of fetal haemoglobin in haemodialysed patients with anaemia due to end-stage kidney. Contrib Nephrol. 1990;87:11–4. [PubMed: 1709603]
  414. Hannah R, Levin NW, London R, et al Renal disease in the managed care setting: Selection and monitoring of outcome criteria Am J Kidney Dis 199933(4):S1–S24. [PubMed: 10214346]
  415. Harnett JD, Kent GM, Foley RN, et al Cardiac function and hematocrit level Am J Kidney Dis 1995 Apr25(4 Suppl 1):S3–7. [PubMed: 7702071]
  416. Harnett JD, Le Cardiovascular effects of erythropoietin Dialysis Transplant 199322(9):–.
  417. Harper G EPO -- one year later: a look at rehabilitation A patient perspective -- from patients. Nephrol News Issues 1990 Jun4(6):–. [PubMed: 2402311]
  418. Harris DC, Chapman JR, Stewart JH, et al Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis Aust NZ J Med 1991 Oct21(5):693–700. [PubMed: 1759917]
  419. Harsfalvi J, Boda Z, Mikita J, et al Effect of recombinant human erythropoietin on plasma von Willebrand factor in chronic hemodialysis patients (4) Am. J. Hematol 199447(2):144–5. [PubMed: 8092134]
  420. Harvengt C Drugs recently released in Belgium. Recombinant human erythropoietin-nizatidine Acta Clin Belg 198944(6):419–20. [PubMed: 2576492]
  421. Hatch FE Reversing the anemia of renal failure Hosp Pract (Off Ed) 1990 Feb 2825(2A):25–34. [PubMed: 2105980]
  422. Hegbrant J, Thysell H, Ekman R Erythropoietin treatment and plasma levels of corticotropin-releasing hormone, delta sleep-inducing peptide and opioid peptides in hemodialysis patients Scand J Urol Nephrol 199226(4):393–6. [PubMed: 1337953]
  423. Held PJ, Port FK, Webb RL, et al Excerpts from the USRDS 1995 annual data report Am J Kidney Dis 199526(4 Suppl.):S1–S186. [PubMed: 7573030]
  424. Held PJ, Port FK, Webb RL, et al United States Renal Data System 1996 annual data report Am J Kidney Dis 199628(3 Suppl.):S1–S165. [PubMed: 8804227]
  425. Hendrix WR Epoetin alfa -- focus on optimal hematocrit. Case study of the anemic patient ANNA J 1996 Feb23(1):46–9. [PubMed: 8702361]
  426. Henry DH, Spivak JL Clinical use of erythropoietin Curr Opin Hematol 1995 Mar2(2):118–24. [PubMed: 9371981]
  427. Henry DH Epoetin alfa and high-dose chemotherapy Semin Oncol 1998 Jun25(3 Suppl 7):54–7. [PubMed: 9671332]
  428. Hensley MK Case management of the anemic patient. Epoetin alfa: focus on nutrition management ANNA J 1990 Oct17(5):390–1. [PubMed: 2241257]
  429. Hisano S, Kaku Y, Ueda K, et al Human erythropoietin in children undergoing continuous ambulatory peritoneal dialysis Acta Paediatr Jpn 1992 Feb34(1):36–41. [PubMed: 1580151]
  430. Hoen B, Paul-Dauphin A, Hestin D, et al EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients J Am Soc Nephrol 19989(5):869–76. [PubMed: 9596085]
  431. Holechek MJ, Watson AJ Case management of the anemic patient. Focus on blood pressure and rHuEPO therapy ANNA J 1990 Feb17(1):72–3. [PubMed: 2317107]
  432. Holley JL, Schmidt RJ, Bender FH, et al Gynecologic and reproductive issues in women on dialysis Am J Kidney Dis 199729(5):685–90. [PubMed: 9159301]
  433. Hood VL, Ingraham A Erythropoietin for chronic ambulatory peritoneal dialysis patients: once a week can be enough J Am Soc Nephrol 1992 Apr2(10):1545–6. [PubMed: 1600126]
  434. Horina JH, Fazekas F, Niederkorn K, et al Cerebral hemodynamic changes following treatment with erythropoietin Nephron 199158(4):407–12. [PubMed: 1922604]
  435. Horina JH, Horn S, Silly H, et al Need for erythropoietin treatment in predialysis patients Lancet 1991 Mar 2337(8740):–. [PubMed: 1671931]
  436. Horl WH, Schaefer RM Recombinant human erythropoietin therapy for renal anemia J. Nephrol 19892(4):277–90.
  437. Hortian B, Schmidt R, Wustenberg PW, et al [Ergometric results of r-erythropoietin treatment of hemodialysis patients] Z Gesamte Inn Med 1990 May15 45(10):274–7. [PubMed: 2392856]
  438. Hosokawa S, Yoshida O Effects of erythropoietin on trace elements in patients with chronic renal failure undergoing hemodialysis Nephron 199365(3):414–7. [PubMed: 8289992]
  439. Hossli S Developing an anemia management protocol. Case study of the anemic patient ANNA J 1997 Dec24(6):678–84; quiz 685. [PubMed: 9444110]
  440. Hou CC, Wu SC, Wu SC, et al Serum transferrin receptor concentration is not indicative of erythropoietic activity in chronic hemodialysis patients with poor response to recombinant human erythropoietin Chin Med J (Taipei) 199861(8):456–62. [PubMed: 9745161]
  441. Hou SH Frequency and outcome of pregnancy in women on dialysis Am J Kidney Dis 1994 Jan23(1):60–3. [PubMed: 8285199]
  442. House AA, Pham B, Page DE Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities Nephrol Dial Transplant 1998 Jul13(7):1763–9. [PubMed: 9681725]
  443. Hsia CC Respiratory function of hemoglobin New England Journal Of Medicine 1998, 0122 1998338(4):239–47. [PubMed: 9435331]
  444. Huang TP, Lin CY Intraperitoneal recombinant human erythropoietin therapy: influence of the duration of continuous ambulatory peritoneal dialysis treatment and peritonitis Am J Nephrol 199515(4):312–7. [PubMed: 7573189]
  445. Hughes RT, Cotes PM, Pippard MJ, et al Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment Br J Haematol 1990 Jun75(2):268–73. [PubMed: 2372513]
  446. Humphries JE Anemia of renal failure. Use of erythropoietin Med Clin North Am 1992 May76(3):711–25. [PubMed: 1578966]
  447. Huppmann M, Hief C, Schenk E, et al [Erythropoietin therapy in renal anemia. Effect on ergospirometry performance parameters] Wien Med Wochenschr Suppl 1989104(suppl):48–50. [PubMed: 2588635]
  448. Hussein MM, Bakir N, Roujouleh H Low-dose recombinant human erythropoietin in dialysis patients living at high altitude Nephrol Dial Transplant 19927(2):173–4. [PubMed: 1314980]
  449. Hymes, Hawthorne, Clowers Impaired response to recombinant human erythropoietin therapy in children with peritonitis Dial Transplant 199423(8):462–3.
  450. Icardi A, Paoletti E, Molinelli G Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD. Adv Perit Dial. 1990;6:292–5. [PubMed: 1982830]
  451. Ifudu O, Chan E, Paul H, et al Anemia severity and missed dialysis treatments in erythropoietin-treated hemodialysis patients ASAIO Journal 199642(3):146–9. [PubMed: 8725679]
  452. Ifudu O, Dawood M, Homel P Erythropoietin-induced elevation in blood pressure is immediate and dose dependent Nephron 1998 Aug79(4):486–7. [PubMed: 9689173]
  453. Ifudu O, Friedman EA Economic implications of inadequate response to erythropoietin inpatients with end-stage renal disease Dial Transplant 199726(10):664–9.
  454. Ifudu O, Macey LJ, Friedman EA Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients ASAIO J 1995 Jul-Sep41(3):M426–30. [PubMed: 8573839]
  455. Ifudu O, Paul H, Mayers JD, et al Pervasive failed rehabilitation in center-based maintenance hemodialysis patients Am J Kidney Dis 1994 Mar23(3):394–400. [PubMed: 8128941]
  456. Imarisio P, Biamino E, Bongiorno P, et al [Erythropoietin treatment in Piedmont and Valle d'Aosta] Minerva Urol Nefrol 1991 Jul-Sep43(3):143–5. [PubMed: 1817336]
  457. Imiela J, Korczak-Kowalska G, Malecki R, et al Immunomodulatory action of human recombinant erythropoietin in man Immunol Lett 1993 Mar35(3):271–5. [PubMed: 8514337]
  458. Isarangkura P, Chantarojanasiri T, Hathirat P, et al Pulmonary and platelet function in mild form of Hb H disease Southeast Asian J Trop Med Public Health 199324 p. 70(Suppl 1):210–2. [PubMed: 7886577]
  459. Iseki K, Nishime K, Uehara H, et al Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients Nephron 199672(1):30–6. [PubMed: 8903858]
  460. Ishiguro N [Effect of recombinant human erythropoietin on cytosolic free calcium concentration in platelets] Nippon Jinzo Gakkai Shi 1994 Mar36(3):250–8. [PubMed: 8196222]
  461. Ishimitsu T, Tsukada H, Ogawa Y, et al Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin Am J Med 1993 Apr94(4):401–6. [PubMed: 8475933]
  462. Ishimura E, Nishizawa Y, Okuno S, et al Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure J Nephrol 1998 Mar-Apr11(2):83–6. [PubMed: 9589379]
  463. Ismail N, Ikizler TA Erythropoietin-induced hypertension J Med Liban 199745(1):25–30. [PubMed: 9421942]
  464. Ismail N Use of erythropoietin, active vitamin D3 metabolites, and alkali agents in predialysis patients Semin Nephrol 1997 Jul17(4):270–84. [PubMed: 9241713]
  465. Ito K, Hattori M [Erythropoietin treatment in children with chronic renal failure] Nippon Rinsho 1991 Dec49(Suppl):688–94. [PubMed: 1808336]
  466. Jaar B, Denis A, Viron B, et al Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation Am J Nephrol 199717(5):399–405. [PubMed: 9382155]
  467. Jabs K, Harmon WE Recombinant human erythropoietin therapy in children on dialysis Adv Ren Replace Ther 1996 Jan3(1):24–36. [PubMed: 8620365]
  468. Jacobs C Normalization of haemoglobin: why not? Nephrol Dial Transplant 199914(suppl 2):75–9. [PubMed: 10334671]
  469. Jacobs C Starting r-HuEPO in chronic renal failure: when, why, and how? Nephrol Dial Transplant 199510(suppl 2):43–7. [PubMed: 7644105]
  470. Jacobs K, Shoemaker C, Rudersdorf R, et al Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313:806–10. [PubMed: 3838366]
  471. Jacquot C, Berthelot JM, Chiappini-Judith D, et al [Treatment of anemia in chronic hemodialysis patients with recombinant human erythropoietin: long-term results in 15 patients] Nephrologie 199011(1):11–6. [PubMed: 2374641]
  472. Jacquot C, Rossert J Does the normalization of hematocrit by recombinant erythropoietin increase the vascular and thrombotic risks in renal failure patients? Sang Thromb Vaiss 19902(5):271–3.
  473. Jacquot C A drug for hospital use: recombinant erythropoietin. Rev Prat Med Gen. 1990;(89):11–3.
  474. Janvier G, Roth C, Benillan N, et al [Blood transfusion in surgery: can it still be reduced by human recombinant erythropoietin]? Ann Fr Anesth Reanim 199615(8):1219–29. [PubMed: 9636798]
  475. Jelkmann W [Recurrence of anemia after discontinuation of erythropoietin substitution.] Dtsch Med Wochenschr 1991 Jul 12116(28-29):–. [PubMed: 2065604]
  476. Jelkmann W Erythropoietin: structure, control of production, and function Physiol Rev 199272(2):449–89. [PubMed: 1557429]
  477. Jelkmann W Recombinant erythropoietin Pharm Ztg 1991136(27):9–13.
  478. Jensen JD, Eiskjaer H, Bagger JP, et al Elevated level of erythropoietin in congestive heart failure relationship to renal perfusion and plasma renin J Intern Med 1993 Feb233(2):125–30. [PubMed: 8433072]
  479. Jensen JD, Madsen JK, Jensen LW, et al Pharmacokinetics of epoetin in dialysis patients before and after correction of the anaemia Drug Invest 19948(5):278–87.
  480. Jensen JD, Madsen JK, Jensen LW Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin Eur J Clin Pharmacol 199650(3):171–7. [PubMed: 8737755]
  481. Ji SM, Li LS, Ji DX [Clinical studies of recombinant human erythropoietin in patients on long-term dialysis] Chung Hua Nei Ko Tsa Chih 1993 Feb32(2):100–2. [PubMed: 8404323]
  482. Jim RT Use of erythropoietin in Jehovah's Witness patients Hawaii Med J 1990 Jun49(6):–. [PubMed: 2397990]
  483. Johnson CA, Rosowski E, Zimmerman SW A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN. Adv Perit Dial. 1992;8:444–7. [PubMed: 1361844]
  484. Johnson WJ, McCarthy JT, Yanagihara T, et al Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability Kidney Int 1990 Nov38(5):919–24. [PubMed: 2266676]
  485. Jones MA, Kingswood JC, Dallyn PE, et al Changes in diurnal blood pressure variation and red cell and plasma volumes in patients with renal failure who develop erythropoietin-induced hypertension Clin Nephrol 1995 Sep44(3):193–200. [PubMed: 8556836]
  486. Jones MA, Kingswood JC, Dallyn PE, et al Haemodynamic changes measured by transthoracic bioimpedance during treatment with recombinant human erythropoietin Clin Exp Hypertens 1996 Jan18(1):51–64. [PubMed: 8822233]
  487. Jonnalagadda V, Bloom E J, Raja R M Importance of iron saturation for erythropoietin responsiveness in chronic peritoneal dialysis. Adv Perit Dial. 1997;13:113–5. [PubMed: 9360662]
  488. Jungers P, Joly D, Massy Z, et al Effect of recombinant erythropoietin therapy on the rate of progression of chronic renal failure. J Am Soc Nephrol. 1998;9:–.
  489. Junor BJ Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful Perit Dial Int 199313(Suppl 2):S535–7. [PubMed: 8399658]
  490. Juric M, Rupcic V, Topuzovic N, et al Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin Nephrol Dial Transplant 199510(8):1398–404. [PubMed: 8538932]
  491. Kaizu K, Uriu K, Eto S Effects of recombinant human erythropoietin (EPOCH) on the coagulation and fibrinolytic systems and platelet function in pre-dialysis patients with chronic renal failure Nippon Jinzo Gakkai Shi 1993 Aug35(8):989–97. [PubMed: 8255011]
  492. Kaizu K, Uriu K, Eto S Effects of recombinant human erythropoietin (epoch) on the coagulation and fibrinolytic systems and platelet function in pre-dialysis patients with chronic renal failure Jpn J Nephrol 199335(8):989–97. [PubMed: 8255011]
  493. Kakuk G, Karpati I, Matyus J [Recombinant human erythropoietin in the therapy of anemia in hemodialyzed patients] Orv Hetil 1990 Oct 28131(43):2365–6, 2369-71. [PubMed: 2234936]
  494. Kamenetz Y, Beloosesky Y, Zeltzer C, et al Relationship between routine hematological parameters, serum IL-3, IL-6 and erythropoietin and mild anemia and degree of function in the elderly Aging (Milano) 1998 Feb10(1):32–8. [PMC free article: PMC305699] [PubMed: 9589749]
  495. Kameyama M, Kosugi E, Kobayashi Het al Effects of recombinant human erythropoietin on intractable leg edema in diabetic patients with predialysis chronic renal failure, and its mechanism Journal Of The Medical Society Of Toho University 199643(4):281–5.
  496. Kampf D Special drug treatment in dialysis patients Pharm Ztg 1993138(47):9–13.
  497. Kaplan BS, Vedaranayanan VV Pathogenesis of the hemolytic uremic syndromes: current concepts Indian J Pediatr 198855(4):512–25. [PubMed: 3049333]
  498. Kaufman JS, Reda DJ, Fye CL, et al Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients N Engl J Med 1998339(9):578–83. [PubMed: 9718376]
  499. Kaupke CJ, Vaziri ND, Sampson JR, et al Effect of erythropoietin therapy on diet and dialysis clearances in hemodialysis patients Int J Artif Organs 1990 Apr13(4):218–22. [PubMed: 2373550]
  500. Kaupke CJ, Vaziri ND Effect of recombinant erythropoietin on electrolytes and nutrition in end-stage renal disease patients Int J Artif Organs 1993 Feb16(2):59–62. [PubMed: 8486413]
  501. Kavadias D, Fourtounas C, Tsouchnikas J, et al L-carnitine and erythropoietin requirements in hemodialysis patients Am J Kidney Dis 1996 Jul28(1):–. [PubMed: 8712214]
  502. Keown PA Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study Group. Contrib Nephrol. 1991;88:81–6; discussion 87-9. [PubMed: 2040199]
  503. Kes P, Reiner Z, Starcevic B, et al Influence of erythropoietin treatment on dialyzer reuse Blood Purif 199715(2):77–83. [PubMed: 9087814]
  504. Kessler M, Legrand E, Mertes M, et al Treatment of chronic renal failure anemia by recombinant erythropoietin and polycythemia following kidney transplantation Nephron 199262(3):370–1. [PubMed: 1436359]
  505. Kinouchi T, Koide K, Shimizu N [Body fluids balance in chronic hemodialysis patients] Nippon Rinsho 1992 Jan50(Suppl):465–74. [PubMed: 1578725]
  506. Kinugasa E, Nabeshima K, Niikura K, et al [The effects of r-HuEPO on platelet function and coagulation factors in hemodialysis patients] Nippon Jinzo Gakkai Shi 1990 Oct32(10):1109–16. [PubMed: 2287103]
  507. Kirlin L Case management of the anemic patient. Epoetin alfa: focus on hematocrit ANNA J 1992 Feb19(1):66–7. [PubMed: 1546890]
  508. Kirlin LF Case management of the anemic patient: epoetin alfa-focus on iron supplementation ANNA J 1993 Dec20(6):678–81. [PubMed: 8267412]
  509. Kirlin LF Case study of the anemic patient: epoetin alfa-focus on iron management ANNA J 1995 Apr22(2):192–5. [PubMed: 7786067]
  510. Klahr S Anemia, dialysis, and dollars N Engl J Med 1996 Feb15 334(7):461–3. [PubMed: 8552151]
  511. Kleinman KS, Schweitzer SU, Perdue ST, et al The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial Am J Kidney Dis 1989 Dec14(6):486–95. [PubMed: 2688405]
  512. Kleinman KS, Schweitzer SU Human recombinant erythropoietin (rHuEPO) treatment of severe anemia associated with progressive renal failure may delay the need to initiate regular dialytic therapy Kid Int 199037(1):–.
  513. Klinkmann H, Schmidt R, Wieczorek L, et al Adverse events of subcutaneous recombinant human erythropoietin therapy. Contrib Nephrol. 1992;100:127–38. [PubMed: 1458898]
  514. Klinkmann H, Wieczorek L, Scigalla P Adverse events of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study Artif Organs 1993 Apr7(4):219–25. [PubMed: 8498900]
  515. Koch KM, Koene RA, Messinger D, et al The use of epoetin beta in anemic predialysis patients with chronic renal failure Clin Nephrol 1995 Sep44(3):201–8. [PubMed: 8556837]
  516. Koch KM [The treatment of renal anemia] Verh Dtsch Ges Inn Med. 1989;95:246–8. [PubMed: 2603482]
  517. Koene RA, Frenken LA Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function? Contrib Nephrol. 1990;87:105–12. [PubMed: 2093536]
  518. Koene RA, Frenken LA Starting r-HuEPO in chronic renal failure: when, why, and how? Nephrol Dial Transplant 199510(Suppl 2):35–42. [PubMed: 7644104]
  519. Kohler M, Morsdorf S, Jung F, et al [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters] Beitr Infusionsther. 1990;26:89–95. [PubMed: 1703909]
  520. Koide K, Arai T [Erythropoietin-complications, side effects] Nippon Rinsho 1991 Dec49(Suppl):679–87. [PubMed: 1808335]
  521. Koide K, Sano M, Takeda F, et al [Anemia in acute renal failure and chronic renal failure] Nippon Rinsho 1991 Mar49(3):685–9. [PubMed: 2041197]
  522. Kokot F, Wiecek A, Grzeszczak W, et al [The effect of erythropoietin treatment on endocrine organ function in patients with terminal-stage kidney failure on hemodialysis] Ter Arkh 199163(6):86–9. [PubMed: 1948756]
  523. Kokot F, Wiecek A, Grzeszczak W, et al Influence of erythropoietin treatment on function of the pituitary-adrenal axis and somatotropin secretion in hemodialyzed patients Clin Nephrol 1990 May33(5):241–6. [PubMed: 2162262]
  524. Kokot F, Wiecek A, Grzeszczak W, et al Influence of erythropoietin treatment on glucose tolerance, insulin, glucagon, gastrin and pancreatic polypeptide secretion in haemodialyzed patients with end-stage renal failure. Contrib Nephrol. 1990;87:42–51. [PubMed: 2093540]
  525. Kokot F, Wiecek A, Schmidt-Gayk H, et al Influence of long-term erythropoietin therapy on endocrine abnormalities in haemodialyzed patients Przegl Lek 199249(1-2):43–9. [PubMed: 1455006]
  526. Kokot F, Wiecek A Evidence that the anemia of renal failure participates in overall uremic toxicity. Kidney Int Suppl. 1997 Nov;62:S83–6. [PubMed: 9350689]
  527. Konoshita T, Okamoto K, Koni I, et al Clinical characteristics of polycystic kidney disease with end-stage renal disease Clinical Nephrology 199850(2):113–7. [PubMed: 9725783]
  528. Kooistra MP, van Es A, Marx JJ, et al Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin Nephrol Dial Transplant 19949(8):1115–20. [PubMed: 7800210]
  529. Kooistra MP, van Es A, Struyvenberg A, et al Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin Br J Haematol 1991 Dec79(4):634–9. [PubMed: 1772785]
  530. Kooman JP, Leunissen KM Malnutrition in patients with end-stage renal disease: diagnosis, pathophysiology and treatment Neth J Med 199750(3):120–32. [PubMed: 9121596]
  531. Korbet SM, Vonesh EF, Firanek CA The effect of hematocrit on peritoneal transport Am J Kidney Dis 1991 Nov18(5):573–8. [PubMed: 1951337]
  532. Koury MJ Investigating erythropoietin resistance N Engl J Med 1993 Jan21;328(3):205–6. [PubMed: 8417388]
  533. Kovac A, Demes M, Gonzalvesova E, et al [Chronic renal insufficiency] Vnitr Lek 1996 Jul42(7):503–6. [PubMed: 8928431]
  534. Kovac A, Demes M, Pavlovic M, et al [Chronic renal insufficiency. Present views on pathogenesis, clinical aspects and treatment] Vnitr Lek 1996 Jan42(1):49–53. [PubMed: 8629361]
  535. Krantz SB Review of patients' responses to epoetin alfa therapy Pharmacotherapy 1990 Mar-Apr10(2(Pt 2)):15S–21S. [PubMed: 2189124]
  536. Krawczyk W, Dmoszynska A, Ledwozyw A, et al Human erythropoietin changes fatty acids composition of blood platelet phospholipids in hemodialyzed patients Nephron 199569(3):–. [PubMed: 7753283]
  537. Krawczyk W, Dmoszynska A, Ledwozyw A [The influence of recombinant human erythropoietin on platelet phospholipid fatty acid composition in patients on long term hemodialysis] Pol Merkuriusz Lek 1996 Dec1(6):394–7. [PubMed: 9273229]
  538. Krmar RT, Gretz N, Klare B, et al Renal function in predialysis children with chronic renal failure treated with erythropoietin Pediatr Nephrol 1997 Feb11(1):69–73. [PubMed: 9035175]
  539. Krug C, Messinger D, Scigalla P Influence of rhepo on renal anaemia and linear growth in children with end-stage renal disease Nieren-Hochdruckkr 199221(3):120–4.
  540. Kubasik A, Debska-Slizien A, Dudziak M, et al [Effect of treatment with erythropoietin (r-EPO) on hemodynamics of the cardiovascular system in patients with chronic renal failure (c.r.f.)] Pol Arch Med Wewn 1994 Sep92(3):217–22. [PubMed: 7808930]
  541. Kubiak W, Karwacki M, Mazur I Human recombinant erythropoietin: progress in clinical development Ann Univ Mariae Curie Sklodowska [Med] 199448(Suppl 3):39–50. [PubMed: 8192531]
  542. Kubitscheck J German-Dutch multicenter study: no aggravation of kidney function due to therapy with erythropoietin Tw Urol Nephrol 19946(3):132–3.
  543. Kulzer P, Schaefer RM, Krahn R, et al Effectiveness and safety of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia of chronic renal failure in non dialysis patients. European Multicentre Study Group Int J Artif Organs 1994 Apr17(4):195–202. [PubMed: 8070941]
  544. Kuo PC, Alfrey EJ, Scandling JD, et al Endovascular stenting of the abdominal aorta following renal transplantation Transplantation 199458(4):522–4. [PubMed: 8073524]
  545. Kurihara S, Marumo F [Aluminum and iron deposition in dialysis patients] Nippon Rinsho 1992 Jan50(Suppl):905–10. [PubMed: 1578787]
  546. Kuriyama S, Hopp L, Yoshida H, et al Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients Am J Hypertens 1996 May9(5):426–31. [PubMed: 8735172]
  547. Kuriyama S, Tomonari H, Yoshida H, et al Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients Nephron 199777(2):176–85. [PubMed: 9346384]
  548. Kurtz A, Eckardt KU Erythropoietin production in chronic renal disease before and after transplantation. Contrib Nephrol. 1990;87:15–25. [PubMed: 2093537]
  549. Kusunoki M, Kimura K, Nakamura M, et al Effects of hematocrit variations on cerebral blood flow and oxygen transport in ischemic cerebrovascular disease J Cereb Blood Flow Metabol 19811(4):413–7. [PubMed: 7328151]
  550. Kutner NG, Cardenas DD, Bower JD Rehabilitation, aging and chronic renal disease Am J Phys Med Rehabil 199271(2):97–101. [PubMed: 1558740]
  551. Lacombe C, Mayeux P, Casadevall N Erythropoietin: its role in the physiopathology of erythropoiesis and therapeutic applications Feuill. Biol 199132(182):11–5.
  552. Lambert KE Recombinant human erythropoietin Can Nurse 1990 Nov86(10):27–8. [PubMed: 2224810]
  553. Landar' VA, Sarycheva TG, Shemetov VD, et al Anemia in patients on systematic hemodialysis for chronic renal failure Urol Nefrol 198954(1):54–5.
  554. Landgraf H, Grutzmacher P, Garcia-Bartels C, et al Effect of erythropoietin treatment on tissue oxygenation in patients with severe transfusion dependent renal anaemia Eur J Med 1993 Aug-Sep2(7):393–7. [PubMed: 8258026]
  555. Lang SM, Schiffl H Losartan and anaemia of end-stage renal disease Lancet 1998352(9141):–. [PubMed: 9853467]
  556. Lankiewicz M, Goodman W, Spivak JL The clinical promise of erythropoietin Im Int Med 199213(5):55–6,59,62-5.
  557. Lasserre JJ, Greger S, Kortsik C, et al Erythropoietin: a safe drug? Nieren-Hochdruckkr 198918(5):205–10.
  558. Lataste A, Chuet C, Finielz P, et al [Megakaryocytes in the blood of a patient treated with erythropoietin] Presse Med 1991 Oct 520(31):–. [PubMed: 1835054]
  559. Laupacis A, Wong C, Churchill D The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group Control Clin Trials 1991 Aug12(4 Suppl):168S–179S. [PubMed: 1663853]
  560. Laupacis A A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients Transplant Proc 199123(2):1825–6. [PubMed: 2053167]
  561. Laupacis A Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group Semin Nephrol 1990 Mar10(2 Suppl 1):11–9. [PubMed: 2192412]
  562. Laurence A, Duley JA, Simmonds HA, et al Erythrocyte CDP-choline accumulation in haemolytic anaemia and renal failure (RF) Adv Exp Med Biol. 1998;431:155–9. [PubMed: 9598050]
  563. Laville M, Fouque D Muscular function in chronic renal failure. Adv Nephrol Necker Hosp. 1995;24:245–69. [PubMed: 7572412]
  564. Lawrence IG, Price DE, Howlett TA, et al Erythropoietin and sexual dysfunction Nephrol Dial Transplant 1997 Apr12(4):741–7. [PubMed: 9141005]
  565. Lazebnik N, Jaffa AJ, Peyeser MR Hemolytic-uremic syndrome in pregnancy. Review of the literature and report of a case Obstet Gynecol Surv 198540(10):618–21. [PubMed: 3903577]
  566. Lebel M, Kingma I, Grose J H, et al Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients Am J Hypertens 1995 Jun8(6):545–51. [PubMed: 7662237]
  567. Leon-Velarde F, Monge CC, Vidal A, et al Serum immunoreactive erythropoietin in high altitude natives with and without excessive erythrocytosis Exp Hematol 1991 May19(4):257–60. [PubMed: 2055289]
  568. Leschke M, Gradaus F, Schoebel FC, et al Coronary heart disease in patients in terminal renal failure Deutsche Medizinische Wochenschrift 1997122(31-32):976–82. [PubMed: 9267338]
  569. Leski M The treatment of chronic renal insufficiency induced anemia with recombinant human erythropoietin Med Hyg 199048(1830):547–49.
  570. Levin A, Singer J, Thompson CR, et al Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention Am J Kidney Dis 1996 Mar27(3):347–54. [PubMed: 8604703]
  571. Levin A, Thompson CR, Ethier J, et al Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin Am J Kidney Dis 199934(1):125–34. [PubMed: 10401026]
  572. Levin A Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention Am J Kidney Dis 199627(3):347–54. [PubMed: 8604703]
  573. Levin NW How should anaemia be managed in pre-dialysis patients? Nephrol Dial Transplant. 1999;14:66–74. [PubMed: 10334670]
  574. Levin NW Quality of life and hematocrit level Am J Kidney Dis 1992 Jul20(1 Suppl 1):16–20. [PubMed: 1626552]
  575. Levin NW, Lazarus JM, Nissenson AR National Cooperative rHu Erythropoietin Study in patients with chronic renal failure-an interim report. The National Cooperative rHu Erythropoietin Study Group Am J Kidney Dis 1993 Aug22(2 Suppl 1):3–12. [PubMed: 8352269]
  576. Levy JK, Leski M Erythropoietin in the treatment of anemia in hemodialysis patients Med. Hyg 198947(1783):561–6.
  577. Lewis NP, Macdougall IC, Willis N, et al The ventilatory cost of exercise compared in chronic heart failure and chronic renal anaemia Q J Med 1992 Jul83(303):523–31. [PubMed: 1484929]
  578. Lim VS Does correction of anemia with recombinant human erythropoietin accelerate the progression of renal insufficiency? Semin Nephrol 1990 Mar10(2 Suppl 1):26–7. [PubMed: 2356366]
  579. Lim VS Recombinant human erythropoietin in predialysis patients Am J Kidney Dis 1991 Oct18(4 Suppl 1):34–7. [PubMed: 1928077]
  580. Lim PS, Yeh CH, Hung TS Effects of recombinant human erythropoietin on echocardiographic findings in elderly dialysis patients Nephrology 19973(2):149–54.
  581. Lim VS, DeGowin RL, Zavala D, et al Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial Ann Intern Med 1989 Jan15 110(2):108–14. [PubMed: 2909202]
  582. Lim VS, Fangman J, Flanigan MJ, et al Effect of recombinant human erythropoietin on renal function in humans Kidney Int 1990 Jan37(1):131–6. [PubMed: 2299799]
  583. Lim VS, Kirchner PT, Fangman J, et al The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency Am J Kidney Dis 1989 Dec14(6):496–506. [PubMed: 2596476]
  584. Lin F-K, Suggs S, Lin C-H et al Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA. 1985;82:7580–84. [PMC free article: PMC391376] [PubMed: 3865178]
  585. Linblad AS, Nolph KD Hematocrit values in the CAPD/CCPD population: a report of the National CAPD Registry Perit Dial Int 199010(4):275–8. [PubMed: 2096927]
  586. Linde T, Wahlberg J, Wikstrom B, et al Outcome of renal transplantation in patients treated with erythropoietin Clin Nephrol 1992 May37(5):260–3. [PubMed: 1606776]
  587. Linde T, Wikstrom B, Andersson LG, et al Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease Scand J Urol Nephrol 1996 Apr30(2):115–20. [PubMed: 8738056]
  588. Lipkin GW, Kendall R, Haggett P, et al Erythropoietin in acute renal failure Lancet 1989 May 61(8645):–. [PubMed: 2565512]
  589. Locatelli F, Conte F, Marcelli D The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-the experience of the Lombardy Dialysis Registry Nephrol Dial Transplant 1998 Jul13(7):1642–4. [PubMed: 9681705]
  590. London G, Marchais S, Guerin A, et al Contributive factors to cardiovascular hypertrophy in renal failure Am J Hypertens 19892(11 Ii Suppl.):261s–265s. [PubMed: 2530994]
  591. Lopez-Gomez JM, Jofre R, Moreno F, et al rHuEpo before dialysis and in dialysed patients Nephrol Dial Transplant 199510(Suppl 6):31–5. [PubMed: 8524491]
  592. Lorch JA, Pollak VE Anemia management: one patient at a time Nephrol News Issues 1997 Sep11(9):–. [PubMed: 9348866]
  593. Low I, Grutzmacher P, Bergmann M, et al Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin Clin Nephrol 1989 Jan31(1):26–30. [PubMed: 2521587]
  594. Low-Friedrich I, Grutzmacher P, Marz W, et al Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients Am J Nephrol 199111(1):54–60. [PubMed: 1828650]
  595. Lowrie EG, Huang WH, Lew NL, et al The relative contribution of measured variables to death risk among hemodialysis patients. In: Friedman EA, ed. Death on hemodialysis. Dordrecht: Kluwer Academic Publishers; 1994. Chapter 13, p. 121-41.
  596. Lubrich-Birkner I, Schollmeyer P, Steinhauer HB One year experience with subcutaneous human erythropoietin in CAPD: correction of renal anemia and increased ultrafiltration. Adv Perit Dial. 1990;6:302–7. [PubMed: 1982833]
  597. Ludwig H, Fritz E, Leitgeb C, et al Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors Ann Oncol 1993Feb 4(2):161–7. [PubMed: 8448084]
  598. Ludwig H, Pecherstorfer M, Leitgeb C, et al Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin Cancer 199473(10):2535–42. [PubMed: 8174050]
  599. Lue TF Normalization of serum prolactin levels in hemodialysis patients on recombinant human erythropoietin: editorial comment J Urol 1990144(2 I):404–5.
  600. Lui SL 1996 Hong Kong renal registry report: central renal committee Nephrology 19973(6):577–581.
  601. Lundin AP, Akerman MJ, Chesler RM, et al Exercise in hemodialysis patients after treatment with recombinant human erythropoietin Nephron 199158(3):315–9. [PubMed: 1910154]
  602. Lundin AP, Delano BG, Quinn-Cefaro R Perspectives on the improvement of quality of life with epoetin alfa therapy Pharmacotherapy 1990 Mar-Apr10(2) Pt 2)):22S–26S. [PubMed: 2345708]
  603. Lundin AP Finding logic in the hematocrit measurement audit Nephrol News Issues 1998Jun 12(6):–. [PubMed: 9697470]
  604. Lundin AP Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy Semin Nephrol 1989 Mar9(1 Suppl 1):22–9. [PubMed: 2648517]
  605. Ma JZ, Ebben J, Xia H, et al Hematocrit level and associated mortality in hemodialysis patients J Am Soc Nephrol 199910(3):610–9. [PubMed: 10073612]
  606. Macdougall IC, Cavill I, Davies ME, et al Subcutaneous recombinant erythropoietin in the treatment of renal anaemia in CAPD patients. Contrib Nephrol. 1989;76:219–26. [PubMed: 2582780]
  607. Macdougall IC, Davies ME, Hutton RD, et al Rheological studies during treatment of renal anaemia with recombinant human erythropoietin Br J Haematol 1991 Apr77(4):550–8. [PubMed: 2025581]
  608. Macdougall IC, Hutton RD, Cavill I, et al Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously BMJ 1989 Jul 15299(6692):157–8. [PMC free article: PMC1837074] [PubMed: 2504356]
  609. Macdougall IC, Lewis NP, Saunders MJ, et al Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin Lancet 1990 Mar 3335(8688):489–93. [PubMed: 1968526]
  610. Macdougall IC, McMahon LP Satellite symposium at XIVth international congress of nephrology, Sydney, Australia, 25 May, 1997, future challenges in optimizing the use of r-huEPO in CRF: Foreword Nephrol Dial Transplant 199813(Suppl. 2):–.
  611. Macdougall IC, Ritz E 2nd European Epoetin Symposium - Optimizing anaemia therapy in CRF - 17-19 April 1998 Crete, Greece - Foreword. Nephrol Dial Transplant. 1999;14:–.
  612. Macdougall IC, Tucker B, Thompson J, et al A randomized controlled study of iron supplementation in patients treated with erythropoietin Kidney Int 1996 Nov50(5):1694–9. [PubMed: 8914038]
  613. Macdougall IC Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin Nephrol Dial Transplant 199813(Suppl 2):23–7. [PubMed: 9566487]
  614. MacDougall IC Poor response to erythropoietin should be fully investigated and treated BMJ 1995310(6992):1424–25. [PMC free article: PMC2549809] [PubMed: 7613268]
  615. Macdougall IC Quality of life and anemia: the nephrology experience Semin Oncol 1998 Jun25(3 Suppl 7):39–42. [PubMed: 9671329]
  616. MacDougall IC The Normal Haematocrit Trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Nephrol Dial Transplant. 1998;13:3030–3. [PubMed: 9870460]
  617. Macdougall IC Treatment of renal anemia with recombinant human erythropoietin Curr Opin Nephrol Hypertens 1992 Dec1(2):210–9. [PubMed: 1345620]
  618. Maddox N, Futral D, Boudreau FT Serologic investigation of fatal hemolytic anemia associated with a multiple drug history and rh-like autoantibody Immunohematology 19928(3):70–76. [PubMed: 15946061]
  619. Madore F, Lowrie E G, Brugnara C, et al Anemia in hemodialysis patients: variables affecting this outcome predictor J Am Soc Nephrol 1997 Dec8(12):1921–9. [PubMed: 9402095]
  620. Mahler W Erythropoietin instead of transfusions Fortschr Med 1990108(34):–.
  621. Mahnensmith RL Advances in nephrology: a selected review of progress in care of the patient with renal failure R I Med J 1990 Nov73(11):507–15. [PubMed: 2263848]
  622. Mailloux LU, Haley WE Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions Am J Kidney Dis 199832(5):705–19. [PubMed: 9820438]
  623. Mairbaurl H, Schobersberger W, Hasibeder W, et al Increase in Hb-O2-affinity at moderate altitude (2000 m) in patients on maintenance hemodialysis Clin Nephrol 198931(4):198–203. [PubMed: 2714024]
  624. Mairbaurl H Red blood cell function in hypoxia at altitude and exercise Int J Sports Med 1994 Feb15(2):51–63. [PubMed: 8157369]
  625. Majdan M, Ksiazek A, Koziol M, et al Comparison of plasma erythropoietin concentrations and iron status in hemodialyzed patients not requiring and requiring rHuEpo therapy Nephron 199673(3):425–9. [PubMed: 8832602]
  626. Mak RH Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia Am J Physiol 1996 May270(5 Pt 2):F839–44. [PubMed: 8928846]
  627. Mak RH Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia J Pediatr 1996 Jul129(1):97–104. [PubMed: 8757568]
  628. Makil D, Gibel LJ, Tzamaloukas AH CAPD in patients with failure of hemodialysis vascular access Perit Dial Int 199818(5):534–6. [PubMed: 9848635]
  629. Mall T, Schmitt HE, Widmer LK Arterial occlusions in iron deficiency anemia with thrombocytosis Vasa 198514(2):188–90. [PubMed: 4013501]
  630. Malone M, Bailie GR, Eisele G The effect of recombinant human erythropoietin on the quality of life of CAPD patients J App Ther 19961(1):39–43.
  631. Malyszko J, Malyszko JS, Borawski J, et al A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy Thromb Res 1995 Jan 1577(2):133–43. [PubMed: 7740505]
  632. Mann JF What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant. 1999;14:29–36. [PubMed: 10334665]
  633. Marichal JF, Brignon P, Fender M, et al Human recombinant erythropoietin: the new treatment of anaemia in hemodialysis patients. Practical sights J Med Strasbourg 199021(8):436–8.
  634. Marichal JF, Masson M [Correction of anemia with human recombinant erythropoietin in a pregnant woman with renal failure] Rev Med Interne 1994 Feb15(2):149–50. [PubMed: 8059125]
  635. Marisavljevic D, Djukanovic LJ, Lezajic V [The effect of recombinant human erythropoietin on erythrocyte lines in patients with anemia and chronic renal insufficiency] Srp Arh Celok Lek 1992 Sep-Oct120(9-10):281–5. [PubMed: 1306020]
  636. Markham A, Bryson HM Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications Drugs 199549(2):232–54. [PubMed: 7729331]
  637. Markowitz GS, Kahn GA, Feingold RE, et al An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin Clin Nephrol 1997 Jul48(1):34–40. [PubMed: 9247776]
  638. Marrades R M, Roca J, Campistol J M, et al Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure J Clin Invest 1996 May 197(9):2092–100. [PMC free article: PMC507284] [PubMed: 8621799]
  639. Marrades RM, Alonso J, Roca J, et al Cellular bioenergetics after erythropoietin therapy in chronic renal failure J Clin Invest 1996 May 197(9):2101–10. [PMC free article: PMC507285] [PubMed: 8621800]
  640. Marsen TA, Pollok M, Baldamus CA [Erythropoietin: from established therapeutic procedures in renal anemia to future areas of use] Med Klin 1992 Apr 1587(4):207–14. [PubMed: 1579099]
  641. Marsh JT, Brown WS, Wolcott D, et al rHuEPO treatment improves brain and cognitive function of anemic dialysis patients Kidney Int 1991 Jan39(1):155–63. [PubMed: 2002629]
  642. Martin GR, Ongkingo JR, Turner ME, et al Recombinant erythropoietin (Epogen) improves cardiac exercise performance in children with end-stage renal disease Pediatr Nephrol 1993 Jun7(3):276–80. [PubMed: 8518098]
  643. Martin JF, Moncada S Blood pressure, erythropoietin, and nitric oxide Lancet 19881(8586):–. [PubMed: 2894570]
  644. Martin-Lester M Cognitive function in dialysis patients. Case study of the anemic patient ANNA J 1997 Jun24(3):359–65; quiz 366. [PubMed: 9238909]
  645. Martino, Vogel, O'Brien, et al Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis J Am Coll Surg 1998187(6):616–9. [PubMed: 9849735]
  646. Martins Prata M, Teixeira de Sousa F, Barbas J, et al [Arterial hypertension in patients with chronic kidney insufficiency in hemodialysis with erythropoietin] Rev Port Cardiol 1990 Feb9(2):119–23. [PubMed: 2346662]
  647. Martins Prata M, Teixeira de Sousa F, Barbas J, et al Blood lipids in haemodialysis patients treated with erythropoietin Nephrol Dial Transplant 19905(6):–. [PubMed: 2122328]
  648. Mason K, McMahon LP Normalization of haemoglobin in haemodialysis patients: A comparative study. 14th International Congress of Nephrology; 1997. S305.
  649. Mason K, Skinner SL, Sangkabutra T, et al Effects of erythropoietin on cardiac mass and function, ambulatory blood pressure and blood volumes at comparative levels of haemoglobin. 14th International Congress of Nephrology; 1997. S305.
  650. Mat O, Stolear JC, Georges B Blood lipid profile in hemodialysis patients treated with human erythropoietin Nephron 199260(2):236–7. [PubMed: 1553011]
  651. Mathers T Epoetin alfa-focus on the geriatric patient. Case study of the anemic patient ANNA J 1995 Oct22(5):494–7. [PubMed: 7487195]
  652. Mathur PC, Kumar N, Shanker A, et al Post exercise electrocardiographic changes in iron deficiency anaemia: effect of iron therapy Indian Heart J 1988 Nov-Dec40(6):488–91. [PubMed: 3248810]
  653. Mathur V, Bretan PN Jr, Tomlanovich S Management of end-stage renal disease: transplantation or dialysis? Curr Opin Urol 19944(2):95–99.
  654. Matsushita Y, Hara S [Glucose intolerance in patients with chronic renal failure] Nippon Rinsho 1998 Jan56(Suppl 3):616–21. [PubMed: 9513487]
  655. Matyus J, Ujhelyi L, Karpati I, et al Usefulness and risk of erythropoietin therapy in pregnancies of patients with chronic renal insufficiency Nephrol Dial Transplant 1996 Aug11(8):1670–1. [PubMed: 8856240]
  656. Mavromatidis K, Fytil C, Kynigopoulou P, et al Serum ferritin levels are increased in patients with acute renal failure Clin Nephrol 1998 May49(5):296–8. [PubMed: 9617492]
  657. Mayer G, Cada EM, Watzinger U, et al Hemodynamic effects of partial correction of chronic anemia by recombinant human erythropoietin in patients on dialysis Am J Kidney Dis 199117(3):286–9. [PubMed: 1996570]
  658. Mayer G, Horl W H Cardiovascular effects of increasing hemoglobin in chronic renal failure Am J Nephrol 199616(4):263–7. [PubMed: 8739276]
  659. Mayer G, Thum J, Graf H Anaemia and reduced exercise capacity in patients on chronic haemodialysis Clin. Sci 198976(3):265–8. [PubMed: 2924518]
  660. McCarthy JT Anemia, cardiovascular disease, and erythropoietin therapy in chronic renal failure patients ACC Curr J Rev 19976(6):29–32.
  661. McEvoy GK, ed Epoetin alfa. In: AHFS drug information 1999. Bethesda: American Society of Health-System Pharmacists; 1999.
  662. McGonigle RJ, Boineau FG, Beckman B, et al Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease J Lab Clin Med 1985 Apr105(4):449–58. [PubMed: 3981057]
  663. McGregor E, Stewart G, Junor BJ, et al Successful use of recombinant human erythropoietin in pregnancy Nephrol Dial Transplant 19916(4):292–3. [PubMed: 1881584]
  664. McMahon LP, Dawborn JK Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin Am J Nephrol 199010(5):404–8. [PubMed: 2080791]
  665. McMahon LP, Dawborn JK Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin Am J Nephrol 199212(3):162–9. [PubMed: 1415377]
  666. McMahon LP, McKenna MJ, Sangkabutra T, et al Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients Nephrol Dial Transplant 199914(5):1182–7. [PubMed: 10344359]
  667. McMahon LP Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant. 1992;7:1199–206. [PubMed: 1337160]
  668. McMahon LP Towards an optimal level of haemoglobin in end-stage renal failure Erythropoiesis: New dimensions in the treatment of anaemia 19956(1):8–15.
  669. McNamee P, van Doorslaer E, Segaar R Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin Int J Technol Assess Health Care 1993 Fall9(4):490–504. [PubMed: 8288425]
  670. Meier W, Paulitschke M, Lerche D, et al Action of rHuEpo on mechanical membrane properties of red blood cells in children with end-stage renal disease Nephrol Dial Transplant 19916(2):110–6. [PubMed: 1857522]
  671. Meierhenrich R, Jedicke H, Voigt A, et al The effect of erythropoietin on lactate, pyruvate and excess lactate under physical exercise in dialysis patients Clin Nephrol 1996 Feb45(2):90–7. [PubMed: 8846536]
  672. Melappioni M, Giansanti R, Boemi M, et al Hemorheologic change before recombinant human erythropoietin treatment in chronic haemodialytic patients Minerva Urol Nefrol 199244(2):155–9. [PubMed: 1411865]
  673. Merkus MP Physical symptoms and quality of life in patients on chronic dialysis: results of the Netherlands Cooperative Study on Adequacy of Dialysis. Nephrol Dial Transplant. 1999;14:1163–70. [PubMed: 10344356]
  674. Metry G, Wikstrom B, Valind S, et al Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients J Am Soc Nephrol 199910(4):854–63. [PubMed: 10203371]
  675. Michel C, Queffelou G, Hufnagel G, et al Recombinant human erythropoietin and chronic kidney failure Hematologie 19973(2 Suppl.):76–9.
  676. Micheloyannis S, Papadaki F, Jannopoulos A The effect of blood transfusion on alpha EEG activity in thalassemic patients Eur Neurol 199131(3):131–5. [PubMed: 2044625]
  677. Mileto G, Mazzeo RS, Princi P, et al Subcutaneous erythropoietin in long term treatment of renal anemia G Ital Nefrol 19918(1):35–42.
  678. Mimura N [Treatment of patients with chronic kidney failure] Nippon Naika Gakkai Zasshi 1992 Mar 1081(3):412–6. [PubMed: 1607806]
  679. Minetti L Erythropoietin treatment in renal anemia. How high should the target hematocrit be? J Nephrol 199710(3):117–9. [PubMed: 9238619]
  680. Mingardi G, Cornalba L, Cortinovis E, et al Health-related quality of life in dialysis patients. A report from an Italian study using the SF-36 Health Survey Nephrol Dial Transplant 199914(6):1503–10. [PubMed: 10383015]
  681. Mittal SK, Maesaka JK, Fishbane S Diagnosis of iron deficiency in end-stage renal disease Seminars in Dialysis 199912(4):231–4.
  682. Mittman N Predictors of mortality in hemodialysis (HD): Analysis of serial data over six years J Am Soc Nephol 1993 Mar3(9):1613–22.
  683. Mizuguchi T, Minakuchi J, Kawahara K, et al [Serum transferrin receptor level as an index of the response to erythropoietin therapy for anemia in pre-dialysis patients with chronic renal failure] Nippon Jinzo Gakkai Shi 1997 Jul39(5):497–502. [PubMed: 9283215]
  684. Mocks J, Franke W, Ehmer B, et al Analysis of safety database for long-term epoetin-beta treatment: a meta-analysiscovering 3697 patients. Chapter 12, In: Koch KM, Stein G, eds Pathogenetic and Therapeutic Aspects of Chronic Renal Failure. New York, Marcel Dekker, Inc. 1997; p. 163-79.
  685. Moczulski D, Grzeszczak W, Zukowska-Szczechowska EA, et al [The influence of recombinant human erythropoietin (rHu-EPO) on circadian rhythm of prolactin secretion in patients with chronic renal failure treated with hemodialysis] Pol Arch Med Wewn 1995 Jan93(1):32–40. [PubMed: 7479216]
  686. Mohini R Clinical efficacy of recombinant human erythropoietin in hemodialysis patients Semin Nephrol 1989 Mar9(1 Suppl 1):16–21. [PubMed: 2648516]
  687. Molzahn M Erythropoietin Dialysis Transplant 198615(10):564–8.
  688. Monge-C C, Arregui A, Leon-Velarde F Pathophysiology and epidemiology of chronic mountain sickness Int J Sports Med 199213(Suppl 1):S79–S81. [PubMed: 1483802]
  689. Montagnac R, Ebikili B, Schillinger F [Autotransfusion using erythropoietin in patients under chronic hemodialysis. 2 cases] Presse Med 1996 Jun 2225(22):–. [PubMed: 8692791]
  690. Montini G, Cazzin M, Suppiej A, et al Clinical results of anaemia treatment with recombinant human erythropoietin in children maintained by haemodialysis G Ital Nefrol 19907(4):259–66.
  691. Montini G, Zacchello G, Perfumo F, et al Pharmacokinetics and hematologic response to subcutaneous administration of recombinant human erythropoietin in children undergoing long-term peritoneal dialysis: a multicenter study J Pediatr 1993 Feb122(2):297–302. [PubMed: 8429450]
  692. Montloin A [Recombinant human erythropoietin] Rev Infirm 1990 Dec40(19):33–4. [PubMed: 2091207]
  693. Moore GE, Bertocci LA, Painter PL 31P-magnetic resonance spectroscopy assessment of subnormal oxidative metabolism in skeletal muscle of renal failure patients J Clin Invest 1993 Feb1(2):420–4. [PMC free article: PMC287944] [PubMed: 8432850]
  694. Moore R Towards long-term graft survival in renal transplantation: the role of erythropoietin Nephrol Dial Transplant 199510(suppl 1):20–2. [PubMed: 7617275]
  695. Moran LJ, Carey P, Johnson CA Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease Am J Hosp Pharm 1992 Jun49(6):1451–4. [PubMed: 1529988]
  696. Morduchowicz G, Boner G Hospitalizations in dialysis end-stage renal failure patients. Nephron 1996:73(3):413-6. [PubMed: 8832599]
  697. Moreno F Quality of life in dialysis patients. A Spanish multicentre study Nephrol Dial Transplant 199611(suppl 2):125–129. [PubMed: 8804012]
  698. Moreno F, Aracil FJ, Perez R, et al Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin Am J Kidney Dis 1996 Apr27(4):548–56. [PubMed: 8678066]
  699. Moreno F, Lopez-Gomez JM, Sanz-Guajardo D, et al Quality of life in dialysis patients. A Spanish multicentre study Nephrol Dial Transplant 199611(Suppl 2):125–9. [PubMed: 8804012]
  700. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology J Am Soc Nephrol 2000 Feb11(2):335–42. [PubMed: 10665941]
  701. Morris K, Skinner J Growth-related changes in echocardiographic measurements Clin Nephrol 1991 Aug36(2):–.
  702. Morris KP, Sharp J, Watson S, et al Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia Arch Dis Child 1993 Nov69(5):580–6. [PMC free article: PMC1029623] [PubMed: 8257180]
  703. Morris KP, Skinner JR, Hunter S, et al Cardiovascular abnormalities in end stage renal failure: the effect of anaemia or uraemia? Arch Dis Child 1994 Aug71(2):119–22. [PMC free article: PMC1029940] [PubMed: 7944530]
  704. Morris KP, Skinner JR, Hunter S, et al Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure Arch Dis Child 1993 May68(5):644–8. [PMC free article: PMC1029333] [PubMed: 8323333]
  705. Mourad G, Chong G, Cristol JP, et al [Post-transfusional anti-HLA hyperimmunization: importance of erythropoietin] Nephrologie 199314(2):91–4. [PubMed: 8327032]
  706. Moynot A, Zins B, Naret C, et al [One-year treatment of 43 chronic hemodialysis patients with recombinant human erythropoietin] Presse Med 1990 Jan 2719(3):111–5. [PubMed: 2137586]
  707. Moynot A [Treatment of anemia in chronically dialyzed patients] Nephrologie 199819(3):125–7. [PubMed: 9633055]
  708. Mrzljak V Recombinant human erythropoietin (r-huepo) in dialysis patients Diabetologia Croatica 199524(4):131–139.
  709. Muirhead N, Bargman J, Burgess E, et al Evidence-based recommendations for the clinical use of recombinant human erythropoietin Am J Kidney Dis 1995 Aug26(2 Suppl 1):S1–S24. [PubMed: 7645549]
  710. Muirhead N, Churchill DN, Goldstein M, et al Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease Am J Nephrol 199212(5):303–10. [PubMed: 1488998]
  711. Muirhead N, Hodsman AB, Hollomby DJ, et al The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients Nephrol Dial Transplant 19916(5):342–5. [PubMed: 1870750]
  712. Muirhead N, Hodsman AB Occult infection and resistance of anaemia to rHuEpo therapy in renal failure Nephrol Dial Transplant 19905(3):232–4. [PubMed: 2113653]
  713. Muirhead N Renal disease. II. The clinical impact of recombinant human erythropoietin J R Coll Physicians Lond 1997 Mar-Apr31(2):125–30. [PubMed: 9131506]
  714. Muller R, Steffen HM, Brunner R, et al Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin (rHuEpo) therapy for renal anemia Clin Invest Med 1991 Dec14(6):614–22. [PubMed: 1665406]
  715. Muller-Wiefel DE, Scigalla P Specific problems of renal anemia in childhood. Contrib Nephrol. 1988;66:71–84. [PubMed: 3292150]
  716. Muthny FA, Koch U Influence of epo-medication on quality of life of hemodialysis patients Nieren- Hochdruckkr 199322(8):375–80.
  717. Nagao K, Tsuchihashi K, Ura N, et al Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease Can J Cardiol 1997 Aug13(8):747–53. [PubMed: 9284841]
  718. Nakamura S, Yang CL, Nakayama K, et al Study of the causes of recombinant human erythropoietin (rHuEPO)-derived hypertension in patients with chronic renal failure J Jpn Soc Dial Ther 199831(9):1251–1257.
  719. Narita M, Shibata A [The abnormalities of blood cells in chronic kidney failure with long-term dialysis] Nippon Rinsho 1992 Jan50(Suppl):763–70. [PubMed: 1578764]
  720. Nasu T, Mitui H, Shinohara Y, et al Effect of erythropoietin in continuous ambulatory peritoneal dialysis patients: comparison between intravenous and intraperitoneal administration Perit Dial Int 199212(4):373–7. [PubMed: 1420496]
  721. National Institute of Diabetes and Digestive and Kidney Diseases Healthy People 2010 Objectives: Chronic kidney disease draft chapter (Kidney Subcommittee). Available at: http://www​.niddk.nih​.gov/federal/kuhdic/kidsub/2010.htm. Last accessed March 2000.
  722. Navarro JF, Teruel JL, Mateos M, et al Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in hemodialysis patients Clin Nephrol 1994 Feb41(2):113–6. [PubMed: 8004827]
  723. Navarro M, Alonso A, Avilla JM, et al Anemia of chronic renal failure: treatment with erythropoietin Child Nephrol Urol 199111(3):146–51. [PubMed: 1777893]
  724. Navarro M Study and conservative treatment of chronic kidney failure in the child An Esp Pediat 198829(Suppl 33):137–42. [PubMed: 3074685]
  725. Neff MS, Goldberg J, Slifkin RF, et al Anemia in chronic renal failure. Acta Endocrinol Suppl (Copenh) 1985;271:80–6. [PubMed: 3865483]
  726. Nemecek K, Bartova V, Jachymova M, et al [Endothelin in patients with chronic kidney failure] Cas Lek Cesk 1995 Aug 23134(16):511–3. [PubMed: 7553749]
  727. Nemecek K, Bartova V, Jachymova M, et al Endothelin in patients with chronic renal failure Ren Fail 1995 Sep17(5):559–63. [PubMed: 8570868]
  728. Nielsen OJ, Thaysen JH Vital indication for erythropoietin in a chronic haemodialysis patient. A case report Dan Med Bull 1989 Dec36(6):590–2. [PubMed: 2612227]
  729. Nielsen OJ Recombinant human erythropoietin. Experimental and clinical applications Dan Med Bull 199138(5):355–70. [PubMed: 1802621]
  730. Nieszporek T, Kokot F, Wiecek A, et al [Influence of long-term treatment with human recombinant erythropoietin on secretion of hormones regulating carbohydrate metabolism in hemodialyzed patients with chronic uremia] Pol Arch Med Wewn 1995 Dec94(6):488–94. [PubMed: 8618811]
  731. Nieszporek T, Kokot F, Wiecek A, et al [Influence of long-term human recombinant erythropoietin treatment on secretion of pancreatic polypeptide and gastrin in hemodialysed patients with chronic renal failure] Przegl Lek 199552(12):590–3. [PubMed: 8834657]
  732. Nikolaev AI, Klepikov PV, Lashutin SV, et al [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency] Ter Arkh 199365(6):45–8. [PubMed: 8378849]
  733. Nikolaev AI, Klepikov PV, Lashutin SV [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia] Ter Arkh 199264(6):90–1. [PubMed: 1440349]
  734. Nishi S, Hirasawa Y [Dialysis-associated heart failure and the prevention and therapy] Nippon Rinsho 1992 Jan50(Suppl):695–9. [PubMed: 1578753]
  735. Nissenson AR, Besarab A, Bolton WK, et al Target haematocrit during erythropoietin therapy [editorial] Nephrol Dial Transplant 1997 Sep12(9):1813–6. [PubMed: 9306325]
  736. Nissenson AR, Pickett JL, Theberge WS, et al Brain function is better in hemodialysis (HD) patients (PTS) when hematocrit (HCT) is normalized with erythropoietin (rHuEPO) J Am Soc Nephrol. 1996;7:–.
  737. Nissenson AR, Rettig RA Medicare's end-stage renal disease program: current status and future prospects Health Aff (Millwood) 1999 Jan-Feb18(1):161–79. [PubMed: 9926654]
  738. Nissenson AR Brain function is better in hemodialysis (HD) patients (PTS) when hematocrit (HCT) is normalized with erythropoietin (rHuEPO) J Am Soc Nephrol. 1996;7:–.
  739. Nissenson AR Epoetin and cognitive function Am J Kidney Dis 1992 Jul20(1 Suppl 1):21–4. [PubMed: 1626553]
  740. Nissenson AR Erythropoietin treatment in peritoneal dialysis patients Perit Dial Int 199414(Suppl 3):S63–S69. [PubMed: 7948280]
  741. Nissenson AR National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group Am J Kidney Dis 1991 Oct18(4 Suppl 1):24–33. [PubMed: 1928075]
  742. Nissenson AR Proceedings from the symposium on end-stage renal disease patient management: strategies for meeting the clinical and economic challenges Am J Kidney Dis 199322(2 Suppl. 1):1–2.
  743. Nissenson AR Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life Semin Nephrol 1989 Mar9(1 Suppl 2):25–31. [PubMed: 2669083]
  744. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure National Kidney Foundation-Dialysis Outcomes Quality Initiative Am J Kidney Dis 1997 Oct30(4 Suppl 3):S192–240. [PubMed: 9339151]
  745. Nonnast-Daniel B, Creutzig A, Kuhn K, et al Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation. Contrib Nephrol. 1988;66:185–94. [PubMed: 3292147]
  746. Nonnast-Daniel B, Schaffer J, Frei U Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin. Contrib Nephrol. 1989;76:283–9; discussion 290-1. [PubMed: 2684528]
  747. Norris SH, Kurtzman NA Minimizing anemia in the chronic hemodialysis patient Int J Artif Organs 19869(4):199–206. [PubMed: 3781644]
  748. Novick AC Renal medicine and renal transplantation Curr Opin Urol 19933(2):97–98.
  749. Novick AC Treatment of the anemia of progressive renal failure with recombinant human erythropoietin: editorial comment J Urol 1990144(6):–.
  750. Nowicki M Erythropoietin and hypertension J Hum Hypertens 1995 Feb9(2):81–8. [PubMed: 7752179]
  751. Nuss R, Loehr JP, Daberkow E, et al Cardiopulmonary function in men with sickle cell trait who reside at moderately high altitude J Lab Clin Med 1993 Oct122(4):382–7. [PubMed: 8228552]
  752. Obert Mak HK Human recombinant erythropoietin (EPO) corrects insulin resistance and hyperlipidemia in patients on peritoneal dialysis (PD) J Am Soc Nephrol. 1996;7:–.
  753. Obrador GT, Ruthazer R, Arora P, et al Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States J Am Soc Nephrol 199910(8):1793–800. [PubMed: 10446948]
  754. Offner G, Hoyer PF, Latta K, et al One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis Pediatr Nephrol 1990 Sep4(5):498–500. [PubMed: 2242315]
  755. Ogden DA Introduction Semin Nephrol 19899(1 Suppl 2):1–2.
  756. Ogden DA Monitoring considerations in recombinant human erythropoietin therapy Semin Nephrol 1989 Mar9(1 Suppl 2):12–5. [PubMed: 2669080]
  757. Ohkubo M, Ishimitsu T, Kawaguchi T, et al [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia] Nippon Jinzo Gakkai Shi 1993 Feb35(2):171–7. [PubMed: 8315880]
  758. Okada T, Takahashi T Effect of low doses of recombinant human erythropoietin on the anemia in hemodialyzed patients (22) Nephron 199159(4):689–690. [PubMed: 1766524]
  759. Okundaye I, Abrinko P, Hou S Registry of pregnancy in dialysis patients Am J Kidney Dis 1998 May31(5):766–73. [PubMed: 9590185]
  760. Oliveira C, Boquinhas H, Gaspar A, et al [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis] Acta Med Port 1992 Jul5(7):351–7. [PubMed: 1442178]
  761. Ongkingco JR, Ruley EJ, Turner ME, et al Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis Am J Nephrol 199414(1):14–8. [PubMed: 8017476]
  762. Ongkingco JR, Ruley EJ, Turner ME Use of low-dose subcutaneous recombinant human erythropoietin in end-stage renal disease: experience with children receiving continuous cycling peritoneal dialysis Am J Kidney Dis 1991 Oct18(4):446–50. [PubMed: 1928063]
  763. Ono K, Hisasue Y Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy Clin Nephrol 1992 Nov38(5):290–2. [PubMed: 1451343]
  764. Ono K, Hisasue Y The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion Clin Nephrol 1992 Jan37(1):23–7. [PubMed: 1531789]
  765. Ortho-Biotech, Inc Procrit® (epoetin alfa) prescribing information. In: Physicians' desk reference. 53rd ed. Montvale: Medical Economics Press; 1999.
  766. Osaka N, Kawaguchi Y [Anemia of end-stage renal disease (ESRD)] Ryoikibetsu Shokogun Shirizu 199717(Pt 2):58–61. [PubMed: 9277860]
  767. Osorio FV, Teitelbaum I Treatment of congestive heart failure in patients with chronic renal insufficiency and end-stage renal disease Congestive Heart Failure 19962(6):11–24.
  768. Owczarzak MT, Debska-Slizien A, Biedunkiewicz B, et al Erythrocyte (RBC) Na-K-ATPase and Mg-ATPase activities in hemodialysis patients receiving recombinant erythropoietin (r-EPO) Annales Academiae Medicae Gedanensis 199525(Suppl 6):113–7.
  769. Owen WF, Lowrie EG C-reactive protein as an outcome predictor for maintenance hemodialysis patients Kidney Int 1998 Aug54(2):627–36. [PubMed: 9690231]
  770. Ozakgun R, Paydas S, Demirtas M, et al Effect of erythropoietin on systolic and diastolic left ventricular function in chronic renal failure with anemia Nephron 199571(1):103–4. [PubMed: 8538829]
  771. Pacyk G, Grzeszczak W [The effect of recombinant human erythropoietin (rHu-EPO) on the autonomic nervous system in patients hemodialyzed for chronic kidney failure] Pol Arch Med Wewn 1997 Jan97(1):22–9. [PubMed: 9235548]
  772. Paganini EP, Abdulhadi MH, Garcia J, et al Recombinant human erythropoietin correction of anemia. Dialysis efficiency, waste retention, and chronic dose variables ASAIO Trans 1989 Jul-Sep35(3):513–5. [PubMed: 2688718]
  773. Paganini EP, Braun WE, Latham D, et al Renal transplantation: results in hemodialysis patients previously treated with recombinant human erythropoietin ASAIO Trans 1989 Jul-Sep35(3):535–8. [PubMed: 2688720]
  774. Paganini EP, Eschbach JW, Lazarus JM, et al Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients Am J Kidney Dis 1995 Aug26(2):331–40. [PubMed: 7645538]
  775. Paganini EP, Latham D, Abdulhadi M Practical considerations of recombinant human erythropoietin therapy Am J Kidney Dis 1989 Aug14(2 Suppl 1):19–25. [PubMed: 2667348]
  776. Paganini EP Adapting the dialysis unit to increased hematocrit levels Am J Kidney Dis 1995 Apr25(4 Suppl 1):S12–7. [PubMed: 7702070]
  777. Paganini EP In search of an optimal hematocrit level in dialysis patients: rehabilitation and quality-of-life implications Am J Kidney Dis 1994 Jul24(1 Suppl 1):S10–6; discussion S31-2. [PubMed: 8023833]
  778. Painter P, Carlson L Case study of the anemic patient: epoetin alfa!focus on exercise ANNA J 1994 May21(3):304–7. [PubMed: 7998811]
  779. Painter P, Moore GE The impact of recombinant human erythropoietin on exercise capacity in hemodialysis patients Adv Ren Replace Ther 1994 Apr1(1):55–65. [PubMed: 7641089]
  780. Painter P The importance of exercise training in rehabilitation of patients with end-stage renal disease Am J Kidney Dis 1994 Jul24(1 Suppl 1):S2–9; discussion S31-2. [PubMed: 8023835]
  781. Pan D, Hsu K, Ray S C Ecchymoses and eschars at sites of injection Lancet 1997 May 10349(9062):–. [PubMed: 9149700]
  782. Panas N, Turkowa M, Zgheib A, et al [Revolution in the treatment of chronic renal insufficiency anemia: the role of recombinant erythropoietin] Rev Med Liege 1990 Jun45(6):280–5. [PubMed: 2367758]
  783. Parfrey PS, Harnett JD, Foley RN Heart failure and ischemic heart disease in chronic uremia Current Opinion In Nephrology And Hypertension 19954(2):105–110. [PubMed: 7600039]
  784. Parfrey PS, Harnett JD Clinical aspects of cardiomyopathy in dialysis patients Blood Purif 199412(4-5):267–76. [PubMed: 7865186]
  785. Parfrey PS Cardiac and cerebrovascular disease in chronic uremia Am J Kidney Dis 1993 Jan21(1):77–80. [PubMed: 8418631]
  786. Park CW, Shin YS, Shin MJ, et al Pyoderma gangrenosum and spinal epidural abscess after subcutaneous administration of recombinant human erythropoietin Nephrol Dial Transplant 199712(7):1506–1508. [PubMed: 9249800]
  787. Park JS, Kim SB, Park SK, et al Effect of recombinant human erythropoietin on muscle energy metabolism in patients with end-stage renal disease: a 31P-nuclear magnetic resonance spectroscopic study Am J Kidney Dis 1993 Jun21(6):612–8. [PubMed: 8503414]
  788. Parker KP, Sands JM Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients J Am Soc Nephrol 1993 Apr3(10):1717–8. [PubMed: 8318688]
  789. Parsons DS, Harris DC A review of quality of life in chronic renal failure Pharmacoeconomics 199712(2):140–160. [PubMed: 10169667]
  790. Pascual J, Teruel JL, Marcen R, et al Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis Int J Artif Organs 1992 Jun15(6):349–53. [PubMed: 1639526]
  791. Pascual J, Teruel JL, Moya JL, et al Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study Clin Nephrol 1991 Jun35(6):280–7. [PubMed: 1831414]
  792. Pascual JF, Lopez JD, Molina M Hemofiltration in children with renal failure Pediatr Clin North Am 198734(3):803–818. [PubMed: 3295728]
  793. Patte D [Quality of life of patients treated for terminal chronic renal failure] Presse Med 1998 Oct 327(29):1499–505. [PubMed: 9798471]
  794. Pena Amaro MP, Garcia Lopez J, Camacho Romera M [Erythropoietin in renal anemia] Rev Enferm 1992 Mar15(163):67–70.
  795. Perez R, Anaya F, Garcia de Vinuesa MS, et al Evolution of panel reactive anti-HLA cytotoxic antibodies (PRA) in patients on dialysis (D) treated with erythropoietin (EPO) Nefrologia 199414(3):333–340.
  796. Perkins SL Normal blood and bone marrow values in humans. In: Lee GR, et al., eds. Wintrobe's clinical hematology. 10th ed. Baltimore: Williams and Wilkins; 1999. Appendix A.
  797. Petersen-Lehmann J, Hilbig WP, Morck H The treatment of endocrine diseases Pharm. Ztg 1991136(5):26–37.
  798. Pfaffl W, Gross HJ, Neumeier D, et al Lymphocyte subsets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin. Contrib Nephrol. 1988;66:195–204. [PubMed: 3391032]
  799. Piccoli A, Puggia RM, Fusaro M, et al A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis Pharmacoeconomics 19957(5):444–456. [PubMed: 10155331]
  800. Pickett JL Normalizing hematocrit in dialysis patients improves brain function Am J Kid Dis 199933(6):1122–1130. [PubMed: 10352201]
  801. Pickett JL, Theberge DC, Brown WS, et al Normalizing hematocrit in dialysis patients improves brain function Am J Kidney Dis 1999 Jun33(6):1122–30. [PubMed: 10352201]
  802. Pietrzak I, Baczyk K, Kubiak W Recombinant human erythropoietin administration improves thiamin content in blood and erythrocytes transketolase activity in pre-dialyzed patients Ann Univ Mariae Curie Sklodowska [Med] 199448(Suppl 3):29–37. [PubMed: 8192530]
  803. Pietrzyk JA, Dyras P, Smolnik T, et al [Effect of using recombinant human erythropoietin on the effectiveness of hemodialysis in children with terminal renal failure] Przegl Lek 199249(1-2):61–5. [PubMed: 1280842]
  804. Pietrzyk JA, Smolnik T, Szymowska M, et al [Effect of recombinant human erythropoietin-rHu-EPO on the metabolism of children treated by long-term hemodialysis] Przegl Lek 199249(1-2):55–60. [PubMed: 1455008]
  805. Pincus T, Olsen NJ, Russell IJ, et al Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis Am J Med 1990 Aug89(2):161–8. [PubMed: 2200263]
  806. Pinevich AJ, Petersen J Erythropoietin therapy in patients with chronic renal failure West J Med 1992 Aug157(2):154–7. [PMC free article: PMC1011236] [PubMed: 1441466]
  807. Polenakovic M, Sikole A Is erythropoietin a survival factor for red blood cells? J Am Soc Nephrol 1996 Aug7(8):1178–82. [PubMed: 8866410]
  808. Pollok M, Bommer J, Gurland HJ, et al Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study. Contrib Nephrol. 1989;76:201–11; discussion 212-8. [PubMed: 2684523]
  809. Porsius AJ Simply aluminium to achieve a phosphate-free environment and an acceptable hormone concentration (ii) Tijdschr Ther Geneesm Onderz 199217(5):121–125.
  810. Port RE, Ding RW, Fies T, et al Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia Br J Clin Pharmacol 199846(5):461–466. [PMC free article: PMC1873696] [PubMed: 9833599]
  811. Portoles J, Torralbo A, Martin P, et al Cardiovascular effects of recombinant human erythropoietin in predialysis patients Am J Kidney Dis 1997 Apr29(4):541–8. [PubMed: 9100042]
  812. Powe N R, Eggers P W, Johnson CB Early adoption of cyclosporine and recombinant human erythropoietin: clinical, economic, and policy issues with emergence of high-cost drugs Am J Kidney Dis 1994 Jul24(1):33–41. [PubMed: 8023822]
  813. Powe NR, Griffiths RI, Anderson GF, et al Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients Am J Kidney Dis 1993 Oct22(4):557–67. [PubMed: 8213796]
  814. Powe NR, Griffiths RI, Bass B Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease J Am Soc Nephrol 1993 Apr3(10):1660–71. [PubMed: 8318682]
  815. Powe NR, Griffiths RI, de Lissovoy G, et al Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval JAMA 1992268(11):1434–1440. [PubMed: 1512912]
  816. Powe NR, Griffiths RI, Greer JW, et al Early dosing practices and effectiveness of recombinant human erythropoietin Kidney Int 1993 May43(5):1125–33. [PubMed: 8510392]
  817. Powe NR, Griffiths RI, Watson AJ, et al Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients J Am Soc Nephrol 1994 Jan4(7):1455–65. [PubMed: 8161727]
  818. Pradella M, Cavill I, d'Onofrio G Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting Clin Lab Haematol 1996 Dec18(Suppl 1):35–7. [PubMed: 9054717]
  819. Prata MM, de Sousa FT, Barbas JV, et al [Treatment of anemia in patients with chronic kidney insufficiency in hemodialysis with erythropoietin] Acta Med Port 1990 May-Jun3(3):149–53. [PubMed: 2220424]
  820. Prichard S, Sniderman A, Cianflone K, et al Cardiovascular disease in peritoneal dialysis Perit Dial Int 199616(Suppl 1):S19–S22. [PubMed: 8728157]
  821. Pugh M, Saylor G Case management of the anemic patient. Focus on hemodynamics ANNA J 1991 Jun18(3):316–7. [PubMed: 2064457]
  822. Quarello F, Martina G, Beltrame G, et al [Effects of erythropoietin on the cardiovascular system and the intradialytic hemodynamic behavior] Minerva Urol Nefrol 1991 Jul-Sep43(3):125–30. [PubMed: 1817333]
  823. Rachmilewitz EA, Aker M The role of recombinant human erythropoietin in the treatment of thalassemia. Ann N Y Acad Sci. 1998 Jun 30;850:129–38. [PubMed: 9668535]
  824. Radermacher J, Koch KM Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system Clin Nephrol 1995 Nov44(Suppl 1):S56–S60. [PubMed: 8608665]
  825. Raine AE, Margreiter R, Brunner FP, et al Report on management of renal failure in Europe, XXII, 1991 Nephrol Dial Transplant 19927(Suppl 2):7–35. [PubMed: 1338121]
  826. Raine AE, Roger SD Effects of erythropoietin on blood pressure Am J Kidney Dis 1991 Oct18(4 Suppl 1):76–83. [PubMed: 1928084]
  827. Raine AE Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy Lancet 1988 Jan 161(8577):97–100. [PubMed: 2891990]
  828. Raman GV The nature and management of advanced diabetic renal disease Pract. Diabetes 19929(4):146–148.
  829. Ramello A, Malcangi U, Bruno M, et al Treatment of anaemia in CAPD patients with recombinant human erythropoietin. Adv Perit Dial. 1990;6:308–11. [PubMed: 1982834]
  830. Ramello A, Perosa P, Bruno M, et al [Utilization of EPO in CAPD] Minerva Urol Nefrol 1991 Jul-Sep43(3):137–41. [PubMed: 1817335]
  831. Ramirez B, Flores A, Perez F, et al Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment Transplant Proc 1991 Apr23(2):1833–4. [PubMed: 2053170]
  832. Ramirez G, Bittle PA, Sanders H, et al The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin J. Clin. Endocrinol. Metab 199478(1):63–69. [PubMed: 8288716]
  833. Rao DS, Shih MS, Mohini R Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia N Engl J Med 1993 Jan 21328(3):171–5. [PubMed: 8417383]
  834. Rapoport I, Engelhardt I, Drung I, et al Influence of erythropoietin treatment on 2,3-bisphosphoglycerate and O2-affinity of red blood cells in children with renal anemia Biomed Biochim Acta 199049(2-3):S280–3. [PubMed: 2386518]
  835. Rault R, Magnone M The effect of parathyroidectomy on hematocrit and erythropoietin dose in patients on hemodialysis ASAIO Journal 199642(5):M901–M903. [PubMed: 8945016]
  836. Reddingius RE, de Boer AW, Schroder CH, et al Increase of the bioavailability of intraperitoneal erythropoietin in children on peritoneal dialysis by administration in small dialysis bags Perit Dial Int 1997 Sep-Oct17(5):467–70. [PubMed: 9358528]
  837. Reisdorff EJ, Prodinger RJ Sudden cardiac death in the athlete Emerg Medicine Clin North Am 199816(2):281–294. [PubMed: 9621845]
  838. Rendo P, Biscigniano L, Turconi A, et al [Treatment of anemia in children undergoing chronic hemodialysis with recombinant human erythropoietin] Medicina (B Aires) 199454(5 Pt 1):392–8. [PMC free article: PMC198880] [PubMed: 7658972]
  839. Revicki DA, Brown RE, Feeny DH, et al Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients Am J Kidney Dis 1995Apr 25(4):548–54. [PubMed: 7702049]
  840. Revicki DA Relationship between health utility and psychometric health status measures Med Care 1992 May30(5 Suppl):MS274–82. [PubMed: 1583939]
  841. Riabov SI, Shostka GD, Petrova NN, et al [The effect of Recormon therapy on the quality of life of patients on hemodialysis treatment] Ter Arkh 199668(8):43–6. [PubMed: 9019831]
  842. Richalet JP, Souberbielle JC, Antezana AM, et al Control of erythropoiesis in humans during prolonged exposure to the altitude of 6,542 m Am J Physiol 1994 Mar266(3 Pt 2):R756–64. [PubMed: 8160868]
  843. Riedel E Total correction of renal anemia improves malnutrition and amino acid (AA) metabolism in hemodialysis (HD) patients. J Am Soc Nephrol. 1996;7:–.
  844. Riedel E, Hampl H, Nundel M, et al Total correction of renal anemia improves malnutrition and amino acid (AA) metabolism in hemodialysis (HD) patients. J Am Soc Nephrol. 1996;7:–.
  845. Riedel E, Hampl H, Scigalla P, et al Correction of amino acid metabolism by recombinant human erythropoietin therapy in hemodialysis patients. Kidney Int Suppl. 1989 Nov;27:S216–S221. [PubMed: 2636662]
  846. Riedel E, Hampl H, Scigalla P, et al Anemia and amino acid homoeostasis in hemodialysis patients Nieren- Hochdruckkr 199019(5):199–204.
  847. Rigalleau V, Pommereau A, Martin L, et al Acute anemia, renal failure and disseminated gastric adenocarcinoma Revue De Medecine Interne 199516(Suppl 2):287s–288s.
  848. Ritz E The conservative treatment of chronic kidney failure: the prevention of late complications Therapiewoche 199141(9):530, 531–534.
  849. Robbins KC, Senger JM, Kerhulas S, et al Iron management in ESRD and the role of the nephrology nurse ANNA J 1997 Apr24(2):265–72; quiz 273-4. [PubMed: 9180431]
  850. Roberts GW, Zoanetti GD Clobazam and n-desmethylclobazam serum concentrations in endstage renal failure and hemodialysis Ann Pharmacother 199428(7-8):966–967. [PubMed: 7949528]
  851. Roberts M 2nd annual international symposium on daily home hemodialysis Dialysis And Transplantation 199625(6):361, 365–366.
  852. Robertson HT, Haley NR, Guthrie M, et al Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients Am J Kidney Dis 1990 Apr15(4):325–32. [PubMed: 2321645]
  853. Robertson JS, Graves J The end stage renal disease program N Engl J Med 1993329(2):139–141. [PubMed: 8510700]
  854. Rockel A, Abdelhamid S, Menth M Secondary manifestations in endstage renal failure and their treatment Med Welt 199243(1):55–60.
  855. Rodriguez RA Use of the medical differential diagnosis to achieve optimal end-stage renal disease outcomes Adv Ren Replace Ther 1997 Apr4(2):97–111. [PubMed: 9113226]
  856. Roger SD, Baker LR, Raine AE Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO) Clin Nephrol 1993 Feb39(2):103–10. [PubMed: 8448912]
  857. Roth D, Smith RD, Schulman G, et al Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients Am J Kidney Dis 1994 Nov24(5):777–84. [PubMed: 7977319]
  858. Rousseau P [Financial impact of anemia in patients with chronic renal insufficiency undergoing hemodialysis at centers] Nephrologie 199011(3):147–52. [PubMed: 2234271]
  859. Royer B, Arock M [Therapeutic use of hematopoietic growth factors. I. Erythropoietin and thrombopoietin] Ann Biol Clin (Paris) 1998 Mar-Apr56(2):143–52. [PubMed: 9754239]
  860. Rozental' RL, Zezina LI, Spudass AV [The use of recombinant erythropoietin with patients on programmed hemodialysis] Ter Arkh 199163(12):110–3. [PubMed: 1803587]
  861. Rud'ko IA, Balashova TS, Kubatiev AA, et al [The effect of recombinant human erythropoietin during hemodialysis on the thrombocyte and erythrocyte functions of patients with chronic kidney failure] Ter Arkh 199466(6):57–60. [PubMed: 7940371]
  862. Rud'ko IA, Pokrovskii IuA, Ermolenko VM, et al [The effect of recombinant human erythropoietin on thrombocyte aggregation capacity and on the blood prostanoid level in patients with chronic kidney failure on hemodialysis] Ter Arkh 199163(10):128–30. [PubMed: 1805410]
  863. Ruedin P Correction of anemia related to chronic renal insufficiency. Practical guideline of recombinant human erythropoietin treatment Medcine Et Hygiene 199755(2152):373–377.
  864. Ruedin P Ten-year of experience with human recombinant erythropoietin Med Hyg 199553(2060):405–8.
  865. Ruedin P Treatment of renal anaemia in predialysis Med Hyg 199856(2229):2081–4.
  866. Rusko HR New aspects of altitude training Am J Sports Med 199624(Suppl):S48–S52. [PubMed: 8947429]
  867. Rutkowski B, Gora E, Barlik J, et al [Histidine in the treatment of anemia in patients with chronic renal failure treated by hemodialysis] Pol Tyg Lek 1987 Aug 2442(34):1031–4. [PubMed: 3422836]
  868. Rutkowski B [Practical aspects of erythropoietin treatment-state of current knowledge] Przegl Lek 199552(3):–. [PubMed: 7644678]
  869. Saatci U, Topaloglu R, Ozen S, et al Does erythropoietin have a beneficial effect on calcium, phosphorus and parathyroid hormone levels in pediatric hemodialysis patients? Nephron 199467(3):–. [PubMed: 7936038]
  870. Sadler JH, Levin GV, Painter, et al Discussion Am J Kidney Dis 199424(1 Suppl):S31–S32.
  871. Sadler JH Race and access to erythropoietin by patients on hemodialysis JAMA 1994 Dec 21272(23):1818–9. [PubMed: 7990207]
  872. Sagales T, Gimeno V, Planella MJ, et al Effects of rHuEPO on Q-EEG and event-related potentials in chronic renal failure Kidney Int 1993 Nov44(5):1109–15. [PubMed: 8264143]
  873. Sakai O [Physiopathology and therapy of chronic kidney failure] Nippon Naika Gakkai Zasshi 1995 Mar 1084(3):480–4. [PubMed: 7751793]
  874. Sakiewicz P, Paganini E The use of iron in patients on chronic dialysis: mistake and misconceptions J Nephrol 1998 Jan-Feb11(1):5–15. [PubMed: 9561479]
  875. Salaman JR Kidney transplantation Curr Pract Surg 19924(4):195–200.
  876. Saldanha LF, Weiler EW, Gonick HC Effect of continuous ambulatory peritoneal dialysis on blood pressure control Am J Kidney Dis 1993 Feb21(2):184–8. [PubMed: 8430680]
  877. Saleh A, Krane NK, Caballero M, et al Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD. Adv Perit Dial. 1991;7:288–91. [PubMed: 1680448]
  878. Salive ME, Cornoni-Huntley J, Guralnik JM, et al Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status J Am Geriatr Soc 199240(5):489–496. [PubMed: 1634703]
  879. Saltissi D, Sauvage D, Westhuyzen J Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (epo) Clin Nephrol 199849(1):45–48. [PubMed: 9491286]
  880. Salvarani C, Lasagni D, Casali B, et al Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease J Rheumatol 1991 Aug18(8):1168–71. [PubMed: 1941817]
  881. Salvati F, Liani M, La Torre M, et al Immunological effects of recombinant human erythropoietin on end-stage renal disease pediatric and adult patients Nephron 199468(4):510–1. [PubMed: 7870240]
  882. Salvati F, Liani M Erythropoietin and thrombotic events Lancet 1998 Oct 31352(9138):–. [PubMed: 9808016]
  883. Samtleben W, Baldamus CA, Bommer J, et al Blood pressure changes during treatment with recombinant human erythropoietin. Contrib Nephrol. 1988;66:114–22. [PubMed: 3292144]
  884. Samtleben W, Baldamus CA, Bommer J, et al Indications and contraindications for recombinant human erythropoietin treatment. Results in hemodialysis patients. Contrib Nephrol. 1989;76:193–200; discussion 212-8. [PubMed: 2684521]
  885. Samtleben W, Ehmer B, Lutz-Knochenhauer I, et al Side effects during recombinant human erythropoietin therapy in 2,000 ESRD patients. Contrib Nephrol. 1991;88:107–16; discussion 117. [PubMed: 2040172]
  886. Samuels MA, Thalinger K Cerebrovascular manifestations of selected hematologic diseases Semin Neurol 199111(4):411–418. [PubMed: 1811296]
  887. Sanders HN, Rabb HA, Bittle P, et al Nutritional implications of recombinant human erythropoietin therapy in renal disease J Am Diet Assoc 1994 Sep94(9):1023–9. [PubMed: 8071484]
  888. Sanderson JE Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables and plasma hormones Br Heart J 1994 May71(5):–. [PMC free article: PMC483735] [PubMed: 8011420]
  889. Sasagawa I, Nakada T, Hashimoto T, et al Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension Int Urol Nephrol 199426(2):237–43. [PubMed: 8034437]
  890. Satoh K, Ikeda Y, Kurokawa S, et al [Effect of recombinant human erythropoietin administration on cardiovascular system in patient with chronic renal failure: an analysis of the blood pressure upward] Kokyu To Junkan 1989 Mar37(3):313–9. [PubMed: 2734509]
  891. Satoh K, Ikeda Y, Kurokawa S, et al Effect of recombinant human erythropoietin administration on cardiovascular system in patients with chronic renal failure: an analysis of the blood pressure upward Respir Circ 198937(3):313–9. [PubMed: 2734509]
  892. Saul F, Lederle RM, Klaus D, et al The influence of erythropoietin on hemodynamics, left ventricular performance and neurohumoral factors in end-stage renal failure Clin. Exp. Hypertens. Part A Theory Pract 199012(3):–.
  893. Savica V, Costantino G, Monardo P, et al Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure Am. J. Nephrol 199515(1):10–14. [PubMed: 7872358]
  894. Savourey G, Garcia N, Besnard Y, et al Pre-adaptation, adaptation and de-adaptation to high altitude in humans: cardio-ventilatory and haematological changes Eur J Appl Physiol 199673(6):529–35. [PubMed: 8817123]
  895. Sawka MN, Young AJ, Rock PB, et al Altitude acclimatization and blood volume: effects of exogenous erythrocyte volume expansion J Appl Physiol 1996 Aug81(2):636–42. [PubMed: 8872628]
  896. Sayinalp N, Erdem Y, Ilhami Ozcebe O, et al Recombinant human erythropoietin increases platelet aggregation in chronic hemodialysis patients Thromb Res 1998 May 1590(4):195–8. [PubMed: 9692619]
  897. Schaefer RM, Heidland A Efficient therapy of renal anemia by recombinant human erythropoietin Nieren Hochdruckkr 198918(11):501–505.
  898. Schaefer RM, Kokot F, Kuerner B, et al Normalization of serum prolactin levels in hemodialysis patients on recombinant human erythropoietin Int J Artif Organs 1989 Jul12(7):445–9. [PubMed: 2767790]
  899. Schaefer RM, Kokot F, Wernze H, et al Improved sexual function in hemodialysis patients on recombinant erythropoietin: a possible role for prolactin Clin Nephrol 1989 Jan31(1):1–5. [PubMed: 2914405]
  900. Schaefer RM, Kuerner B, Zech M, et al Clinical experience with recombinant human erythropoietin in hemodialysis patients Pol Arch Med Wewn 1988 Oct80(4):213–20. [PubMed: 3078210]
  901. Schaefer RM, Kurner B, Zech M, et al [Therapy of renal anemia with recombinant human erythropoietin] Dtsch Med Wochenschr 1988 Jan 29113(4):125–9. [PubMed: 3276487]
  902. Schaefer RM, Leschke M, Strauer B E, et al Blood rheology and hypertension in hemodialysis patients treated with erythropoietin Am J Nephrol 19888(6):449–53. [PubMed: 3218658]
  903. Schaefer RM, Schaefer L Management of iron during rhepo therapy Annales Academiae Medicae Gedanensis 199525(Suppl 6):69–73.
  904. Schaefer RM Impact of recombinant erythropoietin on sexual function in hemodialysis patients. Contrib Nephrol. 1989;76:273–282. [PubMed: 2684527]
  905. Schaller R, Sperschneider H, Thieler H, et al Differences in intravenous and subcutaneous application of recombinant human erythropoietin: a multicenter trial Artif Organs 1994 Aug18(8):552–8. [PubMed: 7993190]
  906. Schardin KE Case management of the anemic patient: epoetin alfa-focus on ventricular function ANNA J 1993 Feb20(1):96–9. [PubMed: 8431032]
  907. Scharer K, Klare B, Braun A, et al Treatment of renal anemia by subcutaneous erythropoietin in children with preterminal chronic renal failure Acta Paediatr 1993 Nov82(11):953–8. [PubMed: 8111177]
  908. Schiffl H, Lang SM Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium Eur J Med Res 1997 Mar 242(3):97–100. [PubMed: 9113497]
  909. Schillinger F, Dubot Ph, Cabanne JF, et al Acquired cystic kidney disease in renal insufficiency: a multicentre study Eur J Med 19932(8):457–460. [PubMed: 8258045]
  910. Schiro KB EPO!one year later. Effects of EPO on nutritional status in CRF Nephrol News Issues 1990 May4(5):–. [PubMed: 2348876]
  911. Schmidt G, Stamminger G, Daniel A, et al Evaluation of indicators of erythropoiesis stimulated by recombinant human erythropoietin in renal anemia Biomed Biochim Acta 199049(2-3):S275–9. [PubMed: 2386517]
  912. Schmidt R, Lerche D, Dorp E, et al Changes in red blood cell volume under recombinant human erythropoietin therapy. Contrib Nephrol. 1990;87:52–8. [PubMed: 2093541]
  913. Schmidt RJ, Holley JL Fertility and contraception in end-stage renal disease Adv Ren Replace Ther 1998 Jan5(1):38–44. [PubMed: 9477214]
  914. Schonhofer B, Wenzel M, Geibel M, et al Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease Crit Care Med 1998 Nov26(11):1824–8. [PubMed: 9824074]
  915. Schwartz A Commentary on "the use of the artificial kidney in the treatment of uremia" J Urban Health 199875(4):919–21. [PMC free article: PMC3456006] [PubMed: 9854252]
  916. Schwartz AB, Orquiza CS The effects of recombinant human erythropoietin on mean corpuscular volume in patients with the anemia of chronic renal failure Clin Nephrol 1995 Apr43(4):256–9. [PubMed: 7606880]
  917. Schwartz AB, Prior JE, Mintz GS, et al Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin Transplant Proc 1991 Apr23(2):1827–30. [PubMed: 2053168]
  918. Schwenk MH, Halstenson CE Recombinant human erythropoietin DICP 1989 Jul-Aug23(7-8):528–36. [PubMed: 2669369]
  919. Scigalla P, Bonzel KE, Bulla M, et al Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease. Contrib Nephrol. 1989;76:227–40; discussion 240-1. [PubMed: 2684524]
  920. Scigalla P, Ehmer B, Herrmann Z, et al Subcutaneous application of recombinant human erythropoietin!the optimal route of administration Nieren-Hochdruckkr 199221(3):114–9.
  921. Scigalla P, Ehmer B, Woll EM, et al Reasons for individual responses to recombinant human erythropoietin inpatients with end-stage renal failure Nieren-Hochdruckkr 199019(5):178–83.
  922. Scigalla P, Wieczorek L, Hirth P Recombinant erythropoietin - a new drug for the treatment of renal anemia Nieren-Hochdruckkr 198716(11):487–2.
  923. Scigalla P Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease. The European Multicenter Study Group. Contrib Nephrol. 1991;88:201–11; discussion 212-4. [PubMed: 2040184]
  924. Scott LL, Ramin SM, Richey M, et al Erythropoietin use in pregnancy: two cases and a review of the literature Am J Perinatol 1995 Jan12(1):22–4. [PubMed: 7710570]
  925. Seguias LF, Zilleruelo G Transferrin saturation in pediatric hemodialysis Pediatr Nephrol 199812(7):–. [PubMed: 9761366]
  926. Seidel C, Schaefer F, Walther U, et al The application of knemometry in renal disease: preliminary observations Pediatr Nephrol 1991 Jul5(4):467–71. [PubMed: 1911123]
  927. Selcuk Y, San A, Sahin M, et al Effects of treatment with recombinant human erythropoietin on hemodynamic functions and vasoactive hormones in renal anemia Turk J Med Sci 199422(4):271–275.
  928. Selmaier A, Samtleben W, Lorenz B, et al Screening of intestinal iron absorption in end-stage renal disease Nieren-Hochdruckkr 199423(2):77–83.
  929. Sennesael JJ, Demanet CG, Verbeelen DL Serum soluble interleukin 2 receptor in hemodialysis patients treated with recombinant human erythropoietin Blood Purif 1995 Nov-Dec13(6):347–56. [PubMed: 8821199]
  930. Shaheen EA, Mansuri, NA Al-Shaikh AM, et al Effect of erythropoietin treatment on hearing loss in anemic patients on hemodialysis Annales Academiae Medicae Gedanensis 199525(Suppl 6):103–6.
  931. Shaheen FA, Mansuri NA, al-Shaikh AM, et al Reversible uremic deafness: is it correlated with the degree of anemia? Ann Otol Rhinol Laryngol 1997 May106(5):391–3. [PubMed: 9153103]
  932. Shanahan M, Walton S Developing an epoetin alfa medication protocol to improve patient care and foster collaboration ANNA J 1995 Oct22(5):471–6. [PubMed: 7487190]
  933. Shand BI, Buttimore AL, Hurrell MA, et al Hemorheology and fistula function in home hemodialysis patients following erythropoietin treatment: a prospective placebo-controlled study Nephron 199364(1):53–7. [PubMed: 7880205]
  934. Shand BI, Buttimore AL, Lynn KL, et al Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity Ren Fail 199416(3):407–13. [PubMed: 8059023]
  935. Shannon JS, Lappin TR The anaemia of chronic renal failure: a potentially treatable catabolic phenomenon? Med Hypotheses 198620(1):29–36. [PubMed: 3523174]
  936. Shannon KM Recombinant erythropoietin in pediatrics: a clinical perspective Pediatr Ann 1990 Mar19(3):197–206. [PubMed: 2181391]
  937. Shaver TR Golper TA Clinical applications of iron management in peritoneal dialysis patients Semin Dialysis 199912(4):257–261.
  938. Sheingold S, Churchill D, Muirhead N, et al The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada Soc Sci Med 1992 May34(9):983–91. [PubMed: 1631611]
  939. Sheingold SH, Churchill DN, Muirhead N, et al Recombinant human erythropoietin: factors to consider in cost-benefit analysis [editorial] Am J Kidney Dis 1991 Jan17(1):86–92. [PubMed: 1898836]
  940. Shepherd JD, Eaves AC Recombinant human erythropoietin: current potential applications Ann R Coll Physicians Surg Can 199023(1):25–28.
  941. Sheridan W, Foote MA Thrombopoietic growth factors. Emerging Drugs. 1998;3:261–9.
  942. Shih YC, Kauf TL Reconciling decision models with the real world - An application to anaemia of renal failure Pharmacoeconomics 199915(5):481–493. [PubMed: 10537965]
  943. Shimosaka A Pharmacokinetics and application of erythropoietin therapy: overview of epoetin alfa studies in Japan. Ann N Y Acad Sci. 1994 Apr 15;718:111–22. [PubMed: 8185220]
  944. Shinzato T, Nakai S, Akiba T, et al Current status of renal replacement therapy in Japan: results of the annual survey of the Japanese Society for Dialysis Therapy [news] [corrected and republished article originally printed in Nephrol Dial Transplant 1996 Nov;11(11):2143-50] Nephrol Dial Transplant 1997 May12(5):889–98. [PubMed: 9175040]
  945. Shrivastava D, Rao TK, Sinert R, et al The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis Am J Kidney Dis 1995 Jun25(6):904–9. [PubMed: 7771487]
  946. Sieniawska M, Roszkowska-Blaim M [Dosage of erythropoietin in children treated with hemodialysis and continuous ambulatory peritoneal dialysis] Pediatr Pol 1995 Dec70(12):1023–8. [PubMed: 8649941]
  947. Sieniawska M, Roszkowska-Blaim M Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal dialysis Pediatr Nephrol 1997 Oct11(5):628–30. [PubMed: 9323294]
  948. Sikole A, Polenakovic M, Spirovska V, et al Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients Artif Organs 1993 Dec17(12):977–84. [PubMed: 8110072]
  949. Sikole A, Stojanovic A, Polenakovic M, et al How erythropoietin affects bone marrow of uremic patients Am J Nephrol 199717(2):128–36. [PubMed: 9096443]
  950. Silberberg J, Racine N, Barre P, et al Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin Can J Cardiol 1990 Jan-Feb6(1):1–4. [PubMed: 2138048]
  951. Silverberg D, Blum M, Peer G, et al Anemia during the predialysis period: A key to cardiac damage in renal failure Nephron 1998 Sep80(1):1–5. [PubMed: 9730696]
  952. Silverberg DS, Blum M, Peer G, et al Intravenous ferric saccharate as an iron supplement in dialysis patients Nephron 199672(3):413–7. [PubMed: 8852489]
  953. Silverberg DS, Blum M, Schwartz, et al Iron management in predialysis patients Seminars in Dialysis 199912(4):262–266.
  954. Silverberg DS, Iaina A, Peer G, et al Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis Am J Kidney Dis 1996 Feb27(2):234–8. [PubMed: 8659499]
  955. Simon P, Ang KS, Benziane A, et al [Isolated systolic hypertension in uremic hemodialyzed patients] Arch Mal Coeur Vaiss 1991 Aug84(8):1205–10. [PubMed: 1835361]
  956. Simon P [Development of extrarenal complications of chronic renal insufficiency in patients treated by peritoneal dialysis] Nephrologie 199516(1):77–83. [PubMed: 7700424]
  957. Simon P [Erythropoietin and arterial hypertension in patients with chronic renal insufficiency] Rev Med Interne 199516(6):457–61. [PubMed: 7652230]
  958. Sinai-Trieman L, Salusky IB, Fine RN Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis J Pediatr 1989 Apr114(4 Pt 1):550–4. [PubMed: 2926567]
  959. Singh AB, Singh M, Palekar S, et al The effects of recombinant human erythropoietin on the cell mediated immune response of renal failure patients J Med 199223(5):289–302. [PubMed: 1469332]
  960. Sinnassamy P, Andre J L, Treize G, et al [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study] Arch Fr Pediatr 1993 Mar50(3):201–8. [PubMed: 8338412]
  961. Sisk JE, Gianfrancesco FD, Coster JM Recombinant erythropoietin and Medicare payment JAMA 1991 Jul 10266(2):247–52. [PubMed: 2056627]
  962. Sivak L, Scuteri RM, Cavalli NH, et al [The correction of anemia with a high requirement for transfusion in patients on maintenance hemodialysis by conventional and reduced doses of recombinant human erythropoietin] Medicina (B Aires) 199252(6):516–22. [PMC free article: PMC198880] [PubMed: 1340900]
  963. Sleasman JW, Scott GB Pediatric HIV infection. An update J Fla Med Assoc 199178(10):673–677. [PubMed: 1753232]
  964. Slingeneyer A, Faller B, Laroche B, et al Self-administered daily subcutaneous recombinant human erythropoietin: an open randomised dose-finding study in ESRD patients receiving peritoneal dialysis Contrib Nephrol 199188(159-68). [PubMed: 2040178]
  965. Smans KA, Van Landeghem FG, D'Haese PC, et al Is there a link between erythropoietin therapy and adynamic bone disease? Nephrol Dial Transplant 1996 Jul11(7):1248–9. [PubMed: 8672017]
  966. Smith BR Use of erythropoietin in AIDS and hematologic disorders Hosp Formul 199126(8):655–661.
  967. Smith DA, Perry PJ The efficacy of ergogenic agents in athletic competition. Part II: Other performance-enhancing agents Ann Pharmacother 1992 May26(5):653–9. [PubMed: 1591427]
  968. Smith PS Management of end-stage renal disease in children Ann Pharmacother 199832(9):929–939. [PubMed: 9762381]
  969. Sobota JT Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials. Contrib Nephrol. 1989;76:166–78; discussion 212-8. [PubMed: 2684519]
  970. Solozabal C, Maduell F, Unzue J, et al Low-dose human erythropoietin in chronic hemodialysis patients Nephron 199157(4):483–4. [PubMed: 2046835]
  971. Sommerburg O, Grune T, Hampl H, et al Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transplant 199813(10):2583–7. [PubMed: 9794564]
  972. Spinowitz B The practical aspects of therapy with rHuEPO Am J Nephrol 199010(Suppl 2):24–8. [PubMed: 2260614]
  973. Spinowitz BS EPO!one year later: a look at rehabilitation. The impact of long-term epoetin beta therapy on ESRD patient quality of life Nephrol News Issues 1990 Jun4(6):35–7. [PubMed: 2205809]
  974. Spivak J Preface Hematol Oncol Clin North Am 19948(5):Ix–Xi.
  975. Sreedhara R, Avram MM, Patel N, et al Correlates of very long term survival in peritoneal dialysis (PD) patients (pts) J Am Soc Nephrol 19967(9):–.
  976. Standage BA, Schuman ES, Ackerman D, et al Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates? Am J Surg 1993 May165(5):650–4. [PubMed: 8488954]
  977. Stasiecki P, Pollok M, Baldamus CA [Erythropoietin as a therapeutic agent. II: Indications, side effects and dangers] Med Klin 198984(4):216–218. [PubMed: 2657364]
  978. Stefanidis C J, Koulieri A, Siapera D, et al Effect of the correction of anemia with recombinant human erythropoietin on growth of children treated with CAPD. Adv Perit Dial. 1992;8:460–3. [PubMed: 1361848]
  979. Stefenelli T, Boszotta A, Kaliman JF, et al Digital vascular reactivity in patients on haemodialysis treated with human recombinant erythropoietin Vasa 199120(1):70–3. [PubMed: 2031404]
  980. Steffen HM, Brunner R, Muller R, et al Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol. 1989;76:292–8. [PubMed: 2582783]
  981. Steffensen G, Aunsholt NA, Ahlbom G Comparative crossover study of intravenously and subcutaneously administered recombinant human erythropoietin in hemodialysis patients Blood Purif 199210(5-6):241–247.
  982. Steffensen G, Aunsholt NA, Povlsen JV Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations Clin Nephrol 1996 Feb45(2):98–103. [PubMed: 8846537]
  983. Steffensen G, Aunsholt NA Impact of human recombinant erythropoietin on plasminogen activator inhibitor, and protein C and S activity Am J Nephrol 199616(5):453–4. [PubMed: 8886186]
  984. Stein RS, Abels RI, Krantz SB Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes Blood 1991 Oct 178(7):1658–63. [PubMed: 1912554]
  985. Steinhauer HB, Lubrich-Birkner I, Dreyling KW, et al Increased ultrafiltration after erythropoietin-induced correction of renal anemia in patients on continuous ambulatory peritoneal dialysis Nephron 198953(1):91–2. [PubMed: 2779711]
  986. Stenver D, Nielsen B, Jeppesen LL, et al Erythropoietin and fibrinolysis effects on platelet activity Lancet 1993 Feb 20341(8843):495–6. [PubMed: 8094516]
  987. Stenver DI, Nielsen B [Erythropoietin treatment of dialysis patients] Ugeskr Laeger 1994 Apr 25156(17):2589–91. [PubMed: 8016967]
  988. Stephens R, Williams A, McKnight T, et al Effects of self-monitored exercise on selected blood chemistry parameters of end-stage renal disease patients Am J Phys Med Rehabil 1991 Jun70(3):149–53. [PubMed: 2039617]
  989. Stevens J M, Auer J, Strong C A, et al Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis Nephrol Dial Transplant 19916(7):487–94. [PubMed: 1922910]
  990. Stevens ME, Summerfield GP, Hall AA, et al Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease BMJ 1992 Feb 22304(6825):474–7. [PMC free article: PMC1881131] [PubMed: 1547417]
  991. Stevenson K, Binkley LS EPO!one year later: a look at rehabilitation. Does EPO impact on rehabilitation of the dialysis patient? A nursing perspective Nephrol News Issues 1990 Jun4(6):30–1. [PubMed: 2402309]
  992. Stifter S, Graf H Treatment of renal anaemia by recombinant human erythropoietin Pol Arch Med Wewn 1991 Jun85(6):329–33. [PubMed: 1896395]
  993. Stivelman JC Injectable medications for hemodialysis patients Am J Nephrol 199616(1):73–8. [PubMed: 8719768]
  994. Stojcheva-Taneva OO, Polenakovic MH Autonomic neuropathy in hemodialysis patients treated with recombinant human erythropoietin Int J Artif Organs 1996 Oct19(10):574–7. [PubMed: 8946232]
  995. Stone WJ, Graber SE, Krantz SB, et al Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial Am J Med Sci 1988 Sep296(3):171–9. [PubMed: 3177433]
  996. Strauss MJ, Port FK, Somen C, et al An estimate of the size of the US predialysis population with renal insufficiency and anemia Am J Kidney Dis 1993 Mar21(3):264–9. [PubMed: 8447302]
  997. Strauss RG Current issues in neonatal transfusions Vox Sang 198651(1):1–9. [PubMed: 3526725]
  998. Stray-Gundersen J, Sams B, Goodkin D, et al Improvement in functional capacity in dialysis patients with regular exercise and correction of anemia. J Am Soc Nephrol. 1997;8:–.
  999. Stummvoll HK, Schindl R, Aigner K, et al [Physiologic respiratory parameters in erythropoietin treatment of patients with chronic renal failure] Wien Med Wochenschr Suppl 1989104(suppl):50–2. [PubMed: 2588636]
  1000. Sulkova S Erythropoietin, an update, and where to in the future? EDTNA-ERCA Journal 199824(3):30–32. [PubMed: 10392076]
  1001. Sulowicz W, Dubiel J, Hanicki Z, et al Influence of recombinant human erythropoietin therapy on selected echocardiographic indices and exercise capacity in patients on maintenance haemodialysis Przegl Lek 199148(12):741–4.
  1002. Sulowicz W, Hanicki Z, Lisiewicz J, et al [Activity of selected neutrophil enzymes of patients maintained on hemodialysis and treated with erythropoietin (rHu EPO)] Pol Arch Med Wewn 1991 Jun85(6):391–5. [PubMed: 1896403]
  1003. Sundal E, Businger J, Kappeler A Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. A European multicentre study in 142 patients to define dose regimen and safety profile Nephrol Dial Transplant 19916(12):955–65. [PubMed: 1798595]
  1004. Sundal E, Kaeser U Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients Nephrol Dial Transplant 19894(11):979–87. [PubMed: 2516891]
  1005. Sunder-Plassmann G, Horl WH Comparative look at intravenous iron agents: Pharmacology, efficacy, and safety of iron dextran, iron saccharate, and ferric gluconate Sem Dial 199912(4):243–248.
  1006. Sunder-Plassmann G, Horl WH Erythropoietin and iron Clin Nephrol 1997 Mar47(3):141–57. [PubMed: 9105761]
  1007. Sunder-Plassmann G, Horl WH Safety aspects of parenteral iron in patients with end-stage renal disease Drug Saf 1997 Oct17(4):241–50. [PubMed: 9352960]
  1008. Sunder-Plassmann G, Horl WH Iron and erythropoietin Klinisches Labor 199642(4):269–77.
  1009. Sungur C, Akpolat T, Ozkuyumcu C, et al False-positive HIV antibody test following alpha-interferon therapy in a chronic hemodialysis patient Nephron 199467(2):–. [PubMed: 8072624]
  1010. Suppiej A, Montini G, Casara G, et al Evoked potentials before and after anemia correction with recombinant human erythropoietin in end-stage renal disease Child Nephrol Urol 199212(4):197–201. [PubMed: 1473092]
  1011. Suzuki M [Countermeasure for patients with anemia due to hemodialysis] Nippon Naika Gakkai Zasshi 1995 Oct 1084(10):1663–7. [PubMed: 8537721]
  1012. Suzuki M Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities Artif Organs 199519(12):1258–61. [PubMed: 8967885]
  1013. Suzuki H, Murakami M, Ichihara A, et al Alterations in sex hormones and sexual function of patients with renal failure treated with recombinant human erythropoietin Jpn J Nephrol 199234(1):79–84. [PubMed: 1593800]
  1014. Suzuki M, Hirasawa Y, Hirashima K, et al Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO. Contrib Nephrol. 1989;76:179–92; discussion 212-8. [PubMed: 2684520]
  1015. Suzuki M, Tsutsui M, Yokoyama A, et al Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities Artif Organs 1995 Dec19(12):1258–61. [PubMed: 8967885]
  1016. Svara F, Spicka I, Sulkova S, et al Erythropoietin (r-HuEPO) for the treatment of anaemia in patients with multiple myeloma and end-stage renal failure Nephrol Dial Transplant 1995 Dec10(12):2374–5. [PubMed: 8808252]
  1017. Svara F, Sulkova S, Kvasnicka J, et al [Iron supplementation during erythropoietin therapy in patients on hemodialysis] Vnitr Lek 1996 Dec42(12):849–52. [PubMed: 9072885]
  1018. Szewczuk J, Mazerska M, Malyszko J, et al Increase in fibrinolytic activity after erythropoietin therapy (4) Thromb. Haemostasis 199267(2):–. [PubMed: 1621253]
  1019. Szolkiewicz M, Manitius J, Kopecka L, et al [Some clinical aspects of erythropoietin action used at doses not affecting erythropoiesis in hemodialysed patients] Pol Arch Med Wewn 199492(Spec No):78–84. [PubMed: 7731903]
  1020. Szurkowski M, Wiecek A, Kokot F, et al Safety and efficiency of recombinant human erythropoietin treatment in anemic pregnant women with a kidney transplant Nephron 199467(2):242–3. [PubMed: 8072619]
  1021. Taaning E, Morling N, Mortensen SA, et al Hemolytic anemia due to graft-derived anti-b production after lung transplantation Transplant Proc 199426(3):–. [PubMed: 8030113]
  1022. Tagawa H [Hypertension in dialysis patients] Nippon Rinsho 1992 May50(Suppl):610–5. [PubMed: 1355139]
  1023. Takasaki M, Tsurumi N, Konjiki O, et al [Causes, diagnosis, and treatment of anemia in the elderly] Nippon Ronen Igakkai Zasshi 199734(3):171–9. [PubMed: 9155190]
  1024. Tan A Recombinant human erythropoietin (r-HuEPO): quality of life and other considerations. J CANNT. 1990;Summer:13–4. [PubMed: 2202375]
  1025. Tanabe R [Numerical and functional alterations in T and B lymphocyte subpopulations in CAPD patients treated with recombinant human erythropoietin] Nippon Jinzo Gakkai Shi 1994 Oct36(10):1159–68. [PubMed: 7815748]
  1026. Tang IY, Vrahnos D, Valaitis D, et al Vascular access thrombosis during recombinant human erythropoietin therapy ASAIO J 1992 Jul-Sep38(3):M528–31. [PubMed: 1457917]
  1027. Tang WW, Stead RA, Goodkin DA Effects of Epoetin alfa on hemostasis in chronic renal failure [editorial] Am J Nephrol 199818(4):263–73. [PubMed: 9653828]
  1028. Tarng DC, Huang TP Uraemic pericarditis: a reversible inflammatory state of resistance to recombinant human erythropoietin in haemodialysis patients Nephrol Dial Transplant 199712(5):1051–1054. [PubMed: 9175071]
  1029. Tassies D, Reverter JC, Cases A, et al Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: association with early improvement in platelet function Am J Hematol 1998 Oct59(2):105–9. [PubMed: 9766793]
  1030. Taylor J, Mactier RA, Stewart WK, et al Effect of erythropoietin on anaemia in patients with myeloma receiving haemodialysis BMJ 1990 Sep 8301(6750):476–7. [PMC free article: PMC1663757] [PubMed: 2207402]
  1031. Taylor JE, Belch JJ, McLaren M, et al Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients Kidney Int 1993 Jul44(1):182–90. [PubMed: 8355460]
  1032. Taylor JE, Henderson IS, Mactier RA, et al Effects of withdrawing erythropoietin BMJ 1991 Feb 2302(6771):272–3. [PMC free article: PMC1668916] [PubMed: 1998794]
  1033. Taylor JE, Henderson IS, Stewart WK, et al Erythropoietin and spontaneous platelet aggregation in haemodialysis patients Lancet 1991 Nov 30338(8779):1361–2. [PubMed: 1682739]
  1034. Taylor JE, Henderson IS, Stewart WK, et al Platelet aggregation in erythropoietin treated dialysis patients Platelets 19923(1):47–52. [PubMed: 21043900]
  1035. Taylor JE, Peat N, Porter C, et al Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients Nephrol Dial Transplant 1996 Jun11(6):1079–83. [PubMed: 8671972]
  1036. Taylor JE Haemostasis and vascular disease in dialysis patients receiving erythropoietin therapy Vasc Med Rev 19934(3):171–182.
  1037. Teehan BP, Benz RL, Sigler MH, et al Early intervention with recombinant human erythropoietin therapy Semin Nephrol 1990 Mar10(2 Suppl 1):28–34. [PubMed: 2192414]
  1038. Teehan BP, Sigler MH, Brown, et al Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients Transplant Proc 198921(6 Suppl 2):63–6.
  1039. Teehan BP Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients Am J Kid Dis 199118(1):50–59. [PubMed: 2063855]
  1040. Teruel JL, Aguilera A, Avila C, et al Effects of androgen therapy on prostatic markers in hemodialyzed patients Scand J Urol Nephrol 1996 Apr30(2):129–31. [PubMed: 8738058]
  1041. Teruel JL, Fernandez Juarez G, Marcen R, et al Effect of angiotensin-converting enzyme inhibitors on anemia in hemodialyzed patients Nephron 199673(1):–. [PubMed: 8742977]
  1042. Thamer M, Richard C, Ray NF, et al The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states Am J Kidney Dis 1996 Aug28(2):235–49. [PubMed: 8768919]
  1043. The US Recombinant Human Erythropoietin Predialysis Study Group Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients Am J Kidney Dis 1991 Jul18(1):50–9. [PubMed: 2063855]
  1044. Toffelmire EB, Barrett BJ, Fenton SS, et al Chapter 2: Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. J Am Soc Nephrol. 1999;10:S292–S296. [PubMed: 10425612]
  1045. Toffelmire EB Iron management in patients using r-HuEPO J CANNT 1994 Fall4(4):20–3. [PubMed: 7612402]
  1046. Tomoda F, Takata M, Izumino K, et al Effects of erythropoietin treatment on thyroid dysfunction in hemodialysis patients with renal anemia Nephron 199466(3):307–11. [PubMed: 8190183]
  1047. Tomson CR End stage renal disease in sickle cell disease: Future directions Postgrad Med J 199268(804):775–8. [PMC free article: PMC2399528] [PubMed: 1461848]
  1048. Tomura S, Nakamura Y, Tachibana K, et al Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis Blood Purif 199311(6):370–7. [PubMed: 8043258]
  1049. Tomura S [Effect of recombinant human erythropoietin on hemodynamics in chronic hemodialysis patients] Nippon Rinsho 1991 Dec49(Suppl):695–701. [PubMed: 1808338]
  1050. Trbojevic J, Zivkovic M [Quality of life in chronic renal insufficiency: the effect of disease development and various method of therapy] Srp Arh Celok Lek 1997 Jul-Aug125(7-8):223–7. [PubMed: 9304236]
  1051. Trembecki J, Kokot F, Wiecek A, et al [Improvement of sexual function in hemodialyzed male patients with chronic renal failure treated with erythropoietin (rHuEPO)] Przegl Lek 199552(9):462–6. [PubMed: 8834648]
  1052. Trembecki J, Kokot F, Wiecek A, et al [Influence of long-term erythropoietin (rHuEPO) therapy on the function of the pituitary-gonadal axis in hemodialyzed male patients with end stage renal failure] Pol Arch Med Wewn 1995 Aug94(2):144–52. [PubMed: 8596749]
  1053. Tufts DA, Haas JD, Beard JL, et al Distribution of hemoglobin and functional consequences of anemia in adult males at high altitude Am J Clin Nutr 1985 Jul42(1):1–11. [PubMed: 4014058]
  1054. Turi S, Nemeth I, Varga I, et al The effect of erythropoietin on the cellular defence mechanism of red blood cells in children with chronic renal failure Pediatr Nephrol 1992 Nov6(6):536–41. [PubMed: 1482641]
  1055. Ucok K, Gokbel H, Yeksan M, et al The effects of rHuEPO administration on pulmonary functions in haemodialysis patients Int J Artif Organs 1996 Jun19(6):336–8. [PubMed: 8814495]
  1056. Uehlinger DE, Frey FJ [Erythropoietin, a milestone in the history of nephrology] Ther Umsch 1995 Oct52(10):672–7. [PubMed: 7482378]
  1057. Uhl D [Erythropoietin] Med Monatsschr Pharm 1990 May13(5):130–1. [PubMed: 2192242]
  1058. Urabe A, Kitamura T, Takaku F Clinical application of erythropoietin Nippon Ketsueki Gakkai Zasshi 1988 Dec51(8):1355–9. [PubMed: 3073611]
  1059. Urabe A, Takaku F, Mizoguchi H, et al Effect of recombinant human erythropoietin on the anemia of chronic renal failure Int J Cell Cloning 1988 May6(3):179–91. [PubMed: 3397592]
  1060. Uthayanaka Y, Jirajan B, Krairithichai U, et al The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis Southeast Asian J Trop Med Public Health 1993 Sep24(3):577–82. [PubMed: 8160072]
  1061. Valderrabano F, Jones EH, Mallick NP Report on management of renal failure in Europe, XXIV, 1993 Nephrol Dial Transplant 199510(Suppl 5):1–25. [PubMed: 7478150]
  1062. Valderrabano F [Erythropoietin in the treatment of anemia in chronic renal insufficiency] An Med Interna 1991 Jun8(Suppl 2):22–3. [PubMed: 1878467]
  1063. Valderrabano F Erythropoietin in chronic renal failure Kidney Int 1996 Oct50(4):1373–91. [PubMed: 8887302]
  1064. Valderrabano F Recombinant erythropoietin: 10 years of clinical experience Nephrol Dial Transplant 199712(Suppl 1):2–9. [PubMed: 9075222]
  1065. Valeri CR, Crowley JP, Loscalzo J Indications for red blood cell transfusion. In: Alternative Approaches to Human Blood Resources in Clinical Practice, CTS Sibinga, PC Das, JC Fratantoni, eds. Dordrecht: Kluwer Academic Publishers; 1998. p. 209-214.
  1066. Vallance P, Benjamin N, Collier J Erythropoietin, haemoglobin, and hypertensive crises Lancet 19881(8594):–. [PubMed: 2896933]
  1067. Van Damme-Lombaerts R, Broyer M, Businger J, et al A study of recombinant human erythropoietin in the treatment of anaemia of chronic renal failure in children on haemodialysis Pediatr Nephrol 1994 Jun8(3):338–42. [PubMed: 7917862]
  1068. Van Damme-Lombaerts R, Herman J Erythropoietin treatment in children with renal failure Pediatric Nephrol 199913(2):148–152. [PubMed: 10229005]
  1069. Van De Voorde J The endocrine functions of the kidney. Iii. Erythropoietin Tijdschr. Geneeskd 199248(23):1763–1768.
  1070. Van Demark RE Sr Erythropoietin S D J Med 1990 Apr43(4):–.
  1071. Van der Linden P, Vincent JL Reevaluation of blood transfusion strategies Minerva Anestesiol 1997 May63(5):143–7. [PubMed: 9339090]
  1072. Van der Niepen P, Sennesael J, Verbeelen D r-HuEPO treatment of anemia associated with multiple myeloma and ESRD Clin Nephrol 1993 Feb39(2):–. [PubMed: 8448915]
  1073. Van Loo A, Vanholder R, Bernaert P, et al Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study Nephrol Dial Transplant 1996 Sep11(9):1815–21. [PubMed: 8918628]
  1074. Van Stone JC Who should receive recombinant human erythropoietin? Semin Nephrol 1989 Mar9(1 Suppl 2):3–7. [PubMed: 2669084]
  1075. Van Wyck D Efficacy and adverse effects of oral iron supplements Semin Dialysis 199912(4):235–236.
  1076. Vanrenterghem Y, Khamis S The management of the failed renal allograft Nephrol Dial Transplant 199611(6):955–958. [PubMed: 8671948]
  1077. Vanrenterghem Y, Vanwalleghem J Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin Nephrol Dial Transplant 199813(Suppl 2):13–5. [PubMed: 9566485]
  1078. Vanrenterghem Y, Vanwalleghem J Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin Nephrol Dial Transplant 199813(Suppl 2):13–15. [PubMed: 9566485]
  1079. VanwalleghemY, Vanrenterghem J The role of epoetin in predialysis and renal transplantation Erythropoiesis: New dimensions in the treatment of anaemia 19978(2):43–8.
  1080. Vasquez EM, Pollak R Effect of pretransplant erythropoietin therapy on renal allograft outcome Transplantation 199662(7):1026–1028. [PubMed: 8878400]
  1081. Vaziri ND Mechanism of erythropoietin-induced hypertension Am J Kidney Disease 199933(5):821–828. [PubMed: 10213636]
  1082. Velasquez MT, Lew SQ, von Albertini B, et al Control of hypertension is better during hemodialysis than during continuous ambulatory peritoneal dialysis in ESRD patients Clin Nephrol 1997 Dec48(6):341–5. [PubMed: 9438091]
  1083. Velasquez MT, von Albertini B, Lew SQ, et al Equal levels of blood pressure control in ESRD patients receiving high-efficiency hemodialysis and conventional hemodialysis Am J Kidney Dis 1998 Apr31(4):618–23. [PubMed: 9531177]
  1084. Vella JP, O'Neill D, Atkins N, et al Sensitization to human leukocyte antigen before and after the introduction of erythropoietin Nephrol Dial Transplant 199813(8):2027–2032. [PubMed: 9719159]
  1085. Venkatesan J, Henrich WL Anemia, hypertension, and myocardial dysfunction in end-stage renal disease Semin Nephrol 199717(4):257–269. [PubMed: 9241712]
  1086. Verbeelen D, Hauglustaine D, Sennesael J Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin Neth J Med 1988 Aug33(1-2):60–7. [PubMed: 3247012]
  1087. Veys N Clinical administration of erythropoietin in nephrology Tijdschr Geneeskd 199349(9):632–6.
  1088. Viale S, Nori G, Magarini C, et al Erytropoietin and hemostasys in uraemic patients G Ital Angiol 199313(4):213–6.
  1089. Villa MP, Rotili PL, Santamaria F, et al Physical performance in patients with thalassemia before and after transfusion Pediatr Pulmonol 1996Jun 21(6):367–72. [PubMed: 8927463]
  1090. Villaverde M, PerezGarcia R, Verde E, et al High-flux polysulfone improves the response to recombinant human erythropoietin (RH-EPO) in patients on long term hemodialysis (HD) Nefrologia 199919(2):161–167.
  1091. Virot JS, Janin G, Guillaumie J, et al Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient? Am J Kidney Dis 1996 Sep28(3):400–8. [PubMed: 8804239]
  1092. Vlassopoulos D, Sonikian M, Dardioti V, et al Target haematocrit during erythropoietin treatment in dialysis patients. Which value is "true-functional haematocrit"? Nephrol Dial Transplant 199914(5):1340–1. [PubMed: 10344405]
  1093. Volpe M, Tritto C, Testa U, et al Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles Am J Cardiol 1994 Sep 174(5):468–73. [PubMed: 8059727]
  1094. Vora M, Gruslin A Erythropoietin in obstetrics Obstet Gynecol Surv 199853(8):500–508. [PubMed: 9702790]
  1095. Vreugdenhil G, Schrey G, van Es PN, et al Erythropoietin production in hypertensive patients with and without renal artery stenosis Nephron 199570(1):137–8. [PubMed: 7617109]
  1096. Vreugdenhil G, Swaak AJ The role of erythropoietin in the anaemia of chronic disease in rheumatoid arthritis Clin Rheumatol 1990 Mar9(1):22–7. [PubMed: 2185909]
  1097. Wahr JA Myocardial ischaemia in anaemic patients Br J Anaesth 199881(Suppl 1):10–5. [PubMed: 10318982]
  1098. Wakeen M, Zimmerman SW Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis Am J Kidney Dis 1998 Sep32(3):488–93. [PubMed: 9740167]
  1099. Warady B, Watkins SL Current advances in the therapy of chronic renal failure and end stage renal disease Semin Nephrol 1998 May18(3):341–54. [PubMed: 9613874]
  1100. Warady BA, Jabs K New hormones in the therapeutic arsenal of chronic renal failure. Growth hormone and erythropoietin Pediatr Clin North Am 1995 Dec42(6):1551–77. [PubMed: 8614600]
  1101. Warady BA, Sabath RJ, Smith CA, et al Recombinant human erythropoietin therapy in pediatric patients receiving long-term peritoneal dialysis Pediatr Nephrol 1991 Nov5(6):718–23. [PubMed: 1768585]
  1102. Wasielewski S The therapeutic possibilities for children with kidney failure Krankenhauspharmazie 199314(7):333–334.
  1103. Watson AJ, Gimenez LF, Cotton S, et al Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin Am J Med 1990 Oct89(4):432–5. [PubMed: 2220877]
  1104. Watson AJ Adverse effects of therapy for the correction of anemia in hemodialysis patients Semin Nephrol 1989 Mar9(1 Suppl 1):30–4. [PubMed: 2648519]
  1105. Watson AR Chronic renal failure in childhood Br J Hosp Med 1996 Mar 20-Apr 255(6):329–31. [PubMed: 8696626]
  1106. Weil C Case study of the anemic patient: epoetin alfa!focus on improving ventricular function ANNA J 1995 Jun22(3):338–41. [PubMed: 7786083]
  1107. Welch TR Renal failure in children Curr Opin Pediatr 19913(2):264–7.
  1108. Welch TR Treatment options for end-stage renal disease in children: where have we been; where are we; and where are we going? Clin Transplant 19915(2 Ii):146–9.
  1109. Wells GA, Coyle D, Lee KM, et al Quality of life effects of normalization of hemoglobin in asymptomatic hemodialysis patients. J Am Soc Nephrol. 1998;9:–.
  1110. Wheby MS Preface Med Clin North Am 199276(3):–.
  1111. White JD A view of the future of end-stage renal disease care: the patient's perspective Advances In Renal Replacement Therapy 19985(4):309–314. [PubMed: 9792086]
  1112. Widmer LK [Acute anemia and angina] Ann Fr Anesth Reanim 199413(1):–. [PubMed: 8092574]
  1113. Wiecek A, Kokot F, Marcinkowski W, et al [Treatment of anemia with erythropoietin (rhuEPO) in patients with chronic kidney failure who are not yet in need of dialysis therapy] Pol Arch Med Wewn 1992 Nov88(5):310–23. [PubMed: 1300551]
  1114. Wiecek A, Kokot F, Spiechowicz U, et al [Requirement for blood in hemodialyzed patients with chronic renal failure in the period before and after introduction to erythropoietin (r-HuEPO) treatment] Przegl Lek 199653(12):866–9. [PubMed: 9163010]
  1115. Wiecek A, Kokot, F Marcinkowski W, et al Effectiveness and safety of recombinant human erythropoietin (rhuepo)in the treatment of anaemia in predialysis uraemic patients. Polish multicenter study Ann Acad Med Gedanensis 199525(Suppl 6):75–81.
  1116. Wiecek A [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy] Przegl Lek 199552(3):93–4. [PubMed: 7644683]
  1117. Wiesholzer M, Kitzwogerer M, Harm F, et al Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin Am J Kidney Dis 199933(4):702–708. [PubMed: 10196012]
  1118. Wiklund I The Nottingham Health Profile!a measure of health-related quality of life. Scand J Prim Health Care Suppl. 1990;1:15–8. [PubMed: 2100359]
  1119. Williams C Haemoglobin!is more better? Nephrol Dial Transplant 199510(Suppl 2):48–55. [PubMed: 7644106]
  1120. Winchester JF, Rakowski TA End-stage renal disease and its management in older adults Clin Geriatr Med 199814(2):255–265. [PubMed: 9536104]
  1121. Winearls CG, Oliver DO, Pippard MJ, et al Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis Lancet 1986;Nov 222(8517):1175–8. [PubMed: 2877323]
  1122. Winearls CG Historical review on the use of recombinant human erythropoietin in chronic renal failure Nephrol Dial Transplant 199510(Suppl 2):3–9. [PubMed: 7644103]
  1123. Winearls CG Treatment of anaemia in renal failure Prescr J 199232(6):238–244.
  1124. Winearls CG Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin Drugs 1989 Sep38(3):342–5. [PubMed: 2806134]
  1125. Wingard RL, Parker RA, Ismail N, et al Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin Am J Kidney Dis 1995 Mar25(3):433–9. [PubMed: 7872321]
  1126. Winslow RM, Chapman KW, Gibson CC, et al Different hematologic responses to hypoxia in Sherpas and Quechua Indians J Appl Physiol 1989 Apr66(4):1561–9. [PubMed: 2732148]
  1127. Wirtz JJ, van Esser JW, Hamulyak K, et al The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients Clin Nephrol 1992 Nov38(5):277–82. [PubMed: 1451341]
  1128. Wish JB Economic issues and future directions in iron management Seminars in Dialysis 199912(4):267–270.
  1129. Wizemann V Follow-up of cardiac changes induce by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron. 1993;64:202–6. [PubMed: 8321352]
  1130. Wolcott DL, Marsh JT, La Rue A, et al Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients Am J Kidney Dis 1989 Dec14(6):478–85. [PubMed: 2596475]
  1131. Wolfe RA, Held PJ, Hulbert-Shearon TE, et al A critical examination of trends in outcomes over the last decade Am J Kidney Dis 1998 Dec32(6 Suppl 4):S9–S15. [PubMed: 9892361]
  1132. Wolfson M, Mundt DJ, Hawley GG Recombinant human erythropoietin utilization in department of veterans affairs dialysis units Am J Kidney Dis 199424(2):184–91. [PubMed: 8048423]
  1133. Wong W-Y, Elliott-Mills D, Powars D Renal failure in sickle cell anemia Hematology/Oncology Clinics Of North America 199610(6):1321–1331. [PubMed: 8956019]
  1134. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure The European best practice guidelines for the management of anaemia in patients with chronic renal failure Nephrol Dial Transplant 199914(Suppl 5):1–50. [PubMed: 10513295]
  1135. Xia H, Ebben J, Ma JZ, et al Hematocrit levels and hospitalization risks in hemodialysis patients J Am Soc Nephrol 199910(6):1309–16. [PubMed: 10361870]
  1136. Yagil Y Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel Isr J Med Sci 1997 Jan33(1):36–44. [PubMed: 9203516]
  1137. Yagil Y Treatment of anemia of CRF in the pre-dialysis stage with low dose once-a-week S.C. erythropoietin (EPO) Nephrol Dial Transplant 199510(6):–.
  1138. Yalcinkaya F, Tumer N, Cakar N, et al Low-dose erythropoietin is effective and safe in children on continuous ambulatory peritoneal dialysis Pediatr Nephrol 1997 Jun11(3):350–2. [PubMed: 9203190]
  1139. Yamazaki C, Itoh A, Yamamoto N, et al [Pharmacokinetics and clinical effect of recombinant human erythropoietin on the anemia of predialysis patients] Nippon Jinzo Gakkai Shi 1992 Jun34(6):701–10. [PubMed: 1479710]
  1140. Yamazaki C, Itoh A, Yamamoto N, et al Pharmacokinetics and clinical effect of recombinant human erythropoietin on the anemia of predialysis patients Jpn J Nephrol 199234(6):701–710. [PubMed: 1479710]
  1141. Yamazaki C, Watanabe Y, Sakamoto N Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients Nippon Jinzo Gakkai Shi 1993 Nov35(11):1233–42. [PubMed: 8139135]
  1142. Yaqoob M, Ahmad R, McClelland P, et al Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy Postgrad Med J 1993 Feb69(808):124–8. [PMC free article: PMC2399608] [PubMed: 8506193]
  1143. Yepez R, Estevez E, Galan P, et al Validity of criteria used to define high-altitude anemia Cah Sante 19944(1):9–13.
  1144. Yepez R, Estrella R, Galan P, et al Hemoglobin response to an iron supplementation trial in schoolchildren living at high altitude Nutr Rep Int 198838(3):629–633.
  1145. York S Current perspectives: iron management during therapy with recombinant human erythropoietin ANNA J 1993 Dec20(6):645–50. [PubMed: 8267408]
  1146. Yoshida Y, Ohmori S, Tohyama K, et al Erythropoietic changes in chronic hemodialysis patients undergoing recombinant human erythropoietin therapy Nippon Ketsueki Gakkai Zasshi 1988 Sep51(6):1092–6. [PubMed: 3201902]
  1147. Zachee P, Ferrant A, Daelemans R, et al Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment Nephron 199365(2):288–93. [PubMed: 8247195]
  1148. Zachee P Controversies in selection of epoetin dosages. Issues and answers Drugs 1995 Apr49(4):536–47. [PubMed: 7789287]
  1149. Zarifian A Case study of the anemic patient: epoetin alfa-focus on sexual function ANNA J 1994 Oct21(6):368–71. [PubMed: 7993143]
  1150. Zehnder C, Blumberg A [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration] Schweiz Med Wochenschr 1990 Feb 17120(7):217–20. [PubMed: 2309110]
  1151. Zehnder C, Blumberg A Recombinant human erythropoietin in anemic patients on hemodialysis: benefits and risks Schweiz Med Wochenschr 1989119(9):269–275. [PubMed: 2711161]
  1152. Zehnder C, Zuber M, Sulzer M, et al Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients Nephron 199261(1):21–5. [PubMed: 1388250]
  1153. Zein ZA, Assefa M The prevalence of anaemia among populations living at different altitudes in north-western Ethiopia Ethiop Med J 1987 Jul25(3):105–11. [PubMed: 3609004]
  1154. Zezina L, Britcina N, Adamsone I, et al Influence of recombinant human erythropoietin on central haemodynamics in haemodialysis patients Annales Academiae Medicae Gedanensis 199525(Suppl 6):151–8.
  1155. Zhang QY, Zhang JY, Wu QW [Clinical and experimental study of kidney tonics plus whole embryo extract in treatment of renal anemia] Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1996 Jun16(6):330–2. [PubMed: 9387758]
  1156. Zheng FL, Bi ZQ, Li RS [The effect of low doses of recombinant human erythropoietin on renal anemia in predialysis patients with chronic renal failure] Chung Hua Nei Ko Tsa Chih 1993 Jul32(7):440–3. [PubMed: 8275819]
  1157. Zins B, Drueke T, Zingraff J, et al Erythropoietin treatment in anaemic patients on haemodialysis Lancet 1986 Dec 62(8519):–. [PubMed: 2878188]
  1158. Zins B, Hannedouche D, Kleinknecht T, et al Effects of erythropoietin treatment on renal function of predialytic uremic patients J Am Soc Nephrol 19912(3):–.
  1159. Zoellner K, Schmidt G, Devaux S The influence of recombinant human erythropoietin on renal anemia in polytransfused children on chronic hemodialysis Nieren-Hochdruckkr 199019(5):211–214.
  1160. Zorsky PE Erythropoietin Drug Ther 199020(9):50, 55–7.
Bookshelf ID: NBK33575
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...